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About this thesis 
 
Most small-molecule drugs are designed to interact with their biological targets under 
equilibrium binding conditions, whereby the desired drug-protein interaction is a rapid and 
reversible (non-covalent) process. However, for a drug to exert its effect, it needs to be bound 
to the target, and hence a common focus of modern drug discovery programs is to maximize 
the strength of these noncovalent molecular interactions. As an extension to this reasoning, a 
less conventional strategy termed ‘covalent interactions’ has recently gained reputation in the 
field of drug discovery [1, 2]. A covalent bond between ligand and receptor can be 
sufficiently long-lived that it is irreversible within the half-life of the target protein, resulting 
in a drug-protein complex that is not subject to classical equilibrium kinetics. Accordingly, 
such drugs were initially less favored owing to concerns over potential nonspecific side 
effects or off-target toxicity [1, 2]. However, one of the oldest drugs in current clinical 
practice, aspirin (acetylsalicylic acid), acts as a covalently binding inhibitor [3]. Hence, in this 
thesis a covalent strategy is applied and shown to be compatible with a target-directed, 
structure-guided discovery paradigm, with a focus on G protein-coupled receptors as drug 
targets. 
Receptor proteins, located on both the cell surface and within the cell, are the targets through 
which many drugs produce their beneficial effects in various disease states. The receptor 
theory was once proposed as the underlying mechanism for drug action by the pioneering 
scientists Paul Ehrlich and John Newport Langley at the beginning of the 20th century. 
Whereas Langley referred to specific sites affected by nicotine as ‘receptive substances’ [4], 
Ehrlich simultaneously envisioned chemical ‘side-chains’ on the cell membrane to which 
toxins could bind [5]. Among the receptors, so-called G protein-coupled receptors (GPCRs) 
are one of the largest and most important drug target families [6]. This chapter provides a 
background for the covalent research strategy for GPCRs presented in this thesis, followed by 







1. G Protein-coupled Receptors (GPCRs) 
G protein-coupled receptors (GPCRs) represent a protein superfamily responsible for vision, 
olfaction, taste and signal transduction by hormones and neurotransmitters [7]. More than 
30% of the current clinically used small-molecular drugs target GPCRs [8]. According to 
Fredriksson and colleagues, this large family in the human genome encompasses five 
subtypes, including Rhodopsin (class A), Secretin (class B), Adhesion (class B), Glutamate 
(class C), and Frizzled/Taste2 (class F), shortened to GRAFS [9]. The main structural features 
of GPCR-family members are the seven hydrophobic, transmembrane, α-helices, termed as 
TM1-TM7 (Figure 1). The N terminus, considered a glycosylation site for most GPCRs, 
together with three extracellular loops (ECL1–ECL3) compose the extracellular section. The 
intracellular part of the receptor contains a C terminus, three corresponding intracellular loops 
(ICL1-ICL3) and an amphipathic helix (H8). Due to their similar role in receptor function, 
such as activation, the seven hydrophobic helices, located in the lipid bilayer, are highly 
conserved, especially in class A GPCRs.  
 
Figure 1. A schematic representation of an inactive class A G protein-coupled receptor (GPCR). 
Class A GPCRs consist of seven hydrophobic α-helices, termed as TM1-TM7, connected with 
extracellular loops (ECL1–ECL3) and three corresponding intracellular loops (ICL1-ICL3). The N 
terminus is directed to the extracellular side, while helix 8 (H8) and C-terminus are located at the 
intracellular side. Activated G proteins regulate diverse signaling cascades, depending on their subtype 
(αs, αi , αq , and α12 families).  
The signaling from the extracellular to intracellular environment is mediated by the 
heterotrimeric G protein, having three subunits, α, β and γ (Figure 1). Activation of the 
receptor results in a conformational change, causing the G protein-bound guanosine 
diphosphate (GDP) to be exchanged for guanosine triphosphate (GTP), leading to dissociation 






Gαi, Gαq and Gα12, and a single GPCR can couple to either one or more families of Gα 
proteins. Each G protein activates several downstream effectors (Figure 1).  
1.1. Adenosine receptors  
Adenosine receptors (ARs) belong to the rhodopsin, or class A subfamily of GPCRs. There 
are four recognized subtypes for ARs-named A1R, A2AR, A2BR and A3R, each of which 
shows an individual pharmacological profile and tissue distribution [11, 12]. The 
classification of ARs is traditionally dependent on their differential coupling to adenylyl 
cyclase (AC), the enzyme responsible for increasing the intracellular concentration of the 
second messenger cyclic adenosine 5’-monophosphate (cAMP). Activation of the A1R and 
A3R will inhibit AC activity, caused predominantly by Gαi protein interaction, ultimately 
leading to a decrease of intracellular cAMP. The A2AR and A2BR are coupled to the Gαs 
protein, resulting in an increase of intracellular cAMP production. So far, only A1R and A2AR  
have been successfully subjected to structure elucidation, including both inactive [13, 14] and 
active states [15-17].  
Figure 2 Crystal structures of the indicated adenosine receptor. (A) DPCPX, docked into the A1R 
structure, leaves a secondary binding site unoccupied. (B) The A2AR crystal structure with binding 
pocket occupied by ZM241385. Reproduced with permission [13]. 
Figure 2 includes the crystal structures of A1R (PDB: 5EUN) docked with antagonist DPCPX 
and A2AR co-crystalized with antagonist ZM241385 (PDB: 4EIY) [13, 14]. It was found that 
the amino acid residues in the orthosteric binding site are highly conserved for both receptor 
subtypes. However, the A2AR accommodates an elongated and narrow binding cavity, while 
in the A1R, transmembrane helices TM1, TM2, TM3, TM7 and ECL3 brought a more open 
and wide binding cavity with a secondary binding pocket. These findings provide important 








1.2. Adenosine receptor as drug target: focus on A1R, A2AR and A3R.   
Adenosine receptors have distinct distributions through the human body and are important 
regulators of many different types of physiological and pathological processes. There is 
accumulating evidence that adenosine receptors are promising therapeutic targets for 
inflammatory, cardiovascular and neurodegenerative diseases, and cancer [18, 19]. In this 
thesis, we will only focus on the A1R, A2AR and A3R subtypes as drug targets. 
A1R is widely expressed throughout the body with particular high abundance at excitatory 
nerve endings [18]. The activation of receptors inhibits AC activity, activates potassium 
channels (including KATP channels in neurons and the myocardium), blocks transient calcium 
channels and increases intracellular calcium ion concentrations and phospholipase C activity 
(PLC). Adenosine acting via A1R plays an important role in various pathological conditions, 
such as ischemia/hypoxia, epileptic seizures, excitotoxic neuronal injury and cardiac 
arrhythmias [20]. As a consequence, A1R agonists might be considered as therapeutic agents 
for the treatment of central nervous system (pain) and cardiovascular (arrhythmia) 
pathologies. Various A1R antagonists have been or are currently being explored for clinical 
applications targeting cognitive and renal dysfunction [19]. 
High expression levels of A2ARs are found in the brain striatum, spleen, leukocytes and blood 
platelets [19, 21]. A2ARs mediate vasodilation, modulate angiogenesis and protect tissues 
from collateral inflammatory damage. In the brain, the A2AR influences motor activity, 
psychiatric behaviors, the sleep-wake cycle and neuronal cell death. The A2AR has been 
validated as a therapeutic/diagnostic target by the clinical use of regadenoson, approved by 
FDA for myocardial perfusion imaging in patients with suspected coronary artery disease 
[22]. Furthermore, A2AR agonists are being investigated as agents to treat a number of 
conditions such as asthma, COPD and diabetic foot ulcers, while A2AR antagonists have 
emerged as an attractive approach for Parkinson disease [21] and, more recently, as adjuvants 
for checkpoint inhibitors in cancer [23] . 
A3Rs have been recognized as a potential therapeutic target and biomarkers due to their 
overexpression in inflammatory and cancer cells compared to healthy cells [19, 24]. The A3R 
has been shown to couple to the Gi and Gq family and its anti-inflammatory activity correlates 
with the upregulation of nuclear factor-κB (NF-κB) signalling and the phosphoinositide 
3-kinase (PI3K)–PKB–AKT signalling pathways. Earlier studies indicated an important role 






disorder. Nevertheless, the medical relevance of the human A3R is enigmatic due to 
paradoxical effects in different therapeutic applications [25]. Currently, agonists are being 
considered as pharmacological agents for rheumatoid arthritis, psoriasis, glaucoma, and 
hepatocellular carcinoma.  
1.3. Targeting adenosine receptors 
From a drug discovery perspective, the wide distribution of adenosine receptors in 
mammalian cell types renders it mandatory to search for high-affinity and highly subtype-
selective agonists and antagonists. The development of AR agonists started from structural 
modification of the endogenous ligand, adenosine, and hence structure-activity relationships 
for such ribose-containing compounds have been extensively investigated [12, 18, 26]. 
Besides these several non-ribose agonists have also been shown to reveal high receptor 
subtype selectivity, such as the A1R agonist capadenoson, a clinical drug candidate for atrial 
fibrillation [27]. Similarly, naturally occurring compounds caffeine and theophylline share a 
xanthine-based scaffold, contributing to the templates of antagonists for all AR subtypes, 
while non-xanthine structures have been explored for better water solubility and consequently 
improved bioavailability [12, 18, 26]. However, the major challenge in developing AR 
ligands for specific clinical applications is the ubiquitous receptor distribution and associated 
complex adenosine signaling, which exerts a broad spectrum of physiological and 
pathophysiological read-outs [19, 28].  The standard pharmacological assays of selectivity and 
efficacy are not sufficient to reveal a drug candidate’s bio-distribution and pharmacokinetics, 
which may lead to potential side effects responsible for their failure in clinical trials. For 
example, the A1R antagonist rolofylline, a drug candidate for patients with acute heart failure 
with impaired renal function, failed in clinical trials due to A1R-mediated (“on target”) safety 
issues leading to an increased frequency of stroke and seizure activity [29]. Thus, it is 
desirable to decipher the distinct AR effects dependent on cellular and tissue specificity and 
disease phase. Moreover, repeated exposure to AR agonists may desensitize receptor 
activation or reduce receptor signaling over time, and consequently result in the development 
of ligand tolerance [19, 28]. Moreover, the daily consumption of AR antagonist caffeine, in 
coffee, tea, etc., undoubtedly complicates clinical trials studying AR-targeted agents [19, 28]. 
Therefore, despite its medical relevance in various diseases, only a few drugs targeting 







2. Covalent ligands for GPCRs 
Covalent ligands, or affinity labels, are defined as compounds that target a specific receptor 
and feature a reactive moiety that forms a covalent interaction with amino acid residues at or 
near the binding pocket [30, 31]. Covalent tools should ideally be able to first bind to the 
receptor non-covalently with high affinity and then form an irreversible interaction with one 
or more nucleophilic amino acid residues. The archetypical example of a covalent ligand-
GPCR complex is the visual pigment rhodopsin, having the 11-cis-retinal chromophore 
covalently bound via a protonated Schiff’s base [32].  
2.1. Applications of covalent ligands 
Although being one of the largest families of membrane proteins, GPCRs are notoriously 
difficult to study due to their low expression levels, intrinsic fragility and flexibility, and often 
low affinity for their endogenous ligand [33]. Covalent ligands may have the potential to 
address some of these challenges, since they are able to irreversibly bind to GPCRs and 
contribute to the formation of a stable and conformationally homogeneous ligand-receptor 
complex [34]. In this way such ligands have emerged already as a promising strategy to 
facilitate the structure elucidation of GPCRs [31]. For instance, the structures of cannabinoid 
receptor CB1 [35] and adenosine A1 receptor [13] have been resolved in the presence of 
chemo-reactive ligands contributing to the formation of stable and functional ligand-receptor 
complexes. The fact that covalent probes are designed to interact irreversibly with residues 
near the binding site has widened their applications to investigate the topology of the GPCR-
ligand binding pocket, receptor signaling and in vivo research [31]. For example, the covalent 
cannabinoid CB1 receptor agonist, (-)-7-isothiocyanato-11-hydroxy-1,1-dimethylheptylhex 
ahydrocannabinol (AM841), was successfully applied to investigate the ligand binding site in 
the CB1 receptor [36, 37], assess its potential use in physiological and pathophysiological in 
vivo studies [38] and demonstrate the differences in binding motifs between the two 
cannabinoid receptor subtypes, CB1 and CB2 [39]. Given the highly dynamic nature of 
GPCRs and the inherent flexibility of their ligand binding sites, the potential of “freezing” a 
conformational state of the receptor by a covalently linked agonist or antagonist is very 
attractive. Moreover, covalent attachment of the ligand/drug to the receptor will lead to an 
infinitely long residence time or receptor occupancy, and thus might contribute to a sustained 
on-target pharmacological efficacy and minimized off-target effect [1, 40]. From this 






with respect to increased biochemical potency and greater selectivity for the targeted 
receptors.  
2.2. Current state and further challenges 
More recently, covalent probes equipped with a ligation handle, termed affinity-based probes 
(AfBPs), have emerged as valuable tools for chemical biology or proteomics studies to gain 
further insight into receptor localization and target engagement [41-43]. This strategy was 
inspired by earlier activity-based protein profiling-click chemistry (ABPP-CC), which helped 
in visualizing and quantifying the activities of drug targets (mainly enzymes) in native 
biological systems [44, 45]. However, different from mechanism-based enzyme inhibitors, 
covalent ligands targeting GPCRs have no specific active center to target and are generally 
armed with a highly electrophilic moiety responsible for the covalent interaction. The 
abundance of nucleophilic groups in biological systems may cause insufficient target-specific 
cross-linking [46] and induce low coupling selectivity [47]. In addition, the low expression of 
GPCRs also hampers successful execution of this otherwise promising technique.  
 
Figure 3 Schematic representations of two-step affinity-based labeling strategy. A small bio-
orthogonal “ligation handle” is incorporated into a covalent ligand for a GPCR. After binding of the 
probe to the target receptor the tag is introduced by “click chemistry”. The tagged probe-treated 
receptors are either visualized/quantified by in-gel fluorescence scanning or mass spectrometry 
analysis.  
As illustrated in Figure 3, AfBPs provide the opportunity to label specific receptors, as they 
are functionalized probes paired with “clickable” reporter tags (e.g., biotin and/or a 
fluorophore), via a Huisgen 1,3-dipolar cycloaddition, to form a stable triazole-linked product. 
In this affinity-based protein profiling (AfBPP) approach the labeled protein targets are 
separated, visualized or affinity-purified, analyzed via the reporter tag using fluorescent SDS–







endogenous GPCR expression and engagement and may provide engineered biomarkers for 
translational drug discovery. Even though the entire GPCR family contains over 800 
members, until recently only three subtypes including mGlu5 receptor, cannabinoid CB2 
receptor and adenosine A2A receptors have been subject of investigation [41-43], of which the 
A2AR will be the showcase in this thesis. 
3. Aims and outline of this thesis 
In this thesis the development and application of chemical tools and strategies are described to 
study three subtypes of ARs, A1R, A2AR and A3R. Combined, this research approach may 
ultimately aid in the discovery and development of novel adenosine receptor-based 
therapeutics that lack potential side effects as much as possible. 
While Chapter 1 serves as an introduction, Chapter 2 provides a comprehensive overview of 
the molecular probes that have been reported to study adenosine receptor distribution, 
expression levels, occupancy, internalization and pharmacology in both in vitro and in vivo 
models. Chapter 3 describes the development and pharmacological profiling of covalent 
ligands targeting A2AR. The rational design of covalent ligands and a research flow chart to 
investigate irreversible ligand-receptor interactions have been applied to the A1R and A3R 
characterization in Chapters 4 and 5. Chapter 4 describes a design and pharmacological 
profiling of the first non-ribose covalent partial A1R agonist. In Chapter 5, a structure-based 
approach was developed for a compound library based on the existing A3R antagonist 1H,3H-
pyrido[2,1-f]purine-2,4-dione scaffold. The aim of this chapter is to identify a covalent ligand 
targeting the A3R and shed light on the details of its binding site. Chapter 6 reports on the 
development of A2AR covalent ligands into an affinity-based probe. In the end, two-step 
affinity labeling with a ZM241385-based probe for A2AR target identification was established. 
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1. Introduction
Adenosine receptors (ARs), which are activated by their endogenous ligand adenosine, belong
to the Class A family of G protein-coupled receptors (GPCRs). These receptors have been
considered potential therapeutic targets in several disorders, including Parkinson’s disease,
schizophrenia, analgesia, ischemia and cancer [1]. To date, four subtypes of adenosine
receptors have been identified, namely A1, A2A, A2B and A3. Activation of A1 and A3
receptors leads to inhibition of adenylate cyclase trough their interaction with a Gi protein,
whereas A2A and A2B receptors stimulate the enzyme through a GS-linked pathway. Until now,
the 3D-structures of the A1 and A2A subtypes have been elucidated [2, 3]; studies on the A2B
and A3 subtypes have yet to be successful. Although structure elucidation was relatively
successful for adenosine receptors, the membrane-bound GPCRs still prove challenging due
to their low expression in native tissue, and their inherent flexibility and instability once
extracted from the membrane, which is often needed for further structural studies. Over the
past decades a diverse array of molecular probes, bifunctional ligands that can be used to
interrogate receptor structure and function, has proven invaluable in GPCR research. From a
chemical perspective, a molecular probe can be defined as a small molecule that binds the
receptor of interest and enables further studies by virtue of a connected tag or functional
group that exhibits specific properties. These conjugated tags or functional groups include
radioactive or fluorescent moieties to enable studies on ligand-receptor binding as well as the
quantification and visualization of receptors. Moreover, tags containing a reactive warhead
capable of irreversibly binding to the receptor have been shown to facilitate structure
elucidation, and when made bifunctional, i.e. combined with a click handle, these can be used
as affinity-based probes (AfBPs). It emerged as valuable tools for chemical biology or
proteomics studies to gain further insight into receptor localization and target engagement [4-
6]. This strategy was inspired by earlier activity-based protein profiling-click chemistry
(ABPP-CC), which helped in visualizing and quantifying the activities of drug targets (mainly
enzymes) in native biological systems [7, 8]. In this review, various chemical probes for
human adenosine receptors will be summarized.  where we will limit this review to molecular
probes compromising radioligands, fluorescent ligands and covalent ligands.
2. Radioligands for in vitro characterization
Some adenosine receptor agonists and antagonists have been developed in a radiolabeled
(‘hot’) form, so-called radioligands. Often, these are high affinity molecules containing







and quantified. The majority of radioligands used for in vitro assays are labeled with either 
[125I]- or [3H-. [125I]-labeled ligands show a higher specific activity (∼2,000 Ci/mmol) and 
shorter half-life (t1/2 = 60 days) compared to tritium-labeled ligands (specific activity ~ 25-120 
Ci/mmol and t1/2 = 12.5 years), where the latter are more biologically indistinguishable from 
the unlabeled parent ligand. These radiolabeled ligands are predominantly used in saturation 
experiments to measure the radioligand’s equilibrium dissociation constant, KD, and receptor 
expression/density (Bmax), in competition displacement experiments to determine the affinity 
(equilibrium inhibitory constant Ki) of non-labelled (‘cold’) compounds, and in binding 
kinetics assays to determine a ligand’s association (kon) and dissociation (koff) rate constants 
[9, 10]. Conventional radioligand binding assays require a filtration step to separate bound 
from unbound radiolabeled ligands and capture the radioligand-receptor complex. A more 
recently developed bead-based assay, the scintillation proximity assay (SPA), has emerged as 
a rapid and sensitive assay to perform high throughput screens in a homogeneous system. Due 
to the diverse applicability of these techniques in receptor research, a diverse set of 
radioligands for the different AR subtypes has been developed. All radioligands that are 
currently commonly used are summarized in Table 1. 
2.1. Radioligands for the adenosine A1 receptor 
The initial agonist radioligands for A1R were all tritiated adenosine-based derivatives. Among 
them [3H]CCPA (Fig. 1; Table 1) showed highest affinity with a KD value of 0.61 nM for 
human A1R (hA1R) [11]. [3H]LUF5834 is a non-nucleoside partial agonist radioligand  (Fig. 
1; Table 1) with nanomolar affinity ( KD = 2.03 ± 0.52 nM ) for the hA1R [12].  Its partial 
agonistic nature allows this radioligand to bind to both G protein-coupled and -uncoupled 
receptors. This radioligand proved a versatile tool to estimate the efficacy and the mechanism 
of action of both agonists and inverse agonists at the hA1R. 
The reference antagonist radioligand for A1R is the xanthine-derived antagonists/inverse 
agonist [3H]DPCPX (Fig. 1; Table 1) [13]. Although this xanthine derivative displays lower 
affinity at the human (KD = 3.86 nM) [13] than the rat receptor (KD = 0.18 nM) [14], it is still 
a very useful tool for the characterization of A1R and consequently discriminate from other 
subtypes. It has been applied to SPA technology, constituting an alternative platform for real-
time measurements of receptor-ligand interactions on hA1R [15]. Antagonist radioligands 
instead of agonists tend to label all receptors present in a cell membrane preparation 
independent of their coupling to a G protein and are therefore used more frequently in AR 
research, and GPCR research in general.  





2.2. Radioligands for the adenosine A2A receptor 
The reference radioligands for binding assays at A2AR include the adenosine-based agonists 
[3H]NECA (Fig.1 ; Table 1) [13] or [3H]CGS21680 (Fig. 1; Table 1) [16]. [3H]NECA bound 
to hA2AR with a KD-value of 20.1 nM. However, this non-selective radioligand also exhibited 
remarkably high affinity for hA3R with a KD-value of 6 nM, threefold higher than at the A2A 
receptor [13]. Later, a more selective radioligand, [3H]CGS21680 showed a moderate affinity 
for human A2AR with a KD value of 22 ± 0.5 nM and has been used in autoradiographic 
studies, revealing the distribution of the A2AR in the basal ganglia of the human brain and an 
increased hA2AR level in the striatum of schizophrenic patients [17-19]. However, besides its 
agonistic binding with high and low affinity states to the receptor, application of this agonist 
radioligand is further limited due to complex binding characteristics related to non-A2A 
binding sites [20] and enhanced affinity by increasing concentrations of Mg2+ ions [16].  
To avoid the issues occurring with agonistic radioligands, two xanthine-based antagonist 
radioligands [3H]XAC (Fig. 1;Table 1) [21] and [3H]MSX-2 (Fig. 1;Table 1) [22] were 
developed to investigate the A2AR. Though the unlabeled compound XAC showed poor 
selectivity for hA2AR over hA1R (30-fold) and hA3R (90-fold) [13], [3H]XAC was used to 
identify the important residues involved in the hA2AR binding pocket with a KD value of 9.4 ± 
2.3 nM [21]. [3H]MSX-2 is a styrylxanthine-based antagonist which bound selectively to 
rA2AR (KD = 8.04 ± 2.62 nM) [22]. Furthermore, in vitro autoradiography using [3H]MSX-2 
showed the greatest binding in the striatum, which is in line with the expected density of 
A2AR in the mouse, rat and pig brain [23]. A preliminary ex vivo study confirmed that 
[3H]MSX-2 penetrated the blood-brain barrier, which is promising for in vivo use [23]. 
Applications of these styrylxanthine derivatives are limited however, due to the tendency to 
undergo photoinduced isomerization [24]. Meanwhile, two non-xanthine antagonist 
radioligands were developed as well. [3H]ZM241385 (Fig. 1; Table 1) showed a high affinity 
and low non-specific binding to hA2AR[25, 26]. However, this radioligand also binds to A2BR  
with nanomolar affinity (KD = 33.6 ± 2.8 nM) [27]. [3H]SCH58261 (Fig. 1; Table 1) showed a 
better selectivity at the hA2AR (hA2B/hA2A = 8352) than [3H]ZM241385 and was used in 
autoradiographic studies to investigate the receptor distribution in the human brain [17, 28]. 
Similarly, [3H]SCH58261 was applied in ex vivo binding studies to study A2AR receptor 
occupancy of various ligands in mouse brain  [29]. Additionally, this radioligand was applied 
to high throughput ligand screening in a SPA set-up and showed comparable sensitivity to the 







2.3. Radioligands for the adenosine A2B receptor 
So far only one selective agonist radioligand has been described for the A2BR, which is tritium 
labeled BAY 60-6583 (Fig. 1; Table 1) [31]. Unfortunately, the specific binding of [3H]BAY 
60-6583 was too low compared to its high non-specific binding to establish a robust 
radioligand binding assay. Until now the non-selective agonist radioligand [3H]NECA, 
despite its low affinity, remains the only molecular tool available to study the active A2BR 
conformation [31, 32].  
The A1R radioligand [3H]DPCPX (Fig. 1; Table 1) was also reported to bind hA2BR (KD = 40 
nM) and has been used to determine the affinity of competing ligands [33, 34]. Another 
commonly used nonselective radioligand is [125I]ABOPX (Fig. 1, Table 1) [35]. It bound to 
A2BR with moderate affinity (KD = 37 nM) and showed a high specific binding to a hA2BR 
overexpressed cell line. The first A2BR-selective antagonist radioligand is [3H]MRS1754 (Fig. 
1; Table 1), bound to hA2BR with a KD value of 1.13 ± 0.12 nM [36]. Later, another xanthine 
analogue radioligand [3H]MRE-2029-F20 was reported with comparable affinity and 
selectivity [37, 38]. Besides, the pyrrolopyrimidine-derivative, OSIP339391 (Fig. 1; Table 1), 
was labeled with tritium, representing a novel selective and high affinity radioligand for the 
hA2BR [39]. However, all these radioligands showed poor selectivity (less than 100-fold) 
toward the hA1R. More recently, Müller et al. investigated the structure-activity relationships 
of 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthine derivatives, yielding a new and potent 
A2B-selective antagonist, PSB-603 [40]. Tritium labeled PSB-603 (Fig. 1; Table 1) was 
subsequently developed and employed as the first high affinity (KD = 0.403 nM) A2BR-
specific radioligand for receptor pharmacological studies. However, the current xanthine-
based radioactive tracers are highly lipophilic compounds that exhibit unfavorable non-
specific to specific binding ratios; this feature confines their application to receptor studies in 
isolated membranes.  
2.4. Radioligands for the adenosine A3 receptor 
Initially, studies on the human A3R (hA3R) were performed using the non-selective agonist 
radioligand [3H]NECA (Fig.1, Table 1) [13]. For binding studies on the rat A3R (rA3R), 
[125I]I-APNEA (Fig. 1, Table 1) was the preferred radioligand [41]. Though [125I]I-APNEA 
showed reasonable affinity for the rA3R (KD =15.5 ± 2.4 nM), it was shown to be even more 
potent for the rA1R (KD = 1.32 ± 0.35 nM) [41, 42]. Another agonist radioligand, [125I]I-AB-
MECA (Fig. 1; Table 1), showed better affinities for both rA3R (KD = 1.48 ± 0.33 nM) and 
hA3R (KD = 1.86 ± 0.69 nM) [42, 43], but still bound to rA1R in nanomolar range (KD = 3.42 





± 0.43 nM) [42]. To tackle the selectivity challenge, Klotz et al. developed the tritiated 
agonist radioligand [3H]HEMADO (Fig. 1, Table 1) [44], which showed high-affinity (KD = 
1.10 nM) and low non-specific binding (1-2% at KD value) to hA3R. Even though no binding 
on the rat rA3R was observed, the enhanced selectivity versus other AR subtypes (>300 fold) 
made [3H]HEMADO a useful tool for A3R binding assays. Subsequent efforts in finding a 
selective ligand for the rA3R resulted in [125I]MRS1898 (Fig. 1; Table 1). It selectively binds 
to rA3R with an improved KD value of 0.17 ± 0.04 nM [45]. Still, there are some liabilities 
caused by the high non-specific binding. The truncation of the 5’-position of the ribose moiety 
generated the latest A3R agonist radioligand [125I]MRS5127 (Fig. 1; Table 1) with a KD value 
of 5.74 ± 0.97 nM [46]. Its major advantage is the low degree of non-specific binding (27±2% 
at a concentration of 5 nM) and its improved selectivity versus the other AR subtypes. These 
benefits, together with the uniformity of its agonistic nature across species, may render 
[125I]MRS5127 the preferred chemical tool for characterizing the A3R in its active state over 
other radioligands reported previously. It is fair to say though that commercially available 
[125I]I-AB-MECA has emerged as a reference radioligand. 
Until now, only two antagonist radioligands, [3H]MRE-3008-F20 (Fig. 1; Table 1) [47, 48] 
and [3H]PSB-11 (Fig. 1; Table 1) [49], have been reported. While both derivatives selectively 
bind the hA3R at (sub)nanomolar concentrations, [3H]PSB-11 shows a much lower degree of 
non-specific binding (2.5 ± 0.1% at KD value) than [3H]MRE-3008-F20 (ca. 25% at KD value). 
The shortage of these structurally diverse heterocyclic antagonists is their low affinity for the 

























A1      
 [3H]CCPA 0.61 Agonist [13] Y 
 [3H]LUF5834 2.03 Agonist [12, 50] N 
 [3H]DPCPX 3.86 Antagonist [13] Y 
A2A      
 [3H]NECA 20.1 Agonist [13] Y 
 [3H]CGS21680 22 Agonist [19] Y 
 [3H]XAC 9.4 Antagonist [21] N 
 [3H]MSX-2 8.04 Antagonist [22] Y 
 [3H]ZM241385 0.60 Antagonist [26] Y 
 [3H]SCH58261 2.3 Antagonist [28] Y 
A2B      
 [3H]NECA 441 Agonist [31] Y 
 [3H]DPCPX 40 Antagonist [33] Y 
 [125I]ABOPX 37 Antagonist [35] N 
 [3H]MRS1754 1.13 Antagonist [36] Y 
 [3H]MRE-2029-F20 2.8 Antagonist [37] Y 
 [3H]OSIP339391 0.17 Antagonist [39] N 
 [3H]PSB-603 0.403 Antagonist [40] N 
A3      
 [3H]NECA 6.18 Agonist [13] Y 
 [125I]APNEA 15.5 (r) Agonist [42] N 
 [125I]AB-MECA 1.86 Agonist [43] Y 
 [3H]HEMADO 1.10 Agonist [44] Y 
 [125I]MRS1898 0.17 (r) Agonist [45] N 
 [125I]MRS5127 5.74 Partial agonist [46] N 
 [3H]MRE-3008-F20 0.80 Antagonist [47] N 
 [3H]PSB-11 4.9 Antagonist [49] N 
a The data are KD-values for radiolabeled compounds (nM) for the indicated human adenosine 
receptors unless a different species is indicated (r = rat). n.d. = not detectable 
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Fig. 1. Chemical structures of commonly used AR radioligands for in vitro studies. Note: 
unlabeled version was drawn for radioligands with unknown radioisotope position (i.e. [3H]LUF5834 







3. Radioligands for in vivo studies –PET/SPECT tracers 
While β-emitting ligands serve their purpose in in vitro or ex vivo experiments, they are not 
suitable for in vivo application. To that end, positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) scanning have emerged and are noninvasive 
quantitative techniques to measure the receptor distribution and function in vivo. Over the 
years an ever-expanding library of [11C]-, [18F]- and [123I]-labelled radiotracers has been 
developed that enables the determination of receptor binding potentials (BPs) in physiological 
and pathophysiological studies. Though the decay of these isotopes is much faster than is the 
case for [3H]- or [125I]-labeled ligands, the relatively safe γ- and photon-emissions make these 
tracers suitable for physiological applications. SPECT radioisotopes, such as γ-emitting [123I] 
(t1/2 = 13.2 hours), typically have a much longer half-life than PET tracers labeled with [11C] 
(t1/2 = 20.3 minutes) or [18F] (t1/2 = 110 minutes), which allow for longer radiosynthetic 
protocols and enables SPECT imaging to be conducted for longer time periods. Nonetheless, 
PET studies of adenosine receptors have been more widely performed due to the higher 
resolution and sensitivity that can generally be achieved compared to SPECT. In the 
development of radiotracers for ARs, particularly in the brain and central nervous system, it is 
desirable to not only optimize for affinity and low non-specific binding capacity, but also for 
blood−brain barrier permeability. A major challenge is that the short radioligand half-life 
requires on-site synthesis and rapid purification and validation of the probes. PET and SPECT 
imaging times, which are also related to radioligand t1/2, are usually insufficient to allow 
radioligand–receptor binding to reach an equilibrium; therefore, appropriate kinetic models 
should be used to correct for this shortcoming. PET imaging of ARs in vivo, and the 
applications thereof in drug discovery have been comprehensively reviewed [51-53]. Here we 
will focus on the recent applications of clinical PET imaging studies on ARs. 
3.1. PET tracers for the adenosine A1 receptor 
Two xanthine derivatives, [18F]CPFPX (Fig. 2, Table 2) and [11C]MPDX (Fig. 2, Table 2), 
have been extensively employed for the characterization of A1R in human brain and their 
results summarized in several reviews [51, 54]. While [18F]CPFPX has a higher affinity for 
A1R than [11C]MPDX, the latter has been shown to be much more stable againstperipheral 
metabolism. Using these PET tracers, the cerebral distribution of the A1R has been 
successfully visualized and quantified in human brain [55, 56]. From these studies a 
correlation between A1R distribution and aging as well as sleep deprivation was established 
[57, 58]. Additional studies on receptor occupancy using PET tracers, for example 





[18F]CPFPX in a bolus-plus-constant-infusion PET assay, showed that repeated intake of 
caffeinated beverages resulted in a 50% occupancy of the cerebral A1Rs during the day [59]. 
This effect might cause adaptive changes and lead to chronic alterations of receptor 
expression and availability. Furthermore, these PET tracers have been valuable tools for 
clinical studies on neurodegenerative diseases, revealing the functional mechanisms and 
pharmacokinetic profiles of new potential drug treatment strategies. In early Parkinson’s 
disease, increased binding of [11C]MPDX was found in the temporal lobe, suggesting a 
compensatory mechanism of A1R expression in non-dopaminergic systems in response to the 
diminished availability of dopamine [60]. With [18F]CPFPX a phase-and region-specific 
change pattern of A1R expression in Huntington’s disease was detected, providing evidence 
that adenosinergic targets are involved in the pathophysiology of this disease [61]. More 
recently, the first partial agonist PET tracer, [11C]MMPD (Fig. 2, Table 2), was evaluated in 
rat brain [62]. It showed suitable blood–brain barrier (BBB) permeability, high specificity and 
subtype selectivity in vivo. This finding may open new routes to visualize receptor occupancy 
of agonists or partial agonists for the A1R in drug development. 
3.2. PET/SPECT tracers for the adenosine A2A receptor 
Several radioligands for PET imaging of cerebral A2ARs have been introduced since the 
1990s. The initial design of PET tracers for the A2AR started from xanthine-based antagonists, 
leading to the discovery of [11C]TMSX (Fig. 2, Table 2), previously abbreviated as 
[11C]KF18446. Though in vivo imaging of the human brain in healthy controls and in patients 
with Parkinson’s disease (PD) was relatively successful [63, 64], these xanthine derivatives 
are prone to photoisomerization, and thus [11C]TMSX could only be applied in PET scans 
under dimmed light. To circumvent this limitation, the first non-xanthine-based PET tracer, 
[11C]SCH442416 (Fig. 2, Table 2), was designed based on a known precursor, SCH58261. An 
increased binding potential of [11C]SCH442416 was observed in the striatum of Parkinson’s 
patients with levodopa-induced dyskinesias (LIDs), providing evidence that A2AR is a 
potential pharmacological target for the management of LIDs [65]. Since the problem of high 
non-specific binding (and consequential low target-to-non-target ratios) still remains for these 
ligands [66], Zhou et al. incorporated the 11C-radionuclide into clinical candidate preladenant. 
PET imaging in rats showed a high uptake of [11C]preladenant (Fig. 2, Table 2) in the striatum 
and low uptake in other regions of the brain, consistent with cerebral A2A distribution [67]. 
Using [11C]preladenant in clinical PET-studies, receptor occupancy by istradefylline, an 
approved A2AR antagonist, was measured in patients with Parkinson's disease. It was 







resulting in near-maximal (93.5%) occupancy in the ventral striatum, thus establishing the 
dosage regimen of such CNS drugs [68]. Subsequently, to extend the half-life of these tracers, 
18F-labeled A2AR antagonist PET tracers have been investigated for human studies. For 
example, two fluorine-18 labeled SCH442416 analogs, [18F]FESCH (Fig. 2, Table 2) and 
[18F]FPSCH (Fig. 2, Table 2), were reported as PET tracers used to image the A2AR in rat 
brain [69]. [18F]FESCH and [18F]FPSCH showed identical striatum-to-cerebellum ratios (4.6 
at 37 min and 25 min post injection, respectively), similar to the ratio obtained with 
[11C]SCH442416. Other examples are preladenant-based ligands, including a SPECT tracer, 
[123I]MNI-420 (Fig. 2, Table 2) and a PET ligand, [18F]MNI-444 (Fig. 2, Table 2). Both have 
been successfully applied in A2AR-imaging studies in the human brain [70, 71]. [123I]MNI-
420 rapidly entered the human brain and showed the highest specific binding in the striatum, 
consistent with known A2AR densities. [18F]MNI-444 showed an improved binding potential 
in the brain compared to [11C]TMSX and [11C]SCH442416, opening up the possibility to 
more broadly use in vivo A2A PET imaging in neuroscience research. 
3.3. PET tracers for the adenosine A2B receptor 
So far only two radioligands for use in in vivo studies have been developed for A2BR, namely 
1-[11C]”4” (Fig. 2, Table 2) and -[18F]”7a” (Fig. 2, Table 2) [72] [73]. The first compound, 
featuring a triazinobenzimidazole scaffold with moderate potency (IC50 = 210.2 ± 12.3 nM) 
toward A2BR, has been applied in PET studies in rats and showed the highest uptake in brown 
adipose tissue, lungs and testes [72]. With a high chemical stability and good pharmacokinetic 
profile, this tool compound represented a good lead for the development of A2BR radiotracers. 
The second A2BR PET tracer was developed on a pyrazine-based antagonist with the potential 
to penetrate the blood-brain barrier [73]. Despite poor selectivity (A2A/A2B=13, A1/A2B=5) this 
radiolabeled ligand was further evaluated for its in vivo pharmacokinetic profile, revealing the 
formation of a radio-metabolite capable of penetrating the blood-brain barrier. With these 
PET studies the stage is set for further A2BR probe design to enhance the selectivity and 
metabolic stability.  
3.4. PET tracers for the adenosine A3 receptor 
The first PET tracer for A3R was developed by radiofluorination FE@SUPPY (Fig. 2, Table 
2), a selective and potent antagonist for hA3R [74, 75]. Though it had already been shown for 
the parent compound that the affinity for rat A3R was 140 fold lower than for human A3R, 
[18F]FE@SUPPY was studied for its biodistribution in rats and specific binding in the rat 
brain was demonstrated using autoradiography [76]. A further preclinical PET study using 
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[18F]FE@SUPPY to image A3R revealed a pronounced uptake in xenografted mice injected 
with cells overexpressing human A3R. This “humanized animal model” inspired to evaluate 
[18F]FE@SUPPY in mice xenografted with a human colorectal cancer cell line (HT-29) 
overexpressing A3R as a tumor marker. Unfortunately, this study to visualize the A3R in vivo 
was unsuccessful, presumably due to insufficient uptake of [18F]FE@SUPPY in the tumors, 
poor conservation of target expression in xenografts or unfavorable pharmacokinetics of the 
tracer in mice [77]. In analogy to this, [18F]FE@SUPPY:2 (Fig. 2, Table 2) was developed by 
transforming the fluoroethylester into a fluoroethylthioester [78]. While a higher specific 
radioactivity was obtained ([18F]FE@SUPPY:2 = 340 ± 140 GBq/mol and [18F]FE@SUPPY 
= 70 ± 26 GBq/mol), the uptake pattern for the two PET tracers is distinct. Especially brain to 
blood ratios are remarkably increased over time for [18F]FE@SUPPY whereas those for 
[18F]FE@SUPPY:2 stayed unaltered. Lastly, a pair of structurally similar ligands (i.e. agonist 
MRS3581 and antagonist MRS5147) were reported as [76Br]-labeled potential PET 
radiotracers [79]. Both ligands showed similar biodistribution in rats: primarily uptake in the 
organs of metabolism and excretion. However, the uptake of agonist [76Br]MRS3581 (Fig. 2, 
Table 2) was an order of magnitude faster than that of antagonist [76Br]MRS5147 (Fig. 2, 
Table 2), possibly due to the presence of a uronamide group in the agonist to influence its 
bioavailability and permeation in vivo. In contrast, the antagonist [76Br]MRS5147 
demonstrated an increased uptake in rat testes, an A3R-rich tissue, suggesting that the 
antagonist may also serve as a viable diagnostic molecular probe for pathological conditions 











A1 A2A A2B A3 
A1        
 [18F]CPFPX 1.26 940 N.D. N.D. Antagonist [51] 
 [11C]MPDX 4.2 (r) 
>100 
(r) 
N.D. N.D. Antagonist [51] 










1600 (r) 5.9 (r) N.D. N.D. Antagonist [80] 
 [11C]SCH442416 1.11 0.05 >10,000 >10,000 Antagonist [81] 








 [18F]FPSCH 1000 53.6 N.D. 1320 Antagonist [84] 
 [18F]MNI-444 N.D. 2.8 N.D. N.D. Antagonist [85] 
 [123I]MNI-420 N.D. 2.0 N.D. N.D. Antagonist [85] 
A2B        
 [11C]”4” 230.3 548.0 210.2 N.A. Antagonist [72] 
 [18F]”7a” 19.0 55.0 4.24 796 Antagonist [73] 
A3        
 [18F]FE@SUPPY 4030 1720 N.D. 6.02 Antagonist [77] 
 [76Br]MRS3581 N.D. N.D. N.D. 0.63 Agonist [79] 
 [76Br]MRS5147 N.D. N.D. N.D. 0.62 Antagonist [79] 
a The data are KD-values of radiolabeled compounds for human adenosine receptors unless otherwise 
indicated (r= rat) or % inhibition at the indicated concentration in bracket. N.D. = not determined, 
N.A. = not active 
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4. Fluorescent probes 
As an alternative to radiolabeled molecular probes, fluorescent ligands have also been 
included into the pharmacological toolbox. This approach avoids the safety concerns 
associated with the disposal of radioisotopes and also provides the opportunity of a “real-
time” readout of the ligand-receptor interaction. Fluorescent ligands for GPCRs are usually 
designed by incorporating a relatively small organic fluorophore, such as a BODIPY-, Alexa 
Fluor-, rhodamine-, or NBD (nitrobenzoxadiazole) moiety into an existing GPCR agonist or 
antagonist pharmacophore via a linker. The use of these fluorescent probes can provide more 
insight in receptor localization, function and regulation, but also  onligand-target binding 
kinetics, thus contributing to a detailed understanding of receptor physiology and 
pathophysiology. In addition, the development of newer fluorescent methods and techniques, 
such as scanning confocal microscopy (SCM), fluorescence polarization (FP), fluorescence 
correlation spectroscopy (FCS), resonance energy transfer (FRET or BRET) and flow 
cytometry (FCM), are boosting the potential use of fluorescent probes in drug discovery. The 
development of fluorescent ligands to characterize adenosine receptors has been the subject of 
intense investigation, which has been summarized in detail by Kozma et al. in 2013 [86]. 
Here we will therefore summarize and review emerging fluorescent ligands for more recent 
applications on ARs. 
4.1. Fluorescent ligands for the adenosine A1 receptor 
To monitor ligand binding to receptors on the surface of living cells, a Nano-luciferase 
(NanoLuc) BRET methodology (NanoBRET) has recently been established [87-89]. This 
approach was also applied to a study of allosteric modulators in intact living cells using 
fluorescent A1R agonists, such as the adenosine-based agonist, ABA-X-BY630 (Fig. 3, Table 
5), and two NECA-based ligands, ABEA-X-BY630 (Fig. 3, Table 5) and BY630-X-(D)-A-
(D)-A-G-ABEA (Fig. 3, Table 5) [90]. The two positive allosteric modulators tested were 
shown to increase the specific binding of the fluorescent A1R agonists, indicative for a switch 
of the A1R population to a more active receptor conformation.  
4.2. Fluorescent ligands for the adenosine A2A receptor 
MRS5424 (Fig. 3, Table 5) is a fluorescent adduct of agonist APEC with Alexa Fluor 532. 
Using this probe, allosteric modulation within A2AR/D2R heterodimers was followed using 
real-time FRET [91]. A negative allosteric effect on A2AR ligand binding and receptor 
activation was found when the D2R agonist quinpirole was added. This heterodimer 
interaction was further validated in a higher-throughput flow cytometry-based assay with the 
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fluorescent agonist MRS5206 (APEC-Alexa Fluor 488) (Fig. 3, Table 5) [92]. These 
experiments provided evidence for a differential D2R-mediated negative allosteric modulation 
of A2AR agonist binding, in particular for apomorphine, a drug used in the treatment of PD. 
Recently, using a fluorescence polarization assay, McNeely et al. employed a fluorescent 
agonist, FITC-APEC (Fig. 3, Table 5), to characterize the binding kinetics of three hA2AR 
ligands [93, 94]. The kinetic parameters of these unlabeled ligands, computed using a 
numerical solution approach, showed good consistency with those determined in a 
conventional radioligand binding assay.   
Endeavors to enhance selectivity towards hA2AR and improve the physicochemical properties 
of fluorescent ligands led to the discovery of MRS7416 (Fig. 3, Table 5), which is based on 
the antagonist SCH442416 [95]. As a fluorescent tracer, MRS7416 displayed low nonspecific 
binding at hA2AR in flow cytometry experiments. From molecular docking studies the 
researchers suggested that the fluorescent AlexaFluor488 moiety present in MRS7416 is 
binding to the hydrophilic extracellular loops of the receptor. This would make the probe 
essentially ‘bitopic’, i.e. bridging two separate domains of the hA2AR.  
4.3. Fluorescent ligands for the adenosine A2B receptor 
The first selective A2B fluorescent ligand reported, PSB-12105 (Fig. 3, Table 5), was 
synthesized by integrating a BODIPY moiety into the pharmacophore of 8-substituted 
xanthine derivatives [96]. Besides fluorescently labeling CHO cells expressing recombinant 
human A2BR, this ligand was used to establish an A2BR binding assay on living cells in a flow 
cytometry set-up.  Barresi et al. reported on another series of (non-selective) fluorescent 
antagonists for labeling A1Rs and A2BRs [97]. In one of the ligands a fluorescent group, 7-
nitrobenzofurazan group (NBD) (Fig. 3, Table 5), was linked to a triazinobenzimidazole 
scaffold. This fluorescent antagonist showed a clear labeling of bone marrow-derived 
mesenchymal stem cell membranes, which was largely prevented by pre-incubation with 
selective agonists for A1R and A2BR. These findings provide an important basis for the design 
of novel fluorescent ligands to monitor the expression and localization of A2BR in living cells.  
4.4. Fluorescent ligands for the adenosine A3 receptor 
The non-selective A1R/A3R antagonist, CA200645, was employed as a tool compound to 
develop a robust competition binding assay to e.g., screen for new chemical templates and 
fragments for A3R at a live cell high content screening system [87, 88]. Besides, CA200645 
was also applied to study the A3R localization on intact human neutrophils. It appeared that 







[98]. Modification of the linker component in CA200645 by the insertion of a dipeptide 
yielded two A3-selective fluorescent ligands, BODIPY 630/650-X-Tyr-Ser-XAC (Fig. 3, 
Table 5) and BODIPY FL-X-Tyr-Ser-XAC (Fig. 3, Table 5) [99]. Both ligands showed 
displaceable membrane binding with little non-specific binding in a fluorescent confocal 
microscopy set-up.  
Fig. 3 Chemical structures of recent fluorescent tools for ARs 
A similar strategy to incorporate a (three amino acid) peptide linker was applied to an existing 
non-selective adenosine-based fluorescent agonist, ABEA-X-BY630, yielding the highly 
potent fluorescent agonist BY630-X-(D)-Ala-(D)-Ala-Gly-ABEA at A3R [100]. This probe 
was used to visualize the internalization of YFP-tagged as well as untagged receptors, and 
appeared to promote the formation of intracellular receptor-arrestin3 complexes. In addition, 
click chemistry serves as a versatile approach to simplify compound synthesis, as it provides 
the means for facile incorporation of fluorescent tags. CGS15943, a triazolo-quinazoline 
antagonist scaffold, was extended with an alkyne moiety to be click-conjugated with Alexa 
Fluor-488, yielding a selective A3R fluorescent probe, MRS5449 (Fig. 3, Table 5) [101]. In 
Molecular Probes for the Human Adenosine Receptors 
37
flow cytometry this molecular probe was used to quantify hA3R and to perform ligand 
screening in intact cells.  
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MRS5449 87.0b 73.0b N.D. 6.4b Antagonist [101]
a The data are pKD-values for compounds for the indicated human adenosine receptors. N.D. = not 
determined 
a KD-value at the bovine adenosine A2A receptor 
b Data are Ki-values of compounds (nM) for the indicated human adenosine receptors or % 
displacement at the indicated concentration in brackets.  
c cAMP production in CHO cells expressing human A2BR at the concentration of 10 nM compound in 
the presence of 100 nM of NECA. Data are expressed as percentage of cAMP production versus 
agonist maximal effect (100%). 
d Data are pKi-values for human A1R from radioligand binding assay.  
5. Covalent ligands
Another class of molecular probes is formed by covalent ligands. The term covalent here
refers to the ability of these compounds to bind the receptor irreversibly by forming a covalent
bond to a specific amino acid residue located at or near the ligand binding site [102]. Some
different considerations can be made depending on the type of covalent interaction induced.







and decrease non-specific or off-target binding, thus improving specific covalent labeling 
[103]. Two types of covalent ligands have been developed until now: electrophilic and 
photoreactive ligands. Choosing the correct functional group (or warhead) that can react with 
the amino acid residues present in the binding site is essential for successful molecular probe 
design. Photoreactive ligands possess a light-sensitive group, such as aryl azide, diazirine or 
benzophenone, which can be irradiated with light of a specific wavelength to yield highly 
reactive nitrene, carbene or benzophenone-derived diradicals. These reactive species can 
subsequently form a covalent bond with a neighboring amino acid residue through a variety of 
insertion reactions [104]. Photoreactive ligands, occasionally combined with mass 
spectometry, have been applied in GPCR research to determine the binding site of ligands and 
to identify the partner-receptor for orphan ligands [105]. When combined with a radioactive 
label, photoaffinity probes emerge, which can be used to study GPCR localization using 
autoradiography [106]. Electrophilic ligands on the other hand possess a reactive electrophile 
as a warhead, such as (iso)thiocynate, sulfonyl fluoride or a Michael acceptor like acrylamide. 
These electrophiles react with nucleophilic amino acid residues such as lysine, serine and 
cysteine near the binding site of the ligand. When combined with in silico modeling and site-
directed mutagenesis studies, these chemo-reactive ligands often enable characterization of 
the GPCR-ligand binding site. Additionally, electrophilic covalent ligands have been applied 
to study receptor reserve, turnover and subtype discrimination [107, 108]. Lastly, binding of a 
covalent ligand stabilizes the receptor into an active or inactive conformation, which in turn 
facilitates crystallization of the receptor-ligand complex. This aids in crystallization studies 
using X-ray or cryoEM, providing valuable insights into the structure and function of GPCRs 
[109]. A prime example of this is the case of the human adenosine A1 receptor which was 
recently co-crystallized with covalent antagonist DU172 [3]. There are numerous reported 
covalent ligands for adenosine receptors that have in some way contributed to the 
characterization of these receptors and their ligand binding sites. These ligands will be 
summarized below and their applications will be discussed. 
5.1. Covalent ligands for the adenosine A1 receptor 
Arguably the first example of photoaffinity labeling of an adenosine receptor dates back to 
1985 when N6-2-(4-aminophenyl)ethyladenosine (APNEA), a nonselective adenosine-based 
agonist with high affinity for both A1R and A3R, was coupled to the A1R [110]. In an attempt 
to characterize the A1R structure, radioiodinated [125I]APNEA (Fig. 4, Table 4) was incubated 
with A1R and reacted with crosslinking reagent N-hydroxysuccinimidyl 6-(4-Azido-2-
nitrophenylamino)hexanoate (SANPAH) in situ  . Subsequent UV-irradiation resulted in a 38 
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kDa protein being covalently labeled with the radioligand in rat cerebral cortex and adipocyte 
membranes. Since this process was completely blocked by co-incubating with a selective A1R 
agonist, this protein was designated as A1R. Strictly speaking, this radioactive ligand is 
obviously not inherently photo-reactive and thus not a photoaffinity probe per se. 
Interestingly, in the same year efforts to develop an inherently photoreactive ligand based on 
the R-PIA scaffold, one of the most selective A1R agonists, were successful. A 
photoactivatable azido group was positioned at the purine core structure, generating the 
photolabile ligand R-AHPIA (Fig. 4, Table 4) [111]. It exhibited similar affinity (Ki = 1.5 nM) 
and efficacy (EC50 = 35 nM) as its parent compound, R-PIA, but after photoactivation it 
showed irreversible inhibition of approximately 40% of the receptor binding sites. Such 
covalent labeling of A1R led to a concentration-dependent reduction of cellular cAMP levels, 
consistent with activation of rA1R and correlating with receptor occupancy [112]. Similar to 
the case of APNEA, when R-AHPIA was radioiodinated to yield [125I]AHPIA (Fig. 4, Table 
4), SDS-PAGE analysis of rat brain membranes that were incubated with this covalent 
radioligand and UV-irradiated, showed the appearance of a single protein band of ~35 kDa 
[111]. Interestingly, even though R-AHPIA is about 60-fold selective for the A1R, it is also a 
partial agonist at the A2AR, and pretreatment with R-AHPIA reduced the stimulatory effect of 
NECA, indicating persistent binding of the ligand and subsequent reduced activation by a full 
agonist. [113]. In the search for covalent antagonists, 4-azidophenethyl xanthine derivative 
[125I]BW-A947U (Fig. 4) was synthesized and optimization (analogous to the development of 
selective A1R antagonist DPCPX) gave the next photoactivatable antagonist, [125I]azido-BW-
A844U (Fig. 4, Table 4) [114-116]. Both ligands are xanthine-based antagonists that have a 
light-sensitive aryl azide located on the xanthine 3-position. Photoaffinity labeling of partially 
purified receptor with [125I]azido-BW-A844U followed by chemical or enzymatic 
fragmentation experiments demonstrated that the covalently modified amino acids were 
located at transmembrane domain III of the A1R. This approach provided clear insight into the 
amino acids surrounding the binding pocket of the A1R and thus aided in the development of 
three-dimensional models of the receptor. 
Initial attempts in the development of chemo-reactive agonist ligands for the A1R were 
focused on functionalizing the adenosine scaffold with isothiocyanates or sulfonyl fluorides to 
serve as warheads [117, 118]. In the first reported case, p- and m-DITC-ADAC (Fig. 4, Table 
4), both adenosine derivatives with nanomolar affinity substituted on the N6-position with an 







concentration both ligands irreversibly occupied approx. half of the A1R binding sites. In a 
functional cAMP accumulation assay both agonists elicited a sustained, antagonist-
insensitive, A1R-mediated response. Since the incorporation of a warhead via the N6-position 
of the adenosine scaffold was well tolerated and showed no negative effect on the ligands’ 
affinities, a series of adenosine derivatives bearing diverse linker types and warheads were 
synthesized and examined. Two promising compounds, isothiocyanate 15b and sulfonyl 
fluoride 15d (Fig. 4, Table 4), were validated as irreversible agonists promoting persistent 
A1R-mediated guanine nucleotide exchange activity in a manner resistant to both agonist and 
antagonist addition [118]. Furthermore, these two ligands demonstrated their capacity to 
thermo-stabilize purified, detergent-solubilized A1R in a ThermoFluor assay to a significantly 
higher degree than the high affinity agonist NECA could. These thermostabilized receptors 
with covalently bound ligands allowed purification of the receptor in a monodisperse state, 
which greatly facilitated structure determination by X-ray crystallography [118].  
 
Fig. 4 Chemical structures of covalent ligands for A1R 
With respect to chemo-reactive antagonists two approaches have been explored, both starting 
from the xanthine scaffold. The first class comprises the 8-substituted 1, 3-dipropylxanthines 
[117]. One such compound is m-DITC-XAC (Fig. 4, Table 4), an isothiocyanate derivative of 
the relatively non-selective AR antagonist XAC. It was found to be a potent A1R antagonist in 
rat brain (Ki = 2.39 ± 0.35 nM), and was used to study the receptor reserve in guinea pig 
atrioventricular nodes [120]. In the second approach the electrophilic fluorosulfonyl group 





was placed on the 3-position of the xanthine core, as was done in covalent tool FSCPX (Fig. 
4, Table 4) [121]. This compound had a good affinity for the A1R (IC50 = 10 ± 3 nM) and 
treatment with 10 or 50 nM FSCPX led to reductions in the available A1R binding sites of 
60% and 74%, respectively. In a follow-up study it demonstrated that FSCPX irreversibly 
antagonized cardiac A1R-mediated responses. Subsequently it was shown that FSCPX was 
unable to significantly decrease the maximal direct inotropic response to four A1R full 
agonists (NECA, CPA, CHA and adenosine) in guinea pig atria, which demonstrated a 
considerable A1R reserve for direct negative inotropy [122]. In in vivo experiments, FSCPX 
was used successfully as a “receptor knock-down” tool when IV-infusion of FSCPX in 
conscious rats attenuated CPA-mediated bradycardia [123]. As the ester bond present near the 
warhead of FSCPX is prone to hydrolysis, a follow-up structural modification was performed 
with a focus on linker types [124, 125]. This resulted in a closely related analog with 
improved stability, DU172 (Fig. 4, Table 4). The affinity of DU172 (IC50 = 24.9 ± 7.6 nM) 
was in line with that of FSCPX and pretreatment of DDT1 MF2 cells with DU172 resulted in 
a concentration-dependent decrease in the A1R binding sites, indicating that it behaved as an 
irreversible ligand indeed. This covalent ligand-receptor interaction has been the basis for the 
structure elucidation of A1R due to improved receptor stability [3].  
5.2. Covalent ligands for the adenosine A2A receptor 
For the A2AR initial characterization of the receptor was aided by a radio-iodinated analog of 
APEC, a prototypical ribose-based selective A2AR agonist. Similar to the initial A1R studies, 
[125I]PAPA-APEC (Fig. 5, Table 4) was cross-linked to the A2AR in bovine striatal 
membranes using SANPAH and was shown to covalently label a 45-kDa protein [126, 127]. 
Both NECA and R-PIA were able to prevent the covalent labeling of the 45-kDa protein by 
[125I]PAPA-APEC, providing evidence that this protein is the A2AR indeed. Subsequently, the 
photoactivatable azido analog [125I]azido-PAPA-APEC (Fig. 5, Table 4) was developed and 
was used to directly label the same 45-kDa protein in bovine striatal membranes with 3-fold 
greater efficiency of photo-incorporation [128]. A further characterization of the binding 
domain was performed by Piersen et al., who performed photoaffinity labeling of the canine 
A2AR overexpressed in COS M6 cells with [125I]azido-PAPA-APEC and tracked the cross-
linked transmembrane domain V [129]. However, no individual amino acid residues 
responsible for the covalent interaction were identified. These studies were later repeated with 
a novel adenosine-based radioligand [125I]APE, which showed less hydrophobic interactions 
than [125I]PAPA-APEC and had higher specific radioactivity than [3H]CGS21680 [130]. Its 







striatal membranes (KD = 1.7 ± 0.5 nM), and photolabeling identified a protein of 45 kDa that 
displayed the appropriate pharmacology of the A2AR. More recently, photoaffinity labeling is 
often combined with mass spectrometry analysis to map detailed ligand-receptor binding 
sites. Muranaka et al. incorporated the trifluoromethyl diazirine group into a not-so-A2AR-
selective SCH58261 analogue to give photoaffinity ligand NUMBER 9 (Fig. 5, Table 4) [131-
133]. When purified hA2AR was photolabeled with this ligand and subjected to protease 
digestion, cross-link positions were identified with LC-MS/MS. The most likely amino acid 
candidate for this ligand was Y2717.36 in transmembrane domain VII. This is the first reported 
case in which the cross-linked amino acid was elucidated by mass spectrometry, which 
demonstrates the power of combining mass spectrometry–based proteomics and covalent 
labeling in the elucidation and characterization of GPCR ligand binding sites. 
 
Fig. 5 Chemical structures of covalent ligands for A2AR 
Analogous to the photo-reactive ligands, APEC also served as a parent ligand for the initial 
design of chemo-reactive ligands for A2AR. One exemplary compound is p-DITC-APEC (Fig. 
5, Table 4), which has a reactive 4-isothiocyanatophenyl residue attached to the C-2 
substituent of the purine ring [127]. It had good affinity (Ki = 7.1 ± 2.3 nM at bovine A2AR) 
[127] and, at a concentration of 100 nM, irreversibly blocked 77% of [3H]CGS21680 binding 
in rabbit striatal membranes [134]. In isolated, perfused guinea pig hearts treatment with p-
DITC-APEC caused a prolonged, persistent, and concentration-dependent coronary 
vasodilatation, which is evidence of an irreversible activation of A2AR [135]. More recently, 
Molecular Probes for the Human Adenosine Receptors 
43
an APEC-analogue bearing an active 2-nitrophenyl ester was synthesized (MRS5854, Fig. 5, 
Table 4). This ligand was designed to bind to the receptor irreversibly and subsequently 
transfer its terminal acyl group to a nucleophilic amino acid residue on extracellular loop 2 
(ECL2) of the A2AR [136]. This acyl transfer would prevent the ECL2-lysine-mediated 
recognition of ligands, effectively blocking the receptor. Preincubation of hA2AR with 
MRS5854 followed by extensive washing indeed showed near-complete inhibition of 
radioligand binding. When ECL2-lysine K153 was mutated to an alanine residue, a partial 
restoration of Bmax was observed after treatment with MRS5854, confirming that K153 is the 
anchor point for the covalent interaction. Interestingly, the KD for the radioligand used 
([3H]ZM241385) was not significantly influenced by this mutation, indicating that the 
targeted lysine residue is not important for ligand binding and that acyl transfer seems to 
prevent binding by blocking entry to the binding pocket instead of preventing the recognition 
of ligands. In parallel, the active acyl was replaced by an azido-pentanoate group to generate 
MRS5854-azide. Though this ligand showed diminished affinity towards the A2AR, it 
nevertheless showed a slight reduction in Bmax, suggesting that at least part of the receptors 
were covalently labeled with the azido-pentanoate. This azido-group could allow for click-
ligation to functionalized alkynes; however, biologic data has not yet been reported.  
Three approaches have been taken to develop electrophilic covalent probes for the A2AR. The 
first example is ISC (Fig. 5, Table 4), an isothiocyanate-functionalized xanthine-based 
antagonist for A2AR, which irreversibly binds to 80% of rA2AR at 20 µM [137]. A second 
approach yielded FSPTP (Fig. 5, Table 4), the para-fluorosulfonyl derivative of SCH58261, 
which was used to investigate the level of A2AR reserve [138]. More recently, our research 
group used the molecular structure of the antagonist ZM241385 as a starting point for the 
design of a third electrophilic covalent ligand. This endeavor yielded LUF7445 (Fig. 5, Table 
4), a potent fluorosulfonyl-equipped antagonist with an apparent affinity for the hA2AR in the 
nanomolar range (pKi = 8.99 ± 0.008) [139]. Aided by site-directed mutagenesis studies, it 
was shown that LUF7445 binds to K153ECL2, the same residue that was also involved in the 
acyl transfer of covalent agonist MRS5854. After optimization of the chemical structure, the 
most potent ligandwas retained for further structural modification and was equipped with an 
alkyne click handle (next to the warhead), resulting in the bifunctional probe LUF7487 (Fig. 
5, Table 4) [6]. This affinity-based probe made it possible to visualize the receptor on SDS-
PAGE via click-ligation with a sulfonated Cy-3 fluorophore. The hA2AR was successfully 







for the further development of probes to study GPCRs. The development of affinity-based 
probes may open the door for the identification and target validation of GPCRs in a more 
native environment. 
5.3. Covalent ligands for the adenosine A3 receptor 
While there are no photo-reactive or chemo-reactive ligands available for the A2BR (i.e. the so 
far least studied AR in general), the case for the A3R is also still rather minimal. No photo-
reactive ligands and only four “classes” of chemo-reactive ligands are available for the A3R. 
MRS1163 (Fig. 6, Table 4), the only irreversibly binding agonist for the A3R, was derived 
from the selective A3R agonist IB-MECA [140]. It features a chemo-reactive isothiocyanate 
moiety, which replaced the iodine substituent on IB-MECA, and showed an apparent Ki value 
in the low nanomolar range (10.0 ± 2.3 nM), which is comparable to IB-MECA. Treatment of 
rA3R with 100 nM of MRS1163 led to a 41% loss in the available receptor binding sites and 
its irreversible nature was demonstrated by the lack of recovery of A3R binding sites after 
extensive washing.  
 
Fig. 6 Chemical structures of covalent ligands for A3R. Note: LUF7714 is a reversible control ligand for 
LUF7602. 
Using a “functionalized congener approach” the Jacobsen group developed an electrophilic 
antagonist for the A3R based on the 1,4-dihydropyridine template, a selective A3R scaffold. A 
fluorosulfonyl-substituted phenyl group was installed on MRS1191, thereby generating the 
functionalized congener SO2F-MRS1191 (Fig. 6, Table 4) [141]. It was reported to possess 
greatly improved affinity (2.42 ± 0.32 nM) over the corresponding sulfonamide compound, 
which displayed moderate potency of only 0.292 ± 0.030 µM. When 100 nM of compound 19 
was incubated with hA3R-transfected HEK-293 cell membranes, approximately 56% of the 
hA3R binding sites were irreversibly occupied. A second covalent antagonist was generated 
based on MRE-3008-F20, a highly potent and selective A3R antagonist [142]. By replacing 
the methoxy group in MRE-3008-F20 with a sulfonyl fluoride moiety an irreversibly binding 
derivative, SO2F-MRE-3008-F20 (Fig. 6, Table 4), was synthesized. At a concentration of 
100 nM, SO2F-MRE-3008-F20 inhibited binding of the radioligand [125I]AB-MECA by 79%. 
By docking the ligand in a homology model of the A3R, it was speculated that two amino 
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acids, Cys251 or Ser247, are the most probable binding partners for covalent interaction. 
Recently, our group used a chemical structure-based approach to design covalent antagonists 
for the hA3R [143]. A series of tricyclic xanthine-derived ligands bearing a fluorosulfonyl 
warhead and varying linkers was synthesized. The most potent ligand, LUF7602 (Fig. 6, 
Table 4) had high affinity for the hA3R (pKi = 8.0 ± 0.05). Additionally, a nonreactive 
methylsulfonyl derivative LUF7714 was developed as a reversible control compound. A 
series of assays, comprising of time-dependent affinity determination, washout experiments, 
and [35S] GTPγS binding assays, then validated LUF7602 as a covalent antagonist. Based on 
homology-docking, tyrosine Y2657.36 was identified as potential covalent anchor and when 
this residue was mutated to phenylalanine the mutant receptor displayed a significant decrease 
in affinity for LUF7602 (pIC50 = 7.8 ± 0.05 for hA3R-WT, pIC50 = 6.0 ± 0.3 for hA3R-
Y2657.36F), while the affinity of LUF7714 (pIC50 = 5.9 ± 0.2 for hA3R-WT, pIC50 = 6.0 ± 0.1 
for hA3R-Y2657.36F) was unaltered. It is worth mentioning that this particular tyrosine residue 
is conserved amongst adenosine receptors, and is also the anchor point of DU172, the 
aforementioned covalent antagonist for the hA1R [124]. Hence, this tyrosine residue 
potentially represents a universal anchor point for covalent probes designed for adenosine 
receptors. In general, covalent probes, supported by molecular modeling and site-directed 
mutagenesis, can serve as powerful tools to characterize the spatial orientation and 











A1 A2A A2B A3 
A1        
 [125I]APNEA 
KD = 2 nM  
(r) 
N.D. N.D. N.D. Agonist [110] 
 R-AHPIA 
1.6 nM  
(r) 
N.D. N.D. N.D. Agonist [110] 
 [125I]AHPIA 
KD = 2 nM  
(r) 




KD = 0.14 nM 
 (b) 
N.D. N.D. N.D. Antagonist [116] 
 p- DITC-ADAC 
0.469 nM  
(r) 
191 nM  
(r) 
N.D. N.D. Agonist [117] 
 m-DITC-ADAC 
0.867 nM  
(r) 
176 nM  
(r) 
N.D. N.D. Agonist [117] 
 m-DITC-XAC 
2.39 nM  
(r) 
343 nM  
(r) 
N.D. N.D. Antagonist [117] 
 FSCPX IC50 = 11.8 nM IC50 = 1200 nM N.D. N.D. Antagonist [124] 
 DU172 IC50 = 21 nM IC50 = 2.8 nM N.D. N.D. Antagonist [124] 




N.D. KD = 1.2 nM N.D. N.D. Agonist [128] 
 [125I]AzPE N.D. KD = 1.7 nM N.D. N.D. Agonist [130] 
 NUMBER 9 N.D. 39.7 nM N.D. N.D. Agonist [133] 
 p-DITC-APEC 
276 nM  
(r) 
35 nM  
(r) 
N.D. N.D. Agonist [127] 
 MRS5854 500 nM 23.0 nM N.D. 207 nM Agonist [136] 
 MRS5854-azide 
30% 
(10 μM ) 
4360 nM N.D. 1810 nM Agonist [136] 
 ISC 20.3 µM 111 nM N.D.  Antagonist [137] 
 LUF7445 372 nM 1.0 nM 
0%  
(1 μM) 
49 nM Antagonist [139] 
 LUF7487 19.1 nM 1.5 nM N.D. 60 nM Antagonist [6] 
A3        
 MRS1163 
145 nM  
(r) 
272 nM  
(r) 
N.D. 




41 % (100 μM) 
(r) 
20% (100 μM) 
(r) 
N.D. 2.42 nM Antagonist [141] 




 LUF7602 79 nM 1.3 μM 
0% (10 
μM ) 
10 nM Antagonist [143] 
aThe data are apparent affinities for the human adenosine receptors or % displacement at the concentration 
in brackets unless indicated otherwise (r = rat, b =bovine). N.D. = not determined 





6. Concluding Remarks 
Molecular probes, including radioligands, fluorescent and covalent ligands, are important tool 
compounds that facilitate the biochemical and structural investigation of GPCRs. As shown in 
this review, these probes provide information about the nature of adenosine receptors, next to 
a deeper understanding of receptor regulation and the pathological /physiological roles of this 
GPCR subfamily. In particular, when combined with other techniques such as receptor 
mutagenesis, X-ray crystallography and homology modelling, these tools provide a powerful 
platform for molecular receptor pharmacology.  
Radioligands are the most developed tools for GPCRs. An established standard radioligand 
binding assay provides crucial and reliable measurements of GPCRs interacting with their 
synthetic ligands as well as newly developed probes. The choice of radioligands may 
influence the quantitative information about the measurement. Binding of an agonist 
radioligand may reveal different apparent affinity states depending on the receptor states (i.e. 
G protein-coupled and G protein-uncoupled) or cell-dependent effector coupling. Thus, 
antagonist radioligands are generally considered more acceptable in receptor classification 
than agonists. Among the adenosine receptors, there is still an urgent need for the 
development of better antagonist radioligands for the A2BR and A3R with high affinity with 
KD values of 1 nM or less, with low non-specific binding and better selectivity. For in vivo 
assays, the development of PET ligands targeting A2BR and A3R has still been limited to 
receptor occupancy studies, biodistribution or pharmacokinetic characterization, while PET 
ligands for A1R and A2AR have blossomed in clinical studies, particularly for neurological 
disorders. Studies on A2BR and A3R are generally considered to be hampered by the low 
expression level of these receptors in endogenous tissue, insufficient affinity of the tool 
compound and unclear mechanisms involved in the receptor function. It is anticipated that 
continued efforts to develop high-affinity and selective PET tracers for adenosine receptors 
will further our understanding of the role these receptors have in disease conditions. 
Concerns about radiation safety and shelf life have fueled the continuing interest in small-
molecule fluorescent tools. Recent examples summarized in this review demonstrate that 
fluorescent probes represent an alternative approach to investigate AR characteristics. 
However, their use is still sub-optimal due to the often high level of non-specific membrane 
binding brought by the hydrophobic pharmacophore and fluorophore. Hence, researchers 
should pay more attention to designing probes with favorable physicochemical properties. 







excitation wavelengths and low tissue penetration [144]. Future development of synthetic 
ligands with a focus on near-infrared (NIR) fluorophores might be advantageous, especially 
since such wavelengths are not harmful to cells and have a relatively low absorption. Such 
NIR probes were already employed to study the cannabinoid CB2 and α1-adrenergic receptors 
[145, 146]. 
Compared to radioligand and fluorescent probes, covalent ligands do not possess any 
detectable functionality for direct quantification or visualization of receptors. When combined 
with site-direct mutagenesis, mass spectrometry and peptide sequencing, they constitute a 
powerful approach to study adenosine receptor subtype and structure, map ligand binding 
sites, investigate the physiological and pathological roles of receptors and determine the 
correlation between receptor occupancy and response. The emergence of the activity-based 
protein profiling technique inspired researchers to equip probes with click handles to yield 
bifunctional probes that can be used to visualize receptors for target validation. In this strategy 
a probe binds the receptor with less perturbation compared to relatively large tags linked to 
ligand scaffolds beforehand, which bridges the field of chemical biology with the field of 
molecular pharmacology to better investigate receptor-ligand interactions. In future research, 
different tags may be introduced; for instance, a biotin-tag would allow for streptavidin-
mediated receptor enrichment followed by LC/MS analysis. Of note, the A2BR has been 
known as the more poorly characterized adenosine receptor subtype. This also has limited the 
development of molecular probes targeting A2BR specifically, especially for the covalently 
binding ligands, where no case has been reported so far. Covalent probes for A2BR and A3R 
may also assist in the structure elucidation of these two adenosine receptor subtypes, which 
are currently still lacking.  
For decades, scientists have been continuously developing tool compounds to study adenosine 
receptors. In this endeavor the use of covalent or reversible probes, whether radiolabeled or 
fluorescent, has been instrumental, i) to discover new chemical entities, ii) to characterize and 
interrogate adenosine receptor subtypes both in vitro and in vivo, and iii) to study their 
behavior in physiological and disease conditions. This review has summarized evidence for 
these applications, but, hopefully, it also serves as an invitation to walk another mile to further 
improve probe characteristics and develop additional tags that interrogate adenosine receptors 
and other GPCRs in even finer detail.  
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Abstract 
The structure of the human A2A adenosine receptor has been elucidated by X-ray 
crystallography with a high affinity non-xanthine antagonist, ZM241385, bound to it. This 
template molecule served as a starting point for the incorporation of reactive moieties that 
cause the ligand to covalently bind to the receptor. In particular, we incorporated a 
fluorosulfonyl moiety onto ZM241385, which yielded LUF7445 (4-((3-((7-amino-2-(furan-2-
yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)propyl)carbamoyl)benzene sulfonyl 
fluoride). 
In a radioligand binding assay LUF7445 acted as a potent antagonist, with an apparent affinity 
for the hA2A receptor in the nanomolar range. Its apparent affinity increased with longer 
incubation time, suggesting an increasing level of covalent binding over time. An in silico 
A2A-structure-based docking model was used to study the binding mode of LUF7445. This led 
us to perform site-directed mutagenesis of the A2A receptor to probe and validate the target 
lysine amino acid K153 for covalent binding. Meanwhile, a functional assay combined with 
wash-out experiments was set up to investigate the efficacy of covalent binding of LUF7445. 
All these experiments led us to conclude LUF7445 is a valuable molecular tool for further 
investigating covalent interactions at this receptor. It may also serve as a prototype for a 
therapeutic approach in which a covalent antagonist may be needed to counteract prolonged 
and persistent presence of the endogenous ligand adenosine. 
Keywords: G protein-coupled receptors, A2A adenosine receptor, adenosine, covalent 








G protein-coupled receptors (GPCRs), all membrane-bound proteins, represent one of the 
largest classes of drug targets, and are the anchor point for approx. one third of all marketed 
drugs [1]. These proteins are notoriously difficult to handle outside of their natural membrane 
context, for instance in receptor purification and crystallization. Recently, however, a 
combination of technological advances has allowed the structure elucidation of an increasing 
number of these important drug targets [2-4]. In this context covalent modification of the 
receptor with ligands is emerging as a useful way to investigate ligand-receptor binding 
domains in membrane proteins, also because such covalent ligands, acting as pharmacological 
chaperones, tend to stabilize the otherwise fragile receptor proteins.  
Covalent binding of both agonists and antagonists to adenosine receptors has known a long 
history in purinoceptor research. In the 1980s the adenosine A1 receptor was the preeminent 
target for such studies [5], eventually leading to the design of a covalently binding 
fluorosulfonyl derivative of the reference antagonist DPCPX, named FSCPX, which appeared 
useful also in an in vivo setting [6,7]. Likewise the adenosine A2A receptor has been subjected 
to such strategies. One existing example is the para-fluorosulfonyl derivative of SCH58261, 
FSPTP, which was used to investigate the level of adenosine A2A receptor reserve for agonist 
activity [8].  The hA2AAR has relevance in various diseases, and thus, agonists for increasing 
blood flow during cardiac nuclear stress tests [9] and an antagonist for the treatment of 
Parkinson’s disease [10] are on the market, and the receptor may also play a role in cancer-
immunotherapy [11]. The hA2AAR has also been one of the first GPCRs to be crystallized and 
a wide variety of crystal structures has been published, including the reported structures co-
crystalized with agonist UK-432097 or antagonist ZM241385 [12-14]. Although covalent 
A2AR antagonists have been previously synthesized and investigated in terms of their affinity 
or potency [8,15-18], little is known about their precise binding mode in the receptor and their 
effects on the kinetics of interaction.  
In this study, we describe our efforts to obtain a covalent antagonist probe for the hA2AAR, as 
a logical extension of our previous research on long residence time antagonists, i.e. 
compounds that dissociate only slowly from the receptor [19]. We used the antagonist 
ZM241385 as the starting point in our design efforts, and synthesized a fluorosulfonyl 
derivative of it, LUF7445. We then validated this compound to bind covalently and inhibit the 
receptor in a number of in vitro experiments, and provide evidence for its point of attachment 
to the receptor.  
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2. Methods and Materials
Chemicals and Reagent The radioligand [3H] ZM241385 with a specific activityof 50 Ci ×
mmol-1 was purchased from ARC Inc. (St.Louis, MO). Unlabelled ZM241385 was a gift from
Dr. S.M.Poucher (Astra Zeneca, Macclesfield, UK). 5’-N-ethylcarboxamidoadenosine
(NECA) was purchased from Sigma-Aldrich (Steinheim, Germany). LUF6632 was
synthesized in our lab, as published previously [19]. Adenosine deaminase (ADA) was
purchased from Boehringer Mannheim (Mannheim, Germany). Bicinchoninic acid (BCA) and
BCA protein assay reagent were obtained from Pierce Chemical Company (Rockford, IL,
USA). HEK293 cells stably expressing the hA2A adenosine receptor (HEK293 hA2AAR) were
kindly provided by Dr J Wang (Biogen/IDEC, Cambridge, MA, USA). All other chemicals
were of analytical grade and obtained from standard commercial sources. Site-Directed
Mutagenesis Site-directed receptor mutant hA2AAR-K153AECL2 was constructed by the same
procedure reported previously [20]. The wild type pcDNA3.1-A2AR plasmid DNA with N-
terminal HA and FLAG tags and C-terminal His tag was used as a template for polymerase
chain reaction (PCR) mutagenesis. Mutant primers for directional PCR product cloning were
designed using the online Quickchange primer design program (Agilent Technologies, Santa
Clara, CA), and primers were obtained from Eurogentec (Maastricht, The Netherlands). All
DNA sequences were verified by Sanger sequencing at LGTC (Leiden, The Netherlands).
Cell culture, transfection and membrane preparation We followed the procedures reported
previously [20,21]. Briefly, human embryonic kidney (HEK) 293 cells were grown as
monolayers in Dulbecco’s modified Eagle’s medium supplemented with stable glutamine,
10% newborn calf serum, 50 µg/mL streptomycin, and 50 IU/mL penicillin at 37°C and 7%
CO2 atmosphere. The cells were transfected with mutant plasmid DNA using the calcium
phosphate precipitation method, followed by a 48-hour incubation. And HEK293 hA2AAR
wild type (hA2AAR-WT) cells were grown as monolayers on 15 cm ø culture plates to 80%-
90% confluency in the same medium as the other HEK293 cells but with the addition of G-
418 (500 mg/ml). For both cells were detached from the plates by scraping them into PBS and
centrifuged to remove PBS buffer. The pellets were resuspended in ice-cold Tris-HCl buffer
(50 mM, pH 7.4) and then homogenized. The cell membrane suspensions were centrifuged at
100,000 × g at 4°C for 20 minutes, after which the procedure was repeated one more time.
After this, Tris-HCl buffer was used to resuspend the pellet, and adenosine deaminase was
added to break down endogenous adenosine. Membranes were stored in 250 μL aliquots at -








Radioligand displacement assay Radioligand displacement experiments were performed as 
follows. Membrane aliquots containing 10 µg of protein were incubated in a total volume of 
100 µL of assay buffer to adjust the assay window to approximately 3000 DPM. Nonspecific 
binding was determined in the presence of 100 µM NECA and represented less than 10% of 
the total binding. Then to each tube were added 25 µL cell membrane (10 µg of protein), 25 
µL of 2.7 nM radioligand [3H] ZM241383, 25 µL of assay buffer [25 mM Tris-HCl, pH 7.4 at 
25°C , supplemented with 5 mM MgCl2 and 0.1% (w/v) 3-[(3-cholamidopropyl) 
dimethylammonio]-1- propanesulfonate (CHAPS)] and 25 µL of the indicated compounds in 
increasing concentrations in the same assay buffer. The mixture was incubated at 25oC for 60 
min to reach equilibrium. Incubations were terminated by rapid vacuum filtration to separate 
the bound and free radioligand through 96-well GF/B filter plates using a Perkin Elmer 
Filtermate-harvester (PerkinElmer, Groningen, Netherlands). Filters were subsequently 
washed three times with 2 mL of ice-cold buffer (25 mM Tris-HCl, pH 7.4, supplemented 
with 5 mM MgCl2). The filter-bound radioactivity was determined by scintillation 
spectrometry using a P-E 1450 Microbeta Wallac Trilux scintillation counter (PerkinElmer). 
Radioligand competition association assay The binding kinetics assay to determine the 
unlabeled ligands was performed as described previously [21]. Briefly, the association of the 
radioligand was followed over time in the absence or presence of a concentration 
corresponding to the IC50 value of unlabeled ZM241385, LUF6632 and LUF7445. In practice, 
to the mixture of equal volumes of radioligand, unlabeled compound and assay buffer was 
added a 25 µL membrane aliquot containing 10 µg of protein at each time point from 0.5 min 
to 240 min at 25oC. Incubation was terminated as described above (radioligand displacement 
assay).  
Irreversible binding of LUF7445 to both hA2AAR-WT and hA2AAR-K153AECL2 cell membranes 
Both hA2AAR-WT and hA2AAR-K153AECL2 cell membrane aliquots were treated the same 
way as described in radioligand displacement assay to determine their assay window. Then 
100 µL assay buffer containing either 1% DMSO (as blank control for total binding and non-
specific binding) or 1 µM ligands (ZM241385 or LUF7445, 400 µM stock in assay buffer) 
was added to 2 mL Eppendorf tubes containing 100 µL cell membrane suspension and 200 µL 
assay buffer and incubated for 1 h at 25 oC. Subsequently, the mixture was centrifuged at 
16,100 × g at 4oC for 5 minutes to remove the buffer with the ’free’ ligands. The membrane 
pellet was resuspended in 1 mL assay buffer and spun for 5 min at 16,100 × g at 4oC. After 
three washing cycles, the cell pellets were resuspended in 300 µL assay buffer to determine 
their radioligand binding activity. Afterwards, all the samples were transferred to test tubes on 





ice and 100 µL (2.7 nM) radioligand [3H] ZM241383 was added, followed by a 0.5 h 
incubation at 25 oC. The incubation was terminated by vacuum filtration through a GF/B filter 
using a Brandel harvester to separate bound and free radioligand. The filters were washed 
three times with ice-cold wash buffer (25 mM Tris-HCl, pH 7.4 supplemented with 5 mM 
MgCl2). After harvesting, 3.5 mL of scintillation liquid was added and the filter-bound 
radioactivity was determined in a Tri-Carb 2900TR liquid scintillation analyser 
(PerkinElmer). Results are expressed as percentage normalized to the maximum specific 
binding in the control group (100%).  
Cyclic AMP functional assay  The LANCE ultra-cAMP 384 kit (PerkinElmer, Groningen, 
Netherlands) was used and all assay components were prepared according to the instructions 
of the manufacturer. Briefly, cAMP was generated in the stimulation buffer (N-2-
hydroxyethylpiperazine-N-ethane sulfonic acid (HEPES), 5 mM; 0.1% (w/v) BSA; 
cilostamide, 50 µM; rolipram, 50 µM; adenosine deaminase (ADA), 0.8 IUmL-1). HEK293 
hA2AAR cells were grown as monolayers to 80%-90% confluency and harvested by 
centrifugation for 5 min at 200 ×  g. Then 5000 cells per well were seeded in a 384 well plate, 
followed by a 1 h co-incubation with a mixture of 10 nM NECA (prepared in the stimulation 
buffer) and the antagonists (LUF7445 or ZM241385)  at a concentration ranging from 1 µM 
to 1 pM. Then the incubation was terminated by adding cAMP Tracer solution and anti-cAMP 
solution. Measurements of the generated fluorescence intensity were done on an EnVision 
Multilabel Reader (PerkinElmer, Groningen, Netherlands). 
Irreversible binding of LUF7445 to HEK293 hA2AAR cells assessed in cyclic AMP functional 
assay  All the assay components were prepared as described in the cAMP functional assay 
above. HEK293  hA2AAR cells were grown as monolayers to 80%-90% confluency and 
harvested by 200 × g centrifugation for 5 min. Then cells were pretreated with ligands at the 
concentration of their IC80 values (determined in the cAMP functional assay above), or with 
stimulation buffer (pH 7.4) for 1 hour. Then, the pretreated cells were centrifuged for 5 min at 
300 × g to remove the supernatant at 4 oC, after which the cell pellet was washed three times 
with 3× 1 mL stimulation buffer, separated by renewed incubation for 10 min at 25oC. These 
washed cells were seeded in a 384 well plate (5000 cells/well) as described in the cAMP 
functional assay above. Briefly, 10 nM NECA (prepared in the stimulation buffer) was co-
incubated to stimulate cAMP production, followed by the termination by cAMP Tracer 
solution and anti-cAMP solution. Measurements of the generated fluorescence intensity were 







Computer Modelling All calculations were performed using the Schrodinger Suite [23]. The high-
resolution crystal structure of the adenosine A2A receptor co-crystalized with a ZM241385 was used 
for the docking studies (PDB:4EIY) [14].  The crystal structure was prepared using the preparation 
wizard, protonation states were assigned using PROPKA [24]. After the protein preparation we used 
the CovDock [25] module to perform covalent docking on residue LYS153EL2.  Figures were 
rendered using PyMol [26]. 
Data analysis All the experimental data were analyzed with GraphPad Prism 6.0 software 
(GraphPad Software Inc., San Diego, CA). The radioligand displacement curves were fitted to 
a one-site binding model. Association data for the radioligand were fitted using one-phase 
exponential association. Values for kon were obtained by converting kobs values using the 
following equation: kon = (kobs − koff ) /[radioligand], where koff values were cited from Guo et 
al [21]. Association and dissociation rates for unlabelled ligands were calculated by fitting the 
data in the competition association model using ‘kinetics of competitive binding’ [21, 27]. 
KA = k1[L] + k2 
KB = k3[L] + k4 
S = Sqrt [(KA - KB)2 + 4 ꞏ k1 ꞏ k3 ꞏ L ꞏ I] 
KF = 0.5 (KA + KB + S) 
Ks = 0.5 (KA + KB - S) 
Q = Bmax ꞏ k1 ꞏ L ꞏ (KF - KS)-1 
Y = Q ꞏ [k4 ꞏ (KF - KS) ꞏ KF-1 ꞏ KS-1 + (k4 – KF) ꞏ KF-1 ꞏ e-KFꞏX - (K4 - KS) ꞏ KS-1 ꞏ e-KSꞏX] 
Where X is the time (min), Y is the specific [3H]-ZM241385 binding (DPM), k1 and k2 are the 
kon (nM-1min-1) and koff (min-1) of [3H]-ZM241385 and were obtained from Guo et al [21], L 
is the concentration of [3H]-ZM241385 used (nM), Bmax the total binding (DPM) and I the 
concentration of unlabeled ligand (nM). Fixing these parameters allows the following 
parameters to be calculated: k3, which is the kon value (nM-1min-1) of the unlabeled ligand and 
k4, which is the koff value (min-1) of the unlabeled ligand. The residence time (RT) was 
calculated using RT = 1 / koff [27]. Functional concentration-effect curves were fitted to a 
three-parameter concentration response model. Values are expressed as mean ± S.E.M. of 
three independent experiments performed in duplicate. Statistical analyses were performed 
using Student’s unpaired t-test (***P < 0.001; **P <0.01; *P < 0.05). 
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3. Results
3.1. Design and synthesis of LUF7445
Over the years our research group has explored series of triazolotriazine derivatives based on 
the reference adenosine A2A antagonist ZM241385, 4-(2-(7-amino-2- (furan-2-yl)-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol (Figure 1), to investigate their 
structure-activity and structure-kinetics relationships (SAR and SKR) [21,29]. We identified 
LUF6632 (Figure 1) as a long residence time (RT) compound compared to other derivatives. 
This compound prompted us to bring the concept of prolonged receptor occupancy further by 
aiming for a covalently binding derivative of ZM241385. Hence, LUF 7445 (Figure 1), 4-((3-
((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)propyl)carbamoyl)benzene sulfonyl fluoride was synthesized in three steps from 
sulfone compound 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4] triazolo[1,5-a]-[1,3,5]triazin-7-
amine as starting reagent. The reaction conditions and other reagents used are described in 
synthetic Scheme S1 of the SI.  
Figure. 1 Chemical structures of the three hA2A receptor antagonists examined in this study. 
3.2. Determination of the affinity (Ki) of LUF7445, LUF6632 and ZM241385 
for the A2A receptor. 
To determine the affinity (Ki) for the A2A receptor LUF7445, LUF6632 and ZM241385 were 
tested in a [3H] ZM241385 displacement experiment (n = 3). All these compounds 
concentration-dependently inhibited specific [3H] ZM241385 binding from human A2A 
receptors overexpressed in HEK293 cell membranes (Figure 2). LUF6632, ZM241385 and 
LUF7445 showed similar affinities in the subnanomolar range (Table 1). It should be 
mentioned that the putative covalent nature of the interaction between receptor and LUF7445 
precludes the determination of equilibrium binding parameters. Therefore, we expressed 














LUF7445c 8.27±0.042 8.99±0.008*** 
LUF6632 9.17±0.007 9.26±0.004* 
ZM241385 8.89±0.019 8.91±0.006 
Data are expressed as means ± SEM of three separate experiments each performed in duplicate. *P < 
0.05, ***P < 0.001 compared with the pKi values in displacement experiments during 0.5h incubation 
time; Student’s t-test.  
aAffinity determined from displacement of specific [3H]ZM241385 binding from the hA2AAR at 25oC 
during 0.5 h incubation;b Affinity determined from displacement of specific [3H]ZM241385 binding 
from the hA2AAR at 25oC during 3 h incubation;c For LUF7445, the covalent antagonist, pKi values 
can only be apparent, as true equilibrium cannot be reached. 
3.3. Time-dependent characterization of affinity for LUF7445, LUF6632 and 
ZM241385.  
We then tested the time dependency of the affinity of the three compounds. To that end a [3H] 
ZM241385 displacement experiment was performed with an incubation time of both 0.5 hr 
and 3 hr. As detailed in Table 1, the affinity of LUF6632 slightly and of LUF7445 strongly 
increased with longer incubation time while ZM241385’s affinity did not change. 
Representative graphs for this effect are in Figure 2, in which the curve representing a 
concentration-dependent inhibition of specific [3H] ZM241385 binding was shifted to the left 
with time for LUF7445 (Figure 2A), with little (LUF6632, Figure 2B) or no difference 
(ZM241385, Figure 2C) for the other two compounds.  
 
Figure. 2 Displacement of specific [3H] ZM241385 binding from the adenosine hA2AAR receptor at 
25°C by LUF7445 (a), LUF6632(b) and ZM241385(c) during an incubation of 0.5h (blue curve) and 
3h (red curve), respectively. Representative graphs are from one experiment performed in duplicate. 
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Notably, compared to the long residence compound LUF6632, LUF7445 showed a more 
pronounced influence with prolonged incubation time, suggesting an increasing level of 
covalent binding over time. The combined data yielded an approx. 5-fold shift in apparent Ki 
value for LUF7445. The affinities of the compound for the other adenosine receptor subtypes 
are reported in Table S1 of the SI, showing that LUF7445 is very selective towards A2A 
receptors. 
3.4. Kinetic characterization of LUF6632, LUF7445 and ZM241385 in a 
competition association binding assay. 
The ‘apparent Ki shift’ of LUF7445 drove us to investigate the irreversible characteristics of 
LUF7445 binding by performing kinetic assays to determine its dissociation rate from the A2A 
adenosine receptor. In our previous research, the kon (k1= 0.24 ± 0.05 ×108 M-1ꞏmin-1) and koff 
(k2 = 0.48 ± 0.03 min-1) values of [3H]-ZM241385 at 25oC have been determined by a 
traditional association and dissociation assay [21]. Here we derived the kinetic parameters, i.e. 
the kon (k3) and koff (k4) values, for the three unlabeled ligands from a competition association 
assay (Figure 3). Both LUF6632 (kon = 1.53 ± 0.083 nM-1 min-1) and ZM241385 (kon = 1.72 ± 
0.36 nM-1 min-1) showed a similar association rate, which was significantly faster than for 
LUF7445 (kon = 0.0059 ± 0.00049 nM-1 min-1).  
Table 2. The (apparent) association and dissociation rate constants of LUF7445, LUF6632 and 
ZM241385 determined in competition association assays with [3H]-ZM241385 binding to HEK293-
hA2AAR membranes  
Compound kon (nM-1 min-1)a koff (min-1)a RT(min) 
LUF7445b (0.0059 ± 0.00049) (1.37 ± 0.68×10-11) (2.86 ± 0.87×1011) 
LUF6632 1.53 ± 0.083 0.15 ± 0.021 6.80 ± 0.97 
ZM241385 1.72 ± 0.36 1.04 ± 0.13 0.96 ± 0.12 
aAssociation [kon] and dissociation [koff] rate constants were determined by competition association 
assay at 25°C; all these values were determined by analyzing the data in the mathematical model 
described by Motulsky and Mahan [27];bFor LUF7445, no equilibrium is reached between receptors 
and ligand, hence the Motulsky/Mahan mathematical model [27] for the competition association assay 
is not valid. The values obtained are therefore considered to provide qualitative insight only, and are in 
brackets. 
As detailed in Table 2, LUF6632 displayed a dissociation rate constant of 0.15 ± 0.021 min-1
which equals to a receptor RT of 6.80 ± 0.97 min, being 7 fold longer than ZM241385’s RT 
which was 0.96 ± 0.12 min at 25oC. Figure 3 shows that LUF7445’s behavior was very 
different, causing an initial ‘overshoot’ of the competition association curve which over time 
progressed to negligible radioligand binding at 240 min. Analyzing this curve with the 
(equilibrium) Motulsky and Mahan model [27] led to a negligible dissociation rate (koff  = 1.37 







Table 2). These data provided further evidence for a putative irreversible binding mode 
between LUF7445 and the hA2A adenosine receptor. This data is qualitatively summarized in a 
simplified scheme in the SI (Scheme 2). 
 
Figure. 3 Competition association binding assay with [3H] ZM241385 in the absence or presence of 
indicated compounds at 25oC. Representative graphs are from one experiment performed in duplicate 
(see Table 2 for kinetic parameters). 
3.5. Binding mode of LUF7445 in the hA2AAR binding pocket 
Although the radioligand binding results above characterized LUF7445 as an irreversibly 
binding ZM241385 derivative, it remained to be tested what the target residue of the reactive 
warhead is. We therefore constructed a binding model based on the reported adenosine A2A 
X-ray crystal structure (PDB code: 4EIY) and chemical structure of LUF7445.  
 
Figure. 4 Binding model of LUF7445 in the hA2A adenosine receptor-binding pocket based on the 
hA2A adenosine receptor crystal structure (PDB code: 4EIY). The black carbon sticks represent the 
structure of LUF7445. The important residues and H-bonds for ligand recognition are indicated by 
yellow dashed lines.  
From the docking result, the ZM241385 core structure, shown as black carbon sticks in Figure 
4, is in the same position as ZM241385 in the A2A crystal structure, participating in H-bond 
formation with residues such as His264, Glu169, Phe168 and Asn253. Due to the flexibility 
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of the three-carbon linker a lysine residue in close proximity of the ligand, K153ECL2, could 
interact with the 4-fluorosulfonylbenzoic warhead in LUF7445 to form a covalent sulfonyl 
amide.  
3.6. Lysine K153ECL2 residue is the possible anchor point for covalent bond 
formation.  
To investigate the structural nature of the interaction between the ligands and receptor, we 
therefore mutated the potential target lysine residue to alanine (A2AAR-K153AECL2 receptor) 
to compare with the wild type receptor and perform a “wash-out” experiment. Following 
preincubation with either LUF7445 or ZM241385, cell membranes overexpressing mutant 
A2AAR-K153AECL2 or wild type A2AAR were washed three times to remove the non-
covalently bound ligands. After this repeated washing cell membranes were incubated with 
the radioligand [3H]ZM241385 to assess the remaining radioligand binding.  
Figure 5. Involvement of Lys153 in the binding of LUF7445. HEK293 cell membranes 
overexpressing wild type or K153A mutant hA2A AR were pretreated with buffer (vehicle) or 1 µM of 
LUF7445 or ZM241385 for 1h followed by 3 wash cycles. The membranes were then subjected to a 
standard [3H] ZM241385 radioligand binding assay to measure remaining specific [3H] ZM241385 
binding. Results were obtained from three independent experiments performed in duplicate. Data are 
normalized to 100% of the vehicle group response. Error bars indicate SEM values.**Significant 
difference between groups (P<0.01); Student’s t-test 
In the absence of antagonist (labeled ‘+ vehicle’ in Figure 5) both the mutant A2AAR-
K153AECL2 and the wild type A2AAR receptor containing membranes had a similar recovery 
of radioligand binding, which we normalized to 100% recovery. LUF7445 caused a 
significant decrease of radioligand binding on the A2AAR WT cell membranes with only 10.4 
± 3.0% recovery of specific binding despite the extensive washing, while more radioligand 
binding was ‘saved’ at the cell membranes overexpressing A2AAR-K153AECL2 (32.8 ± 0.9% 
remaining). As a control, both cell membrane preparations preincubated with ZM241385 
showed that ZM241385 was rapidly washed off the membranes, as a full recovery of 







3.7. Functional characterization of LUF7445 and ZM241385 in cAMP assay 
Functional characterization of these compounds in a cAMP assay on the HEK cells expressing 
the hA2AAR showed their antagonist behavior. The cAMP production was stimulated by the 
addition of the reference agonist NECA (10 nM). Both LUF7445 and ZM241385 caused a 
concentration-dependent inhibition of NECA’s effect (100% in the absence of antagonist, see 
Figure 6a). The potency of LUF7445 (pIC50 = 8.10 ± 0.044) was somewhat lower than of 
ZM241385 ( pIC50 = 8.71 ± 0.13). Again, it should be mentioned that LUF7445 precludes a 
true equilibrium affinity determination.  
 
Figure.6 Functional characterization of LUF7445 and ZM241385 on hA2A AR expressed in HEK293 
cells (a) Concentration-inhibition curves for LUF7445 and ZM241385 in a cAMP assay in the 
presence of 10 nM NECA (100%). Results were obtained from three independent experiments 
performed in triplicate.  (b) Recovery of cAMP production. Cells were pretreated with a concentration 
corresponding to the IC80 value (retrieved from Fig.6a) of the indicated compound, or with buffer 
(control) for 1 hour. Then, 3 wash cycles were applied, followed by adding 10 nM NECA to stimulate 
cAMP production. Data are expressed as means ± SEM of three separate experiments each performed 
in duplicate. ***Significant difference between groups (P<0.001); Student’s t-test  
From Figure 6a we determined the IC80 values of the two compounds, which concentrations 
were then used to pretreat the HEK-A2AAR cells, followed by three wash steps. Thereafter, 
we stimulated the cAMP production in these cells with 10 nM NECA, resulting in a sustained 
inhibition of cAMP production in the presence of LUF7445 (48 ± 1%), while ZM241385 
showed no difference in restoration of cAMP production compared to the control cells in the 
absence of any indicated compound (Figure 6b). Apparently, the cAMP production induced 
by NECA in the presence of LUF7445 was inhibited under conditions where a reference 
antagonist did not, further validating LUF7445 as a covalent antagonist forming an 
irreversible bond with the hA2AAR.  
4. Discussion  
Covalent ligands for GPCRs are emerging as a useful tool for receptor structure-elucidation 
and the chartering of the ligand-receptor binding pocket. As an example, the 3D architecture 
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of the beta2-adrenergic receptor in an active conformation has been recently determined in the 
presence of a covalently binding derivative of noradrenaline [4,30]. In the current study we 
designed and synthesized a covalent antagonist (LUF7445) to investigate ligand-receptor 
interaction in the binding pocket of the hA2AAR, and compared its behavior to the reference 
antagonist ZM241,385 and the long residence time ZM-derivative LUF6632 [19]. All three 
compounds showed a high affinity for the hA2AAR.  
The rational ligand design came from the reported crystal structures of the hA2AAR bound to 
ZM241385, providing a clear blueprint of ligand-binding interactions [13,14,31]. A deep, 
planar, and narrow cavity holds the aromatic core and furan ring of ZM241385, while the 
phenylethylamine substituent is directed to the extracellular region (EL2 and EL3). The 
architecture of the ligand binding pocket offered us a good starting point for the structural 
modification of ZM241385. Therefore, instead of the 4-hydroxyphenylethylamine side chain 
in ZM241,385, the electrophilic fluorosulfonyl group, chosen to permit a possible nitrogen-to-
sulfur bond between the ligand and a nearby free amino group in the receptor, was introduced 
and incorporated in a linker to yield LUF7445.  
A first hint of the covalent nature of LUF7445 was found in incubation time-dependent 
radioligand displacement assays. A longer incubation time rendered LUF7445 more potent in 
displacing the radioligand from the receptor, while this was not or hardly the case for 
ZM241384 and LUF6632, respectively. LUF6632 had previously been identified as an 
antagonist with a long residence time (>300 min) at the receptor, when assessed at 4 oC [19]. 
The current set of experiments was performed at 25 oC, making LUF6632 dissociate faster 
(RT = 6.8 min, Table 2) from the receptor with no substantial pKi shift in affinity at the two 
incubation times. Similar experiments on other GPCRs, such as CB1 cannabinoid receptor 
[32,33] and histamine H2 receptor [34], demonstrated that the covalent interaction between 
the ligand and the receptor resulted in a time-dependent affinity change.  
However, it is far from conclusive to identify a presumed covalent ligand from an affinity 
shift alone, as pseudo-irreversible interactions can also occur caused by slow dissociation 
rates. From a kinetic perspective, a covalent ligand refers to a ligand that stays at the receptor 
for an infinite time period. If the incubation time is long enough, all receptors will be 
occupied by the covalent compound, rendering competitive radioligand binding impossible. In 
accordance with this, a continuing decrease of specific radioligand binding was observed in 







Motulsky-Mahan equations [27] to fit this data is further evidence for the non-equilibrium 
features of the binding of LUF7445 to the receptor. Furthermore, extensive washing did not 
free the receptors from LUF7445, as demonstrated by the lack of [3H]ZM241385 binding 
(Figure 5, WT receptor), compared to a full recovery of membranes pretreated with 
ZM241385. This confirms the washing steps did remove the reversible ligand from the 
receptors, and in return validates the irreversible binding of LUF7445 to the hA2AAR. Similar 
findings were obtained on the adenosine A1 receptor and histamine H4 receptor where 
preincubation of a covalently binding ligand concentration-dependently decreased radioligand 
binding after extensive washing of the cell membrane preparation [7, 35].  
Based on the ZM241385 binding mode of the hA2AAR, we hypothesized that LUF7445 
covalently interacts with a lysine residue, K153ECL2, resulting in a sulfonamide bond 
formation (Figure 4). Hence, the K153AECL2 mutant construct, potentially preventing the 
covalent bond from being formed, was made to perform a similar wash-out experiment as 
described above. Since ZM241385 showed a similar affinity for both the K153AECL2 mutant 
(pKi = 7.83 ± 0.04) and WT receptors (pKi = 7.91 ± 0.05) [20], we assumed that the 
difference in radioligand binding recovery was not due to a point mutation within a receptor 
binding site, which has the potential of altering ligand binding properties. Moreover, in the 
absence of either LUF7445 or ZM241385, the apparently same binding capacity (data not 
shown) proved that the washing steps had little influence on the integrity of both WT hA2AAR 
and mutant A2AAR-K153AECL2. The mutation led to a three-fold increase of binding recovery 
indicating a substantially decreased level of covalent binding to the cell membranes, resulting 
from a decreased possibility to form a covalent bond between the warhead and a target 
residue. The mutation did not lead to a full recovery of radioligand binding, however, 
suggesting that other unidentified residues may play a similar role. Likewise, Nijmeijer et al 
identified a cysteine amino acid to be the linking residue for the covalent probe at the 
histamine H4 receptor mentioned above [35], and it may be that the very reactive 
fluorosulfonyl warhead in LUF7445 also targets other residues such as cysteines [36].   
A covalent antagonist will decrease the maximal agonist-induced effect by a permanent 
occupancy of the available receptors, which was indeed demonstrated in the functional assay. 
The concentration-effect curves obtained in the cAMP functional assay showed an 
antagonistic behavior of LUF7445 (Figure 6A). A much lower stimulation by AR receptor 
agonist NECA was observed as the number of available receptors was most likely reduced by 
the irreversible binding of LUF7445 (Figure 6B). A similar experiment at the adenosine A1 
A Covalent Antagonist for the Human A2AR 
73
receptor showed that the irreversible binding by FSCPX decreased the maximal effect in the 
agonist dose-response curves [37]. All these results contributed to our hypothesis that 
LUF7445 is an insurmountable antagonist for the hA2AAR indeed, and that the fluorosulfonyl 
group present in LUF7445 reacts with K153ECL2 via a covalent modification.    
Besides in clinical trials for Parkinson’s disease, A2A antagonists have risen to prominence as 
a future add-on to cancer combination therapy. Under chronic hypoxic conditions within the 
tumor microenvironment, increased accumulation of extracellular adenosine around the tumor 
tissue activates A2AARs in the vicinity, which promotes peripheral tolerance by inducing T-
cell anergy and the generation of adaptive regulatory T cells [38]. In contrast, blockade of 
A2AARs plays a vital role in retardation of tumor growth, relieving immune cells from their 
repressed conditions, reducing the metastasis of tumors [39], and thus boosting antitumor 
immunity. As a consequence, potent A2A receptor antagonists are now being considered as 
potential therapeutics in diminishing the rate of cancer development [40,41]. The starting 
point of our design strategy, ZM241385, has been reported to significantly inhibit melanoma 
growth and reinforce the antineoplastic immune response, when combined with anti-
CTLA4mAb [42]. However, in vivo tumor rejection during treatment with ZM241385 failed 
to take place most likely because of ZM241385’s short half-life [11]. In addition, we 
speculate that the relatively short receptor residence time of ZM241385 at physiological 
temperature is another aspect that allows the massive amounts of adenosine produced in the 
tumor environment to continue to activate the A2AAR. Thus, a covalently binding antagonist 
such as LUF7445 may be a better proposition under these conditions.   
5. Conclusion
The structure-based design of LUF7445, an antagonist for the human A2AAR, is reported in
this study. In a number of in vitro assays, we obtained accumulating evidence for the covalent
nature of the ligand’s interaction with the receptor. More specifically, LUF7445 appeared to
bind covalently to a lysine residue in the extracellular domain of the receptor (K153ECL2). Its
antagonistic nature was confirmed in a functional assay, as it blocked hA2AAR-mediated
cAMP accumulation by agonist NECA. The results contribute to a better understanding of
long-lasting effects caused by ligands covalently reacting/interacting with GPCRs. In itself
LUF7445 may be a probe to explore the added value of covalent antagonists for the adenosine
A2A receptor in certain disease states such as cancer immunology, in which high adenosine







new technologies such as activity-based protein profiling with the perspective of imaging or 
structural probing of GPCRs.  
 
6. Supporting information 
6.1. Chemistry 
All solvents and reagents were purchased from commercial sources and were of analytical 
grade. 1H NMR spectra were recorded on a Bruker AV 400 liquid spectrometer (1H NMR, 
400 MHz) at ambient temperature. Chemical shifts are reported in parts per million (ppm), are 
designated by δ. Coupling-constants are reported in Hz and are designated as J. Analytical 
purity of the final compounds was determined by high pressure liquid chromatography 
(HPLC) with a Phenomenex Gemini 3μ C18 110A column (50 × 4.6 mm, 3 μm), measuring 
UV absorbance at 254 nm. Sample preparation and HPLC method was as follows: 0.5 mg of 
compound was dissolved in 1 mL of a 1:1:1 mixture of CH3CN/H2O/tBuOH and eluted from 
the column within 15 min, with a three component system of H2O/CH3CN/1% TFA in H2O, 
decreasing polarity of the solvent mixture in time from 80/10/10 to 0/90/10. All compounds 
showed a single peak at the designated retention time and are at least 95% pure. Liquid 
chromatography–mass spectrometry (LC–MS) analyses were performed using Thermo 
Finnigan Surveyor – LCQ Advantage Max LC-MS system and a Gemini C18 Phenomenex 
column (50 × 4.6 mm, 3 μm). The sample preparation was the same as for HPLC analysis. 
The elution method was set up as follows: 1–4 min isocratic system of H2O/CH3CN/1% TFA 
in H2O, 80:10:10, from the 4th min, a gradient was applied from 80:10:10 to 0:90:10 within 9 
min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer 
chromatography (TLC) was routinely performed to monitor the progress of reactions, using 
aluminum coated Merck silica gel F254 plates. Purification by column chromatography was 
achieved by use of Grace Davison Davisil silica column material (LC60A 30–200 micron). 
Solutions were concentrated using a Heidolph laborota W8 2000 efficient rotary evaporation 
apparatus and by a high vacuum on a Binder APT line Vacuum Drying Oven. The procedure 
for the synthesis of similar compounds is given as a general procedure. 
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Scheme 1. Synthesis route of LUF7445. 
Reagents and conditions: A) tert-Butyl (3-aminopropyl) carbamate, MeCN, reflux, 60 h; B) 
TFA, DCM, room temperature, 0.5 h; C) SOCl2, reflux, 2 h ; D) triethylamine, dry dioxane, 
70 °C, 18 h.  
tert-Butyl (3-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)propyl)carbamate (2) 2-(Furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-amine (1) (280 mg, 1 mmol, 1 eq) , which was synthesized as previously 
reported [20],  was suspended in acetonitrile (to give a 0.1 M solution). tert-Butyl (3-
aminopropyl)carbamate (0.19 mL, 1.10 mmol, 1.1 eq) was added. The mixture was heated to 
70 °C for 60 h. The final crude mixture was purified using flash column chromatography 
(DCM:EtOAc → EtOAc). Flash column (DCM:EtOAc, 50% → 100% EtOAc) gave a 
yellowish solid (310 mg, 0.83 mmol, 41% yield).1H NMR (400 MHz, DMSO-d6) δ 8.50–7.94 
(m, 2H), 7.91–7.83 (m, 1H), 7.48–7.40 (m, rotamer 1, 0.30H), 7.36 (t, J = 5.6 Hz, rotamer 2, 
0.70H), 7.04 (d, J = 3.3 Hz, 1H), 6.90–6.76 (m, 1H), 6.67 (dd, J = 3.0, 1.7 Hz, rotamer 3, 
0.85H), 6.49–6.39 (m, rotamer 4, 0.15), 3.24 (q, J = 6.7 Hz, 2H), 2.97 (q, J = 6.4 Hz, 2H), 
1.72–1.56 (m, 2H), 1.37 (s, 9H) ppm. 
N5-(3-aminopropyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (3) 
Boc protecting groups were removed by dissolving (2) (374 mg, 1 mmol, 1 eq) in DCM, 
adding TFA (3.9 mL, 50 mmol, 50 eq) and removal of solvents after the reaction was 
finished. The remaining material was co-evaporated thrice with H2O and once with acetone, 
affording the triple TFA salt in quantitative yield. 1H NMR (400 MHz, DMSO-d6) δ 8.61–
8.04 (m, 2H), 7.88 (s, 1H), 7.70 (brs, 3H), 7.63-7.53 (m, 1H), 7.12–7.01 (m, 1H), 6.68 (dd, J 
= 3.3, 1.7 Hz, rotamer, 0.95H), 6.64–6.59 (m, rotamer, 0.05H), 3.40–3.28 (m,  2H), 2.85 (q, J 
= 6.7 Hz, 2H), 1.89–1.68 (m, 2H) ppm. 
4-Fluorosulfonyl benzoylchloride (5) Commercially available 4-fluorosulfonylbenzoic acid
(500 mg, 2.45 mmo, 1 eql) was dissolved in thionyl chloride (8.89 mL, 122.4 mmol, 50 eq)
and heated at 70 °C under N2 atmosphere. After 2 h, all material was dissolved and the thionyl







toluene to give a brown liquid that solidified when it cooled down to room temperature. The 
resulting product was used directly in the next step. 1H NMR (400 MHz, Acetone-d6) δ 8.52 
(d, J = 8.5 Hz, 2H), 8.39 (d, J = 8.7 Hz, 2H). 
4-((3-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)propyl)carbamoyl) benzene    sulfonyl fluoride (6)  LUF7445(3) (TFA salt, 322 
mg, 0.83 mmol, 1 eq) was added to dry dioxane (5 mL). (5) (184 mg, 0.92 mmol, 1.1 eq) was 
added along with triethylamine (0.3 mL, 2.49 mmol, 3 eq). The mixture was heated to 70 °C 
for 18 h. The reaction was finished, solvents were removed and a flash column (EtOAc→ 
99% EtOAc + 1% AcOH) was used. Subsequent washing with acetone of the obtained solids 
gave the title compound as a white solid (77mg, 0.18 mmol, 22% yield).1H NMR (400 MHz, 
DMSO-d6) δ 8.90 (t, J = 6.0 Hz, 1H), 8.52–8.02 (m, 6H), 7.87 (s, 1H), 7.58–7.44 (m, 1H), 
7.04 (d, J = 3.3 Hz, 1H), 6.68 (dd, J = 3.3, 1.8 Hz, 1H), 3.36-3.33 (m, 4H), 1.80 (pent, J = 6.3 
Hz, 2H) ppm. HPLC: 96.7%, RT 7.40 min. LC-MS: [ESI+H]+: 461.13 
 
6.2. Biology. 
Table S1. Affinities of LUF7445 at the other adenosine receptor subtypes. Data are expressed 
as means ± SEM or percentage displacement at 1 μM of three separate experiments each 
performed in duplicate.  
Compound 
pKi or displacement at 1 μM (%) 
        hA1a                  hA2Ab                           hA2Bc                           hA3d 
LUF7445 6.43 ± 0.095 8.99 ± 0.008 0.0% (2.0, -4.7,-2.6) 7.31 ± 0.083 
aAffinity determined from displacement of specific [3H]DPCPX binding on CHO cell membranes 
stably expressing human adenosine A1 receptors at 25oC during 3h incubation;  
b Affinity determined from displacement of specific [3H]ZM241385 binding from the hA2AAR at 25oC 
during 3h incubation; 
c% displacement at 1 μM concentrations of specific [3H]PSB603 binding on CHO cell membranes 
stably expressing human adenosine A2B receptors at 25oC during 3h incubation; 
dAffinity determined from displacement of specific [3H]PSB-11 binding on CHO cell membranes 
stably expressing human adenosine A3 receptors at 25oC during 3h incubation 
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Scheme 2. Simplified representation of interaction between LUF7445 and hA2AAR during a 
competition association assay. The radiolabeled ZM-receptor complex ([RZM]) is being measured. If 
a compound L, such as LUF7445, binds covalently, the equilibrium shifts to the right ([RL]). The 
longer the incubation, the more receptors will be occupied by LUF7445. 
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Abstract 
The development of covalent ligands for G protein-coupled receptors (GPCRs) is not a trivial 
process. Here, we report a streamlined workflow thereto from synthesis to validation, 
exemplified by the discovery of a covalent antagonist for the human adenosine A3 receptor 
(hA3AR). Based on the 1H,3H-pyrido[2,1-f]purine-2,4-dione scaffold, a series of ligands 
bearing a fluorosulfonyl warhead and varying linker was synthesized. This series was 
subjected to an affinity screen, revealing compound 17b as the most potent antagonist. In 
addition, a nonreactive methylsulfonyl derivative 19 was developed as a reversible control 
compound. A series of assays, comprising time-dependent affinity determination, washout 
experiments and [35S]GTPγS binding assays, then validated 17b as covalent antagonist. A 
combined in silico hA3AR-homology model- and site-directed mutagenesis study was 
performed to demonstrate that amino acid residue Y2657.36 was the unique anchor point of the 
covalent interaction. This workflow might be applied to other GPCRs to guide the discovery 







1. Introduction  
The adenosine A3 receptor (A3AR) is one of four G protein-coupled receptor subtypes 
stimulated by adenosine [1]. Different from the other subtypes (A1, A2A and A2B) A3AR was 
identified by molecular biology studies prior to its pharmacological characterization [2]. The 
initial studies indicated its important role in both physiological and  pathophysiological 
conditions, such as cell proliferation, cell differentiation, neuroprotection, cardioprotection 
and apoptosis [3]. Nevertheless, the medical relevance of the human adenosine A3 receptor 
(hA3AR) is enigmatic due to its dichotomy in different therapeutic applications [3]. In this 
regard, there is a continuing interest in the development of the selective ligands of the hA3AR 
to investigate its pharmacological effects. For instance, selective A3AR antagonists have been 
applied for the treatment of glaucoma [4] and respiratory tract inflammation such as asthma 
[5]. In particular, a tricyclic xanthine derivative, 1-benzyl-8-methoxy-3-propyl-1H,3H-
pyrido[2,1-f]purine-2,4-dione (compound 1, Figure 1a), has been reported to exert high 
affinity for the hA3AR [6-8]. 
 
Figure 1. (A) Reference antagonist (1) for hA3AR. (B) DU172 (2), a covalent antagonist for hA1AR. 
Initial efforts to study the structural biology of GPCRs suffered from numerous limitations, 
such as low expression, dynamic conformational states, and inherent instability. Covalent 
ligands, i.e., compounds that irreversibly bind to the receptor and possess a reactive moiety to 
target specific amino acid residues, helped to solve some of these obstacles [9].This is also the 
case for adenosine receptors. For example, the structure of the human adenosine A1 receptor, 
having the highest similarity to hA3AR among all adenosine receptors subtypes  (61% of 
sequence homology) [10], has been elucidated by X-ray crystallography with a covalent 
antagonist DU172 (2) (Figure 1b) [11]. However, the application of covalent ligands in 
hA3AR studies has been limited to the characterization of the receptor type [12-14], far from 
providing a comprehensive study of receptor structure elucidation, pharmacological 
characteristics and ligand-receptor binding description.   





To this end, we devoted our efforts to the discovery of a well-defined covalent antagonist 
based on xanthine analogue 1 mentioned above. Inspired by the resemblance in chemical 
structure between the potent hA3AR antagonist 1 and irreversible adenosine A1 receptor 
antagonist 2, we incorporated the reactive moiety, a fluorosulfonyl benzoyl group, connected 
to a spacer, at the N1 position of the scaffold. Using a structured approach to bring the reactive 
fluorosulfonyl group in close proximity to a nucleophilic amino acid residue, we diversied the 
type of linker, linker length and position of the fluorosulfonyl substituent on the phenyl group, 
resulting in a series of analogues with a wide range of affinities. Our efforts led to the 
discovery of a best-in-class antagonist, 17b, which bound to hA3AR with an apparent affinity 
in the nanomolar range. To keep the chemical structure similarity, we replaced the warhead 
with a methylsulfonyl moiety to obtain a non-reactive derivative 19 as a reversible control 
compound. 17b was then validated to covalently bind and inactivate the hA3AR in an 
insurmountable manner. Molecular modelling suggested the fluorosulfonyl functionality of 
17b in close proximity to Y2657.36  , which was identified as the unique anchor point of the 
covalent interaction in a subsequent mutagenesis study. The confirmed binding mode between 
this novel covalent antagonist and hA3AR opens the door for exploring other ligand binding 
motifs and will benefit receptor stabilization and further structure elucidation of the hA3AR. 
2. Results and Discussion 
2.1. Design of Covalent hA3AR Antagonists 
In previous studies, our research group disclosed several series of hA3AR antagonists based 
on the pyrido[2,1-f]purine-2,4-dione scaffold [6-8]. Using compound 1, a nanomolar probe 
from the previous series, as the starting point, we further designed and synthesized 
compounds based on a previously suggested binding mode of the pyrido[2,1-f]purine-2,4-
dione scaffold [7]. When examining the suggested binding mode of this scaffold, we noted 
that this scaffold inserted into the binding pocket with a receptor interaction between TM3, 
TM6 and EL2. Two key H-bonds include the carbonyl-oxygen at the C4-position with residue 
N2506.55 and the methoxy substituent at the C8-position bonding to Q167EL2. Taking this into 
account, we reasoned the only available space to incorporate the reactive warhead is limited to 
C1-position substituents.  
To explore the chemical space required to optimally position the warhead in close proximity 
to a nucleophilic amino acid residue, we examined various linker systems, connecting the 
warhead and the pyrido[2,1-f]purine-2,4-dione scaffold. First, variation in the length of the 







fluorosulfonyl group to orient toward an adjacent nucleophilic residue in the receptor binding 
site [15, 16]. Additionally, the type of chemical bond connecting the warhead to the spacer 
was varied between the slightly differently oriented ester or amide bond. Finally, since the 
exact position of an appropriate nucleophilic residue is unknown, the sulfonyl fluoride moiety 
was positioned at either the 3- or 4-position of the phenyl ring. To this end, four series of 
compounds 13a-c, 14a-c, 17a-c and 18a-c, bearing three different spacer lengths, ester or 
amide linkage and 3- or 4-fluorosulfonylphenyl warhead were targeted for synthesis. 
2.2. Synthesis.  
Scaffold. The scaffold, 8-methoxy-3-propyl-1H,3H-pyrido-[2, 1-f]purine-2, 4-dione (1), was 
synthesized according to the previously published procedure [6-8]. Starting from the 
commercially available benzylurea (3), the fused tricyclic intermediate (6) was generated by 
excess NBS bromination and 4-methoxypyridine cyclization (Scheme 1). Then alkylation at 
the N3-nitrogen by 1-bromopropane in dry DMF, using dry potassium carbonate as a weak 
base, afforded the reference compound (1) in 73% yield. Removing the benzyl protecting 
group by palladium hydroxide afforded the fused xanthine core (7).  
Scheme 1. Synthetic route towards scaffold 7 
 
Reagents and conditions: (a) i) Ac2O, 80 oC, 2 h; ii) Et2O, rt,1 h; iii) 3M NaOH, 85 ˚C, 1 h; iv) HCl 
(37%), 25%; (b) i) NBS, MeCN, 80 oC; ii) 4-methoxypyridine, 80 oC, 64%; (c) 1-bromopropane, 
DBU, MeCN, 70 oC, 73%; (d) Pd(OH)2/C, HCOONH4, EtOH, reflux, 40%. 
Ester Linker The fluorosulfonyl warhead is notorious for its reactivity resulting in undesired 
side reactions or hydrolysis under several harsh reactions [17]. So we adopted a convergent 
synthetic strategy in which the fluorosulfonyl phenyl linker unit was prepared separately and 
attached directly to scaffold 7 at the N3 position. This approach offers the flexibility to 
accommodate a variety of different linker lengths. The warhead was synthesized from 
commercially available chlorosulfonylbenzoic acids (8a and 8b) (Scheme 2), followed by a 2 
M solution of potassium bifluoride treatment to afford fluorosulfonylbenzoic acids (9a and 9b) 
in good yields. [18] The next step converted the carboxylic acids to acid chlorides (10a and 
10b) by excess thionyl chloride treatment. These acyl chlorides are prone to hydrolysis and  
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Scheme 2. Synthetic route towards the bromoalkyl fluorosulfonylbenzoates 13a-c and 14a-c 
Reagents and conditions: (a) 2M KHF2 solution, dioxane, rt, 1h, 87%-90%; (b) SOCl2 reflux; (c) 
corresponding bromoalkylalcohol, anhydrous dioxane, 100 ˚C, 18h, 55%-83%, (d) 11a-c or 12a-c, 
K2CO3, anhydrous DMF, 50 oC, 5%-57%. 
were thus used in the next step reaction without further purification. To incorporate the acyl 
chlorides with the corresponding bromoalkylalcohols, compounds 10a and 10b were heated to 
100 °C with the addition of bromoalkylalcohols to afford the desired bromoalkyl 
fluorosulfonylbenzoates (11a-c and 12a-c) in decent yields. The final step was to couple the 
core to the corresponding bromoalkyl fluorosulfonylbenzoates. In order to preserve the 
functional fluorosulfonyl group, the reactions were carried out under mild conditions at low 
temperature. Additionally, excess DMF was removed by multiple washing steps, instead of 
vacuum removal at high temperature. Six final products (13a-c and 14a-c) were obtained in 
acceptable yields.  
Amide Linker A similar synthetic approach was initially pursued to prepare analogues with an 
amide linker. However, the basicity and instability of bromoalkylamine caused complex side 
reactions with itself and with the warhead, ending up with an unacceptably low yield of 
amide-linked building blocks. An alternative synthetic route was devised, where 1-
phthalimidopropyl bromide was attached directly to the N3 position of scaffold 6, to afford the 
substituted intermediates 15a-c (Scheme 3). Liberation of the amine took place by treatment 
with hydrazine monohydrate in methanol to obtain compound 16a-c in moderate yield. Then 
16b and 16c were acylated with acyl chlorides 10a and 10b, respectively, to obtain 17c and 
18b. However, impurities brought by the acylation reaction were not easily removed by 







Scheme 3. Synthetic route towards the amide-linker antagonists 17a-c, 18a-c and 19  
 
Reagents and conditions: (a) N-(bromoalkyl)phthalimide, K2CO3, DMF, 100 oC, 5-96%; (b) N2H4ꞏH2O, 
MeOH reflux, 86-90%; (c) EDC, corresponding acid (9a-b), CHCl3 or CH2Cl2, rt; (d) SOCl2, K2CO3, 
dry DMF, 40 oC, 3-78% 
To overcome this, we used peptide coupling conditions with the corresponding benzoic acids 
(9a and 9b) to convert the free amine to the target compounds (17a-b, 18a and 18c) in good 
yields (Scheme 4). A similar synthetic strategy was adapted to obtain reversible ligand 19 as a 
control compound.  
2.3. Pharmacological Evaluation.  
Determination of the apparent affinity (Ki) of synthetized ligands. To determine the binding 
affinity for the hA3AR receptor, all compounds were tested in a radioligand displacement 
binding assay in the presence of 10 nM [3H]PSB-11 at 25 °C according to previously reported 
procedures [7, 19]. All compounds were able to concentration-dependently inhibit specific 
[3H]PSB-11 binding to the hA3AR. As detailed in Table 1, all putative covalent compounds, 
except the two carbon linker compounds (13a, 14a, 17a and 18a), displayed high affinities for 
the hA3AR (Ki < 100 nM). It should be mentioned that the putative covalent nature of the 
interaction between hA3AR and ligands precludes the determination of equilibrium binding 
parameters. Therefore, we expressed the ligands’ affinity for the hA3AR as “apparent Ki”. Of 
note, 17b, bearing three carbon atoms with amide linkage and positioning the sulfonyl 
fluoride at the 4-position of phenyl ring, interacted with hA3AR with comparable affinity (10 
nM) as the parent compound 1. High affinity is desirable for covalent ligand design, as it 
allows sufficient receptor occupancy with the electrophilic warhead in proximity to a 
nucleophilic residue in the binding site over time concomitant with putatively negligible or 
less interaction with off-targets. Thus, we chose compound 17b for further studies. However, 
featuring an electrophilic fluorosulfonyl functionality, 17b was no longer a close analogue of 
compound 1, while a non-reactive control compound, chemically similar to the designed 





Table 1. Apparent Affinities of Pyrido[2,1-f]purine-2,4-dione Derivatives 13-19. 
  
Compound n X R1 
pKi ± SEMa 
or disp. at 10 μM (%) 
13a 1 O 4-SO2F 6.7 ± 0.1 
13b 2 O 4-SO2F 7.7 ± 0.1 
13c 3 O 4-SO2F 7.5 ± 0.1 
14a 1 O 3-SO2F 6.4 ± 0.1 
14b 2 O 3-SO2F 7.0 ± 0.05 
14c 3 O 3-SO2F 7.1 ± 0.05 
17a 1 NH 4-SO2F 27% 
17b 
(LUF7602) 
2 NH 4-SO2F 8.0 ± 0.05 
17c 3 NH 4-SO2F 7.5 ± 0.05 
18a 1 NH 3-SO2F 18% 
18b 2 NH 3-SO2F 7.5 ± 0.01 
18c 3 NH 3-SO2F 6.8 ± 0.1 
19 
(LUF7714) 
2 NH 4-SO2Me 6.3 ± 0.03 
a Data are expressed as means ± SEM of three separate experiments each performed in duplicate. 
Apparent affinity determined from displacement of specific [3H]PSB-11 binding from the hA3AR 
stably expressed on CHO cell membranes at 25 °C during 2 h incubation. 
covalent ligand, is needed for the further pharmacological characterization. A non-substituted 
phenyl to replace the warhead might impose different steric and electronic characteristics of 
the ligand. To avoid this, we performed a conservative structural modification to replace the 
reactive warhead with an electron-withdrawing methylsulfonyl group, yielding derivative 19 










Table 2. (Apparent) Affinities of 17b and 19 for all adenosine receptor subtypes, hA3AR-WT and 
hA3AR-Y265F7.36 





cpd pKi ± SEM 
Displ. (%) 





pIC50 ± SEMe 
17bh 6.1 ± 0.03 5.9 ± 0.09 
0% 
 (7, -7) 
6.9 ± 0.06 8.0 ± 0.01** 7.6 ± 0.05 6.0 ± 0.3* 
19 4.8 ± 0.20 5.2 ± 0.20 
0%  
(-10, -13) 
6.2 ± 0.03 6.1 ± 0.06NS 5.9 ± 0.02 6.1 ± 0.1NS 
Values represent mean ± SEM of three separate experiments each performed in duplicate or 
percent age displacement at 1 μM of two separate experiments each performed in duplicate. 
aAffinity determined from displacement of specific [3H]DPCPX binding on CHO cell membranes 
stably expressing human adenosine A1 receptors at 25 oC during 2 h incubation;  
bAffinity determined from displacement of specific [3H]ZM241385 binding on HEK293 cell 
membranes stably expressing human adenosine A2A receptors at 25 oC during 2 h incubation; 
c% displacement at 1 μM concentration of specific [3H]PSB-603 binding on CHO cell membranes 
stably expressing human adenosine A2B receptors at 25 oC during 2 h incubation. 
dDisplacement of specific [3H]PSB-11 binding on CHO cell membranes stably expressing hA3AR at 
25 °C during 0.5 h incubation. 
eDisplacement of specific [3H]PSB-11 binding from CHO cell membranes stably expressing hA3AR 
preincubated with antagonist for 4 h at 25 °C, followed by a 0.5 h co-incubation with [3H]PSB-11. P < 
0.01** compared with the pKi values in displacement experiments during 0.5 h incubation time; NS: no 
significant difference compared with the pKi values in displacement experiments during 0.5 h 
incubation time; Student’s test.  
fDisplacement of specific [3H]PSB-11 binding from CHO-K1 cell membranes transiently transfected 
with hA3AR-WT at 25 °C during 2 h incubation 
gDisplacement of specific [3H]PSB-11 binding from CHO-K1 cell membranes transiently transfected 
with hA3AR-Y265F7.36 at 25 °C during 2 h incubation. P < 0.01* compared with the pIC50 values in 
displacement experiments on hA3AR-WT. NS: no significant difference compared with the pIC50 
values in displacement experiments on hA3AR-WT  membranes; Student’s test. 
hFor 17b, pKi values are apparent affinity values as no dynamic equilibrium can be obtained. 
To better understand the time-dependent binding characteristics of these compounds, we 
carried out radioligand displacement assays under two different protocols. In detail, the CHO 
cell membranes overexpressing hA3AR were either pre-incubated with the indicated 
compound for 4 h, followed by a 0.5 h co-incubation or only co-incubated for 0.5 h with the 
radioligand [3H]PSB-11. As detailed in Table 2, both compounds had comparable binding 
affinity in the low micromolar range (pKi = 6.9 ± 0.06 for 17b and pKi = 6.2 ± 0.03 for 19) at 
0.5 h incubation time. However, compound 17b showed a significantly increased affinity (pKi 
= 8.0 ± 0.01) when it was pre-incubated with hA3AR, while the affinity of compound 19 did 
not change (pKi = 6.1 ± 0.06).  






Figure 2. (A) Displacement of [3H]PSB-11 binding from hA3AR at 25oC by 17b with and without a 
pre-incubation of 4 h. (B) Displacement of [3H]PSB-11 binding from hA3AR at 25oC by 19 with and 
without a pre-incubation of 4 h. Data represent the mean ± SEM of three individual experiments 
performed in duplicate.   
The effect of pre-incubation on the affinity of 17b and 19 is illustrated in Figure 2, i.e. the 
[3H]PSB-11 displacement curve was shifted to the left with an increased incubation time for 
compound 17b (Figure 2A), while no difference was observed for compound 19 (Figure 2B). 
Presumably this time-dependent binding affinity of compound 17b (i.e. resulting from an 
increased receptor occupancy over time) is a result of an increasing level of covalent binding. 
Similar results on other GPCRs, such as 2 adrenergic receptor [20] and A2A adenosine 
receptor [21], showed that covalent bond formation generates an increased affinity over time. 
Meanwhile, control compound 19 showed no substantial pKi shift in affinity at the two 
incubation times, indicating that a dynamic equilibrium was achieved at both incubation times. 
We can thus speculate that the possible covalent interaction between compound 17b and the 
receptor may be attributed to the presence of a reactive warhead. Finally, we tested 17b and 
19 for their affinity on the other adenosine receptor subtypes, and learned that the two 
compounds were at least modestly selective for the hA3AR (Table 2).Finally, we tested 17b 
and 19 for their affinity on the other adenosine receptor subtypes, and learned that the two 
compounds were at least modestly selective for the hA3AR (Table 2). 
Kinetic characterization of the covalent ligand. Subsequently, the significant shift in 
“apparent Ki” drove us to explore the binding kinetic profile of 17b at the hA3AR, and 
specifically its dissociation rate and residence time (RT). Previously, the kon (k1= 0.281 ± 0.04 
×108 M-1ꞏmin-1) and koff (k2 = 0.3992 ± 0.02 min-1) values of [3H]PSB-11 at 25 °C had been 
determined in our laboratory by traditional association and dissociation assays. Here we 
performed a competition association assay to characterize the binding kinetics of 17b and 19 
following previously reported procedures from our research group [7]. Using the on- and off-
rate constants from [3H]PSB, the kon (k3) and koff (k4) values for 17b were determined using 







slower association rate (kon = 3.48 ± 0.22 x105 M-1 min-1) than the radioligand and a negligible 
dissociation rate (koff  = 1.38 ± 0.22 x10-12 min-1), yielding an almost infinite residence time 
(RT = 7.63 ± 1.19×1011 min), indicative of irreversible receptor binding by 17b. The 
inadequacy of the Motulsky-Mahan equations to fit this data is further evidence for the non-
equilibrium features of the binding of 17b to the receptor. Compound 19 showed fast 
association and dissociation rate constants (Figure 3). Unfortunately, the data did not 
converge in the fitting procedure, possibly due to the low binding affinity of compound 19 (Ki 
= 525 nM).  
 
Figure 3. Competition association assay of [3H]PSB-11 in the absence (control) or presence of 17b 
and 19 at the indicated concentration. Association and dissociation rate constants for the unlabeled 
ligands were calculated by fitting the data to the equations described in the experimental section (“data 
analysis”). Representative graphs are from one experiment performed in duplicate.  
As detailed in Figure 3, the control curve represented the association curve of radioligand 
[3H]PSB-11 alone, approaching equilibrium over time. Compound 19 equally associated to 
and dissociated from the receptor and reached equilibrium within 30 min, evidenced by the 
same curve shape as the control curve. Of note, 17b’s behavior caused an initial ‘overshoot’ 
of the competition association curve, followed by a linear decline over time indicating that no 
equilibrium was reached. The shape of 17b’s kinetic curve is a quintessential example for the 
irreversible interaction, similar to the reported covalent ligands’ behavior for the adenosine 
A2A receptor [21] and mGlu2 receptor [23].   
Wash-resistant interaction between 17b and hA3AR. Inspired by the negligible dissociation of 
compound 17b from the hA3AR, we performed a “washout” experiment to ascertain the 
irreversible binding between the ligand and receptor. A protocol previously reported by our 
laboratory [21] was adapted. We first exposed hA3AR cell membranes to 17b or 19 both at  
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Figure 4. hA3AR membranes pre-incubated with buffer (vehicle) or a 10 × Ki concentration of 
indicated ligand, followed by no washing (Control) or four-cycle washing treatment (4x wash) before 
being exposed to [3H]PSB-11. Data represent the mean ± SEM of three individual experiments 
performed in duplicate, normalized to the vehicle (set at 100%). Statistics were determined using 
unpaired Student’s t test. NS: no significant difference, ****P < 0.0001, significant difference between 
indicated groups. 
10-fold Ki for 2 h, and without washing the samples were supplemented with [3H]PSB-11 to
assess the competitive binding capacity of the receptor (‘Control group’ in Figure 4). For
washed samples, hA3AR cell membranes were subjected to four-cycle washing steps to
remove unbound ligand following the pre-incubation (‘4x wash group’ in Figure 4), after
which the membranes were exposed to [3H]PSB-11 to determine the remaining binding
capacity. In the absence of ligand (labeled ‘+ vehicle’ in Figure 4), we normalized membranes’
binding ability to 100%. Following preincubation with 17b, membranes containing the
hA3AR lost most of the ability to bind to the radioligand (11.3 ± 1.2% binding remaining).
Furthermore, after the pre-incubation, membranes were washed by cycles of centrifugation in
an attempt to regenerate binding capacity. However, washing steps failed to restore hA3AR
binding of  [3H]PSB-11 (8.7 ± 3.8%). This was in contrast to preincubation of the hA3AR-
expressing membranes with ligand 19, in which binding function was completely restored
from 19.8 ± 4.7% to 97.6 ± 4.5% following four washing steps. This result indicates 19 is a
reversible ligand which can be rapidly washed off the membranes, while 17b forms a wash-
resistant bond between the ligand and the receptor. Similar experiments on other GPCRs, such
as adenosine A1 [24, 25] and A2A [21] receptors and the metabotropic glutamate receptor 2
(mGluR2) [23], demonstrated that the covalent interaction between the ligand and the receptor
resulted in a wash-resistant bond formation.
Insurmountable antagonism caused by covalent interaction. To further evaluate the effect of
irreversible inhibition by covalent ligand 17b on receptor function, we performed a membrane
functional assay using [35S]GTPγS, which is a typical readout for activation of receptor-








Figure 5. Effects of 17b and 19 on hA3AR activation as measured by [35S]GTPγS binding. (A, B) 
Compound 17b (A) or 19 (B) were pre-incubated with hA3AR stably expressed on CHO cell 
membranes (25 °C) for 60 min prior to the addition of 2-Cl-IB-MECA at a concentration ranging from 
0.1 nM to 10 µM for 30 min. (C, D) Compound 17b (C) or 19 (D) were co-incubated with 2-Cl-IB-
MECA, at a concentration ranging from 0.1 nM to 10 µM, for 30 min. The agonist curves were 
generated in the presence of increasing concentrations of antagonists, namely 0.3-, 1-, 3-, 10-fold their 
respective Ki values. Data are from three independent experiments performed in duplicate, normalized 
according to the maximal response (100%) produced by 10 µM 2-Cl-IB-MECA alone. The shift in 
agonist EC50 values was determined to perform Schild analyses.  
Pretreatment of hA3AR with increasing concentrations of ligand 17b, prior to the stimulation 
with hA3AR agonist 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-
N-methyl-β-D-ribofuranuronamide (2-Cl-IB-MECA), produced rightward shifts of agonist 
concentration-response curves with a concomitant decline in maximal stimulation (Figure 5a). 
Therefore, the covalent ligand 17b generated insurmountable antagonism in the pre-
incubation experiment. In contrast, pretreatment of hA3AR with 19, followed by 2-Cl-IB-
MECA agonist exposure resulted in surmountable antagonism (Figure 5b), i.e. shifting dose-
response curves to the right with no alteration of its maximum effect. The extent of the shifts 
was used to construct a Schild plot as previously described [7], which would have a slope of 
unity if the interaction is competitive and the pA2-value corresponds to the pKi of the 
antagonist. The slope for 19 was found to be 1.1 ± 0.1 and the compound’s pA2 value was 5.9 
± 0.1, comparable with its pKi value (6.3 ± 0.03), suggesting that 19 competed with 2-Cl-IB-
MECA for the same receptor binding site. 
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Table 3. Functional Analysis of hA3AR Antagonism from [35S]GTPγS Binding Assays 
Pre-incubation Co-incubation 







17b N.A. N.A. 7.4 ± 0.1 1.1 ± 0.1 Competitive Insurmountable 
19 5.9 ± 0.1 1.1 ± 0.1 6.2 ± 0.1 1.0 ± 0.1 Competitive Surmountable 
Values represent mean ± SEM of three separate experiments each performed in duplicate. 
To unravel the molecular mechanism responsible for the insurmountable antagonism of 17b, 
we also co-incubated either 17b or 19 with hA3AR in the presence of 2-Cl-IB-MECA. Both 
ligands produced a rightward shift of the agonist's concentration–response curve (Figure 5c 
and 5d) with no suppression of maximal response, indicative of surmountable antagonism. 
The Schild plot showed that both antagonists inhibited receptor activation in a competitive 
manner, with their Schild-slopes close to unity (1.1 ± 0.1 for 17b, 1.0 ± 0.1 for 19, Table 3). 
In addition, 19’s  pA2 value was in agreement with that from the pre-incubation experiments 
(6.2 ± 0.1, Table 3), and the pA2 value of 17b was also comparable with its pKi value (7.4 ± 
0.1 vs 8.0 ± 0.05).Taken together, both ligands fully competed with 2-Cl-IB-MECA bound to 
hA3AR. Notably, it is likely that the insurmountable behavior relates to covalent binding of 
17b due to an irreversible blockade that reduces the total receptor population available.  
Binding model for 17b in the hA3AR receptor-binding pocket. To examine the interaction between 
receptor residues possibly involved in covalent binding, we docked 17b into a ligand optimized 
homology model on the basis of the A2A receptor crystal structure (PDB: 4EIY [27]), as described 
previously [7]. As detailed in Figure 6, the core structure of compound 17b interacted with the TM3, 
TM6 and EL2 regions. Additionally, the carbonyl-oxygen at the C4-position participated in H-bond 
formation with residue N2506.55 and the methoxyl moiety at the C8-position functioned as H-bond 
acceptor with Q167EL2. Interestingly, the latter is a unique residue in hA3AR, as it is not conserved in 
other subtypes of adenosine receptors. Due to the flexibility of the three-carbon linker, the tyrosine 
residue Y2657.36 is in close proximity of the ligand, and could therefore interact with the 4-
fluorosulfonylbenzoic warhead to form a covalent sulfonyl amide. Similarly, the same residue Y2717.36 
located within the human adenosine A1 receptor has also been reported to covalently interact with the 
fluorosulfonyl warhead of compound 2 [11]. Comparison of the binding modes of compound 2 and 
ligand 17b in an A1/A3 receptor overlay showed that key interactions between ligands and binding 








Figure 6. Proposed binding mode of compound 17b (green carbon sticks) in a homology model (violet 
ribbons) of hA3AR. The hA3AR homology model was based on the high-resolution antagonist-bound 
crystal structure of the adenosine A2A receptor (PDB: 4EIY [27]). Atoms color code: red = oxygen, 
blue = nitrogen, white = hydrogen, yellow = sulfur, cyan = fluorine. Hydrogen bonds between ligand 
and receptor are indicated by yellow dashed lines. Residue Y2657.36 is in the proximity of the 
fluorosulfonyl warhead. 
Y2657.36 as an anchor point for the covalent bond. Based on the docking study, we postulated 
that Y2657.36 is the anchor point for covalent bond formation. To investigate our hypothesis 
this tyrosine was mutated to phenylalanine (hA3AR-Y265F7.36), to remove the nucleophilic 
reactivity of the phenolic hydroxyl group. First we performed standard [3H]PSB-11 
displacement assays to investigate the binding affinity of 17b and 19 using CHO-K1 cell 
membranes transiently transfected with either wild type (hA3AR-WT) or mutant receptors 
(hA3AR-Y265F7.36). As shown in Table 2 and Figure 7, the affinity of control compound 19 
on hA3AR-Y265F7.36 (pIC50 = 6.09 ± 0.11) was similar to the affinity to hA3AR-WT (pIC50 = 
5.95 ± 0,03), indicating that the mutation has no impact on the binding affinity of the 
reversible ligand. In marked contrast, 17b’s affinity was decreased nearly 43-fold relative to 
WT, from an IC50 value of 27 nM to 1072 nM, indicative of the loss of irreversible interaction. 
Moreover, there were no marked affinity differences on hA3AR-Y265F7.36 between 17b and 
19. This suggests that the chemically dissimilar ligands 17b (reactive) and 19 (nonreactive) 
exhibit a similar binding interaction with hA3AR-Y265F7.36. We thus speculate the amino acid 
in position 7.36 plays a prominent role in the covalent bond formation between the 
fluorosulfonyl warhead and receptor. To support this idea, we repeated the “washout” assay 
on hA3AR-Y265F7.36. Membranes treated with 17b at 10-fold IC50 inhibited the specific 
[3H]PSB-11 binding to 7.2 ± 0.6%. After extensive washing, hA3AR-Y265F7.36 showed a 
complete recovery of [3H]PSB-11 binding to 91 ± 2% (Figure 7c). This full recovery for 
mutant hA3AR-Y265F7.36 is in sharp contrast to the findings in the wild type washout assay 
(Figure 4), indicating Y265F7.36 completely prevented the wash-resistant bond formation. In  





Figure 7. (A, B) Displacement of specific [3H]PSB-11 binding from transiently transfected hA3AR-
WT and hA3AR-Y265F7.36 at 25°C by compound 17b (A) and 19 (B) during an incubation of 2 h. (C) 
hA3AR-Y265F7.36 cell membranes were pretreated with buffer (vehicle) or 10 × IC50 of compound 17b  
for 2 h followed by no washing (Control) or four-cycle washing treatment (4x wash) before exposed to 
[3H]PSB-11. Data represent the mean ± SEM of three individual experiments performed in duplicate, 
normalized to the vehicle (set at 100%). NS: no significant difference between groups; ***Significant 
difference between groups (P<0.001); Student’s t-test 
other words Y2657.36 is the unique amino acid residue involved in the covalent attachment of 
17b’s fluorosulfonyl group within the hA3AR binding pocket. A similar approach was also 
adopted to pinpoint the anchor point between covalent probes and other subtypes of GPCRs, 
such as  the adenosine A2A receptor [21] mGlu2 receptor [23]  and cannabinoid CB1 receptor 
[28]. 17b can be a useful structural biology tool as it would be expected to stabilize the 7TM 
domain in its inactive state, thereby potentially facilitating crystallization of receptor material. 
This could be highly valuable for the structure elucidation of hA3AR which up to now 
remains unreported. Furthermore, understanding the precise molecular interactions between 
ligand and receptor may stimulate the more rational design of novel ligands. Such ligands 
may have improved receptor subtype selectivity, fewer undesirable side effects, and enhanced 
potency and efficacy, leading to potentially attractive therapeutic agents that produce their 
effects by modulating the functionality of the adenosine system. Given that GPCR-targeted 
covalent drugs went through clinical success across various indications,[29] our covalent 
compound 17b may serve as a probe to explore the problematic translation of hA3AR ligands 
into clinical utility in certain disease states such as eye disorder glaucoma, in which an 
increased A3 adenosine receptor mRNA and protein level have been detected.  
3. Conclusions 
By introducing a reactive sulfonyl fluoride warhead onto the 1-benzyl-3-propyl-1H,3H-pyrido 
[2,1-f]purine-2,4-dione scaffold, we designed and synthesized a series of novel covalent 
hA3AR antagonists. Compound 17b acted as the most potent antagonist, with a time 
dependent apparent affinity in the low nanomolar range. Meanwhile, we removed the warhead 
and inserted a methylsulfonyl moiety into the scaffold, to obtain ligand 19 as a reversible 







resistant nature and insurmountable antagonism in [35S]GTPγS binding assays. In silico 
homology-docking suggested that Y2657.36 is responsible for the covalent interaction. Site-
directed mutagenesis showed that removal of the nucleophilic tyrosine phenolic hydroxyl 
group resulted in the complete loss of covalent binding, validating that Y2657.36 is the only 
anchor point of reactive covalent ligand 17b. The results contribute to a better understanding 
of pharmacological behaviors caused by covalent interaction with GPCRs. In the end, we 
developed a structured approach to quickly obtain a well-defined covalent ligand. Besides, we 
envisioned that a methylsulfonyl replacement would be suitable for providing a non-reactive 
sulfonyl-bearing control compound. The rational design of covalent probes may have further 
value in receptor structure elucidation or in new technologies such as affinity-based protein 
profiling [15, 30] with the perspective of imaging or structurally probing GPCRs.  
4. Experimental Section 
4.1. Chemistry All solvents and reagents were purchased from commercial sources and 
were of analytical grade. Demineralized water is simply referred to as H2O, and was used in 
all cases unless stated otherwise (i.e. brine). 1H were recorded on a Bruker AV 400 liquid 
spectrometer (1H NMR, 400 MHz) at ambient temperature and 13C NMR spectra was 
performed on a Bruker AV 600 liquid spectrometer (13C NMR, 125 MHz) at indicated 
temperature. Chemical shifts are reported in parts per million (ppm), using residual solvent as 
the internal reference in all cases. The values are given in δ scale. Coupling-constants are 
reported in Hz and are designated as J. Analytical purity of the final compounds was 
determined by high performance liquid chromatography (HPLC) with a Phenomenex Gemini 
3μm C18 110Å column (50 × 4.6 mm, 3 μm), measuring UV absorbance at 254 nm. Sample 
preparation and HPLC method was as follows: 0.3-1.0 mg of compound was dissolved in 1 
mL of a 1:1:1 mixture of MeCN/H2O/tBuOH and eluted from the column within 15 minutes 
at a flow rate of 1.3 mL/min with a three component system of H2O/MeCN/1% TFA in H2O. 
The elution method was set up as follows: 1–4 min isocratic system of H2O/MeCN/1% TFA 
in H2O, 80:10:10, from the 4th min, a gradient was applied from 80:10:10 to 0:90:10 within 9 
min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. All final 
compounds showed a single peak at the designated retention time and are at least 95% pure. 
Liquid chromatography–mass spectrometry (LC-MS) analyses were performed using Thermo 
Finnigan Surveyor - LCQ Advantage Max LC-MS system and a Gemini C18 Phenomenex 
column (50 × 4.6 mm, 3 μm). High resolution mass spectrometry (HRMS) analyses were 
performed using a Thermo Scientific™ LTQ Orbitrap XL™ Hybrid Ion Trap-Orbitrap Mass 
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Spectrometer. The sample preparation was the same as for HPLC and HRMS analysis. The 
compounds were eluted from the column within 15 minutes after injection, with a three 
component system of H2O/MeCN/0.2% TFA in H2O, decreasing polarity of the solvent 
mixture in time from 80:10:10 to 0:90:10. Thin-layer chromatography (TLC) was routinely 
consulted to monitor the progress of reactions, using aluminum coated Merck silica gel F254 
plates. Purification by column chromatography was achieved by use of Grace Davison Davisil 
silica column material (LC60A 30-200 micron). Solutions were concentrated using a 
Heidolph Laborota W8 2000 efficient rotary evaporation apparatus. All reactions in the 
synthetic routes were performed under nitrogen atmosphere unless stated otherwise. The 
procedure for a series of similar compounds is given as a general procedure for all within that 
series, annotated by the numbers of the compounds.  
1-benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f]purine-2,4-dione (1) [7, 8]. To a stirred
suspension of 6 (6.0 g, 19 mmol, 1.0 equiv) in MeCN (120 mL) were added 1-bromopropane
(5.6  mL, 57mmol, 3.0 equiv) and DBU (50 mL, 57 mmol, 3.0 equiv). This mixture was
stirred at 70 °C overnight. Conversion of starting material was confirmed by TLC (2% MeOH
in CH2Cl2) and the solvent was removed under vacuum. The residue was suspended in
CH2Cl2 (200 mL) and the organic phase was washed with 1M HCl (200 mL), H2O (200 mL),
brine (200 mL) and dried over MgSO4, filtered and concentrated in vacuo. The crude was
purified by column chromatography (0.5% MeOH in CH2Cl2) to obtain 1 as a white solid (5.0
g, 14 mmol, 73%). 1H NMR (400 MHz, CDCl3): δ 8.82 (d, J = 7.6 Hz, 1H), 7.58 – 7.51 (m,
2H), 7.34 – 7.22 (m, 3H), 6.98 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.4, 2.2 Hz, 1H), 5.36 (s, 2H),
4.04 – 3.97 (m, 2H), 3.92 (s, 3H), 1.76 – 1.65 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H)
6-amino-1-benzyl-1,3-dihydropyrimidine-2,4-dione (5)[7, 8]. The synthesis of the
compounds adapted from the procedure reported before [7, 8]. Benzylurea (3) (25 g, 167
mmol, 1.0 equiv) and 4  (16 g, 191 mmol, 1.1 equiv) were dissolved in acetic anhydride (100
mL). This mixture was stirred at 80 °C for 2 h. After the mixture was cooled to room
temperature, diethyl ether (150 mL) was added followed by 1 hour of stirring at room
temperature. The precipitate was filtered off and suspended in a mixture of EtOH (75 mL) and
H2O (150 mL). This mixture was heated to 85 °C and 3 M NaOH (aq.) (50 mL) was added
dropwise. After 1 h, the mixture was concentrated and neutralized dropwise with HCl (37 %).
The precipitate was filtered off and washed with acetone, obtaining 5 as a white solid (9.0 g,
42 mmol, 25%). 1H NMR (400 MHz, DMSO-d6): δ 10.42 (brs, 1H), 7.48 – 7.08 (m, 5H), 6.85







1-benzyl-8-methoxy-1H,3H-pyrido[2,1-f]purine-2,4-dione (6) [7, 8]. To the intermediate (5) 
(9.0 g, 42 mmol, 1.0 equiv) and NBS (15 g, 83 mmol, 2.0 equiv) was added MeCN (100 mL). 
This mixture was stirred at 80 °C. After 1.5 h conversion of starting material was confirmed 
by TLC (10% MeOH in CH2Cl2), 4-methoxypyridine (13 g, 125 mmol, 3.0 equiv) was added 
and the reaction mixture was stirred at 80 °C for 4.5 h. After cooling to room temperature, the 
precipitate was filtered off and washed with diethyl ether and MeOH, yielding product 6 as a 
white solid (8.5 g, 26 mmol, 64%). 1H NMR (400 MHz, DMSO-d6): δ 11.31 (br s, 1H), 8.70 
(d, J = 7.2 Hz, 1H), 7.38 – 7.16 (m, 6H), 6.90 (dd, J = 7.4, 2.2 Hz, 1H), 5.18 (s, 2H), 3.89 (s, 
3H)  
8-methoxy-3-propyl-1H,3H-pyrido[2,1-f]purine-2,4-dione (7) [7, 8]. To a mixture of the 
intermediate 1 (1.1 g, 3.0 mmol, 1.0 equiv), Pd(OH)2/C (2.0 g, 14 mmol, 1.0 equiv) and 
ammonium formate (0.20 g, 3.0 mmol, 1.0 equiv) was added EtOH (250 mL). During the 
reaction, five portions of ammonium formate (0.20 g, 3.0 mmol, 1.0 equiv) was added, after 
which  completion of the reaction was observed on TLC (5% MeOH in CH2Cl2). The reaction 
was filtered over Celite and the residue was extracted with hot DMF. Purification of the crude 
product by column chromatography using 2-10% MeOH in CH2Cl2 to obtained 5 as a white 
solid (0.30 g, 1.2 mmol, 40%). 1H NMR (400 MHz, DMSO-d6): δ 12.05 (s, 1H), 8.73 (d, J = 
7.2 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 6.89 (dd, J = 7.4, 2.6 Hz, 1H), 3.90 (s, 3H), 3.85 – 3.78 
(m, 2H), 1.64 – 1.52 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H) 
General procedure for the synthesis of fluorosulfonylbenzoic acids (9a–b). To a solution 
of chlorosulfonylbenzoic acid (8a-b) (2.2 g, 10 mmol, 1.0 equiv) in dioxane (25 mL) was 
added a solution of HF:KF (15 mL, 2.0 M, 3.0 equiv). The mixture was stirred at room 
temperature. After 1 h, the reaction mixture was dilute with EtOAc (80 mL). The organic 
phase was washed with H2O (50 mL), dried over MgSO4, filtered and concentrated in vacuo. 
3-(fluorosulfonyl)benzoic acid (9a). White solid (1.9 g, 8.7 mmol, 87%). 1H NMR (400MHz, 
DMSO-d6): δ 8.47-8.44 (m, 2H), 8.4 (d, J = 8.0 Hz, 1H), 7.94 (t, J = 7.6 Hz, 1H). 
4-(fluorosulfonyl)benzoic acid (9b). White solid (2.0 g, 9.0 mmol, 90%). 1H NMR (400 
MHz, DMSO-d6): δ 13.86 (s, 1H), 8.28 (s, 4H)  
General procedure for the synthesis of bromoalkyl (fluorosulfonyl)benzoates (11a-c and 
12a-c) A mixture of thionyl chloride (8 mL) and fluorosulfonylbenzoic acid (9a-b) (1 equiv) 
was refluxed at 75 °C for 3 h. The solvent was removed under vacuum. And the product was 
used in the next step without further analysis. Dry dioxane (6 mL) was added to the 
(fluorosulfonyl)benzoyl chloride (10a-b). To this solution the corresponding 
bromoalkylalcohol (0.85 equiv) was added and the mixture was refluxed overnight. After 
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completion was observed on TLC (CH2Cl2) the volatiles were removed in vacuo and the 
crude product was purified by column chromatography using CH2Cl2 as an eluent to afford 
the products. 
2-bromoethyl-4-(fluorosulfonyl)benzoate (11a) Colorless oil (0.088 g, 0.28 mmol, 23%)  1H
NMR (400 MHz, DMSO-d6): δ 8.31 (d, J = 8.2 Hz, 2H), 8.11 (d, J = 8.5 Hz, 2H), 4.69 (t, J =
5.9 Hz, 2H), 3.67 (t, J = 5.9 Hz, 2H).
3-bromopropyl-4-(fluorosulfonyl)benzoate (11b) White solid (2.0 g, 6.2 mmol, 50%) 1H
NMR (400 MHz, CDCl3): δ 8.27 (d, J = 8.4 Hz, 2H ), 8.09 (d, J = 8.4 Hz, 2H), 4.54 (t, J = 6.0
Hz, 2H), 3.54(d, J = 6.4 Hz, 2H), 2.35 (m, 2H).
4-bromobutyl-4-(fluorosulfonyl)benzoate (11c) White solid (0.30 g, 0.89 mmol, 45%)
Compound was used without further purification.
2-bromoethyl-3-(fluorosulfonyl)benzoate (12a). Colorless Oil (0.51 g, 1.7 mmol, 55%) 1H
NMR (400 MHz, CDCl3): δ 8.69 (s, 1H), 8.47 (d, J = 7.6 Hz, 1H), 8.25 – 8.20 (m, 1H), 7.78 (t,
J = 8.0 Hz, 1H), 4.71 (t, J = 6.0 Hz, 2H), 3.68 (t, J = 6.0 Hz, 2H).
3-bromopropyl-3-(fluorosulfonyl)benzoate (12b).Colorless oil (0.12 g, 0.38 mmol, 23%)
1H NMR (400 MHz, CDCl3) δ 8.65 (t, J = 1.6 Hz, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.21 (d, J =
8.0 Hz, 1H), 7.76 (t, J = 7.9 Hz, 1H), 4.55 (t, J = 6.1 Hz, 1H), 3.55 (t, J = 6.4 Hz, 1H), 2.37 (p,
J = 6.3 Hz, 1H).
4-bromobutyl-3-(fluorosulfonyl)benzoate (12c). Colorless Oil (0.84 g, 2.5 mmol, 83%,) 1H
NMR (400 MHz, CDCl3): δ 8.65 (s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H),
7.78 (t, J = 7.6 Hz, 1H), 4.44 (t, J = 6.0 Hz, 2H), 3.50 (t, J = 6.4 Hz, 2H), 2.11 – 1.85 (m, 4H).
General procedure for the synthesis of 13a–c and 14a–c
The synthesis of these compounds were adapted from the conditions previously described by
Priego et al [6]. The scaffold, 8-methoxy-3-propyl-1H,3H-pyrido[2,1-f]purine-2,4-dione 7
(1.0 equiv), and K2CO3 (1.6 equiv) were suspended in anhydrous DMF. The mixture was
added dropwise to a stirred solution of the corresponding bromoalkyl
(fluorosulfonyl)benzoate (11a-c or 12a-c) (1.0 equiv) in anhydrous DMF (4 mL). The
reaction was stirred at 50 °C overnight. After conversion on TLC was observed, excess
amount of CH2Cl2 was added. Then the mixture was washed with 1M HCl (aq.), water and
brine. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude
product was purified by column chromatography, followed to a prep TLC was used to further
purify the compound if necessary.
2-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purine-1(2H)-yl)ethyl 4-







(1% CH3OH in CH2Cl2) to give the desired product as white solid (0.038 g, 0.07 mmol, 52%). 
1H NMR (400 MHz, CDCl3): δ 8.80 (d, J = 8.0 Hz, 1H), 8.17 (d, J = 8.0 Hz, 2H), 7.98 (d, J = 
8.4 Hz, 2H), 6.76-6.73 (m, 2H), 4.78 (t, J = 4.8 Hz, 2H), 4.64 (t, J = 5.2 Hz, 2H), 4.00 (t, J = 
7.6 Hz, 2H), 3.89 (s, 3H), 1.73-1.62 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). MS: [ESI+H]+: 505.1. 
HPLC: 9.99 min 
3-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purine-1(2H)-yl)propyl 4-
(fluorosulfonyl)benzoate (13b) Prepared from 11b and purified by column chromatography 
(1% CH3OH in CH2Cl2) to give the desired product as white solid (0.096 g, 0.19 mmol, 76%). 
1H NMR (400 MHz, CDCl3): δ 8.76 (d, J = 7.2 Hz, 1H), 8.23 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 
8.4 Hz, 2H), 6.77 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 4.50 (t, J = 6.0 Hz, 2H), 
4.41 (t, J = 6.8 Hz, 2H), 4.00 (t, J = 7.2 Hz, 2H), 3.90 (s, 3H), 2.38 (pentet, J = 6.0 Hz, 2H), 
1.71 (sextet, J = 7.2 Hz, 2H), 0.99 (t, J = 7.6 Hz, 3H). MS: [ESI+H]+: 519.1. HPLC: 10.18 
min 
4-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purine-1(2H)-yl)butyl 4-
(fluorosulfonyl)benzoate(13c) Prepared from 11c and purified by column chromatography (2% 
CH3OH in CH2Cl2) to give the desired product as white solid (0.010 g, 0.019 mmol, 5.2%.) 
1H NMR (400 MHz, CDCl3): δ 8.83 (dd, J = 7.6, 0.8 Hz, 1H), 8.27 (d, J = 8.0 Hz, 2H), 8.07 
(d, J = 8.8 Hz, 2H), 6.93 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 7.6, 2.4 Hz, 1H), 4.46 (t, J = 6.4 Hz, 
2H), 4.28 (t, J = 6.8 Hz, 2H), 4.02 (t, J = 7.2 Hz, 2H), 3.93 (s, 3H), 2.05 – 1.90 (m, 4H), 1.77 
– 1.68 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H). MS: [ESI+H]+: 533.1.  HPLC: 9.40 min 
2-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purine-1(2H)-yl)ethyl 3-
(fluorosulfonyl)benzoate (14a) Prepared from 12a and without purification to give the 
desired product as white solid ( 0.19 g, 0.36 mmol, 57%).  1H NMR (400 MHz, CDCl3) ): δ 
8.80 (d, J = 7.2 Hz, 1H), 8.51 (s, 1H), 8.36 (d, J = 7.6 Hz, 1H), 8.14 – 8.09 (m, 1H), 7.66 (t, J 
= 7.8 Hz, 1H), 6.84 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.6, 2.6 Hz, 1H), 4.78 (t, J = 4.8 Hz, 2H), 
4.65 (t, J = 4.8 Hz, 2H), 4.04 – 3.97 (m, 2H), 3.90 (s, 3H), 1.68 (sextet, J = 7.6 Hz, 2H), 0.96 
(t, J = 7.4 Hz, 3H). MS: [ESI+H]+: 505.1. HPLC: 8.47 min 
3-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purine-1(2H)-yl)propyl 3-
(fluorosulfonyl)benzoate (14b) Prepared from 12b and purified by column chromatography 
(1% CH3OH in CH2Cl2)  to give the desired product as white solid ( 0.035 g, 0.068 mmol, 
34%). 1H NMR (400 MHz, CDCl3): δ 8.74 (d, J = 7.6 Hz, 1H), 8.65 (s, 1H), 8.36 (d, J = 8.0 
Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.73 (t, J = 8.0 Hz, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.72 (dd, 
J = 7.2, 2.4 Hz, 1H), 4.51 (t, J = 6.0 Hz, 2H), 4.41 (t, J = 6.0 Hz, 2H), 3.99 (t, J = 7.6 Hz, 2H), 
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3.91 (s, 3H), 2.39 (pentet, J = 6.0 Hz, 2H), 1.70 (sextet, J = 7.6 Hz, 2H), 0.98 (t, J = 7.6 Hz, 
3H). MS: [ESI+H]+: 519.1. HPLC: 8.84 min 
4-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purine-1(2H)-yl)butyl 3-
(fluorosulfonyl)benzoate(14c) Prepared from 12c and purified by column chromatography 
(first 30% DCM in EtOAc). Further purification by another column (4:1= MTBE: PET) gives 
the desired product as white solid (0.20g, 0.37 mmol, 38%). 1H NMR (400 MHz, CDCl3): δ 
8.85 (d, J = 7.2 Hz, 1H), 8.67 (s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.75 
(t, J = 8.0 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 7.2, 2.4 Hz, 1H), 4.49 (t, J = 6.4 Hz, 
2H), 4.30 (t, J = 7.2 Hz, 2H), 4.08 – 4.01 (m, 2H), 3.95 (s, 3H), 2.10 – 2.00 (m, 2H), 2.00 – 
1.89 (m, 2H), 1.81 – 1.69 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H). MS: [ESI+H]+: 533.1. HPLC: 
9.14 min 
General procedure for the synthesis 1-(2-(1,3-dioxoisoindolin-2-yl)alkyl)-8-methoxy-3-
propyl-1H,3H-pyrido-[2,1-f]purine-2,4-dione (15a-c). To a mixture of the core (7) (0.8 
mmol, 1 equiv), N-(bromoalkyl)phthalimide (1.2 mmol, 1.5 equiv) and K2CO3 (1.2 mmol, 1.5 
equiv) was added anhydrous DMF (8 mL). The mixture was refluxed at 100 °C. After 
completion of the reaction, monitored by TLC (1% MeOH in CH2Cl2), the mixture was 
concentrated in vacuo and diluted with EtOAc (30 mL). The organic layer was washed with 
H2O (3 × 30 mL), brine (15 mL) and dried over MgSO4. The solvent was evaporated under 
reduced pressure, and the residue was purified by column chromatography using 1% MeOH 
as an eluent to give 15a–c as solids. 
1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f]purine-
2,4-dione (15a) Prepared from N-(2-bromoethyl)phthalimide and purified by column 
chromatography to give the desired product as white solid (0.20 g, 0.44 mmol, 5%). 1H NMR 
(CDCl3): δ  8.77 (d, J = 6.8 Hz, 1H), 7.73 (s, 2H), 7.64 (s, 2H), 6.69 (d, J = 14.0 Hz, 2H), 4.53 
(s, 2H), 4.17 (s, 2H), 3.89 (d, J = 6.2 Hz, 2H), 3.85 (s, 3H), 1.58 – 1.45 (m, 3H), 0.86 (t, J = 
7.2 Hz, 3H). 
1-(2-(1,3-dioxoisoindolin-2-yl)propyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f]purine-
2,4-dione (15b) Prepared from N-(3-bromoethyl)phthalimide and purified by column 
chromatography to give the desired product as yellow solid (0.31 g, 0.66 mmol, 66%). 1H 
NMR (400 MHz, CDCl3): δ 8.81 – 8.75 (m, 1H), 7.86 – 7.76 (m, 2H), 7.73 – 7.61 (m, 2H), 
6.80 (s, 1H), 6.72 (dd, J = 7.2, 2.4 Hz, 1H), 4.29 (t, J = 6.8 Hz, 2H), 4.04 – 3.93 (m, 2H), 3.90 
(s, 3H), 3.86 – 3.78 (m, 2H), 2.35 – 2.20 (m, 2H), 1.78 – 1.60 (m, 2H), 1.06 – 0.87 (m, 3H). 
1-(2-(1,3-dioxoisoindolin-2-yl)butyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f]purine-







chromatography to give the desired product as white solid (0.37 g, 0.76 mmol, 96%). 1H 
NMR (400 MHz, CDCl3): δ 8.82 (d, J = 7.2 Hz, 1H), 7.82 (dd, J = 5.2, 2.8 Hz, 2H), 7.70 (dd, 
J = 5.2, 2.8 Hz, 2H), 6.93 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.2, 2.4 Hz, 1H), 4.22 (d, J = 7.2 
Hz, 2H), 4.04 – 3.96 (m, 2H), 3.92 (s, 3H), 3.75 (d, J = 7.2 Hz, 2H), 1.95 – 1.85 (m, 2H), 1.85 
– 1.77 (m, 2H), 1.74 – 1.65 (m, 3H), 0.97 (d, J = 7.6 Hz, 3H). 
General procedure for the synthesis 1-(2-aminoalkyl)-8-methoxy-3-propyl-1H,3H-
pyrido-[2,1-f]purine-2,4-dione (16a-c). To a stirred suspension of 15a-c (0.66 mmol, 1 equiv) 
in MeOH (8 mL) was added excess hydrazine monohydrate (4.8 mL, 99 mmol). The mixture 
was stirred for 2–4 h at reflux. After conversion of the starting material, the mixture was 
cooled to room temperature. The solvents were removed under vacuum and the residue was 
dissolved in 2 M NaOH (aq.) (25 mL). This aques phase was extracted three times with 
CH2Cl2 (25 mL). The organic layers were combined, dried over MgSO4 and concentrated in 
vacuo to obtain 16a-c.  
1-(2-aminoethyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f]purine-2,4-dione (16a). 
Prepared from 15a and purified by column chromatography to give the desired product as 
white solid (0.13 g, 0.39 mmol, 90%). 1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 7.6 Hz, 1H), 
6.95 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.2, 2.4 Hz, 1H), 4.27 (t, J = 6.4 Hz, 2H), 4.05 – 3.99 
(m, 2H), 3.93 (s, 3H), 3.15 (t, J = 6.4 Hz, 2H), 1.78 – 1.67 (m, 2H), 0.99 (d, J = 7.6 Hz, 3H). 
1-(3-aminopropyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f]purine-2,4-dione (16b). 
Prepared from 15b and purified by column chromatography to give the desired product as 
white solid (0.25 g, 0.75 mmol, 97%). 1H NMR (400 MHz, CDCl3): δ 8.82 (d, J = 7.2 Hz, 1H), 
6.95 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.6, 2.4 Hz, 1H), 4.29 (t, J = 6.8 Hz, 2H), 4.07 – 3.98 
(m, 2H), 3.93 (s, 3H), 2.75 (t, J = 6.6 Hz, 2H), 1.98 (p, J = 6.6 Hz, 2H), 1.78 – 1.65 (m, 2H), 
0.99 (t, J = 7.4 Hz, 3H). 
1-(4-aminobutyl)- 8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f]purine-2,4-dione (16c). 
Prepared from 15c and purified by column chromatography to give the desired product as 
white solid (0.23 g, 0.66 mmol, 86%). 1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 7.6 Hz, 1H), 
6.97 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.2, 2.4 Hz, 1H), 4.20 (t, J = 7.2 Hz, 2H), 4.06 – 3.98 
(m, 2H), 3.92 (s, 3H), 2.77 (d, J = 6.8 Hz, 2H), 1.92 – 1.82 (m, 2H), 1.78 – 1.66 (m, 2H), 1.63 
– 1.53 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H). 
4-((2-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-
yl)ethyl)carbamoyl)benzenesulfonyl fluoride (17a) EDC (0.12 g, 0.60 mmol, 1.2 equiv) 
was dissolved in CHCl3 (4 mL). To this stirring solution was added the acid (9a) (0.11g, 0.55 
mmol, 1.1 equiv). The amine (16a) (0.16 g, 0.50 mmol, 1.0 equiv) was suspended in CHCl3 (6 
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mL), then was added dropwise via an automatic syringe at a rate of 0.2 mL/min. The reaction 
was stirred for 1.5 h at room temperature and monitored by TLC (CH2Cl2: acetone = 3:2). 
After completion the solvent was removed under vacuum and the residue was redissolved in 
CHCl3 (40 mL). The organic layer was washed with 1 M HCl (40 mL), H2O (2 × 40 mL), 
dried over MgSO4 and concentrated in vacuo to obtain 17a as white solid (0.20 g, 0.39 mmol, 
78%). 1H NMR (400 MHz, CDCl3): δ 8.83 (d, J = 7.2 Hz, 1H), 8.07 – 8.00 (m, 5H), 6.91 (d, J 
= 2.4 Hz, 1H), 6.80 (dd, J = 7.2, 2.0 Hz, 1H), 4.62 – 4.55 (m, 2H), 4.03 (t, J = 7.6 Hz, 2H), 
3.95 (s, 3H), 3.94 – 3.89 (m, 2H), 1.68 (sextet, J = 7.6 Hz, 2H), 0.97 (t, J = 7.2 Hz, 3H). MS: 
[ESI+H]+: 504.1. HPLC: 7.93 min.  
4-((3(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-
1(2H)yl)propyl)carbamoyl)benzenesulfonyl fluoride (17b). To a suspension of EDC (0.22 
g, 0.80 mmol, 1.5 equiv) and 9a (0.16 g, 0.80 mmol 1.05 equiv) was dissolved in CH2Cl2 (4 
mL). To this stirring solution was added the amine (16b) (0.25 g, 0.76 mmol, 1.0 equiv) at 
room temperature. The reaction was stirred for 2 h and monitored by TLC (3% MeOH in 
CH2Cl2). After completion, the solvent was removed in vacuo and the residue was dissolved 
in CHCl3 (40 mL). The organic layer was washed with 1 M HCl (40 mL), twice with H2O (2 
× 40 mL), dried over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography using 2% MeOH in CH2Cl2 to afford the title compound as white solid (0.26 
g, 0.50 mmol, 66%). 1H NMR (400MHz, CDCl3) δ: 8.86 (d, J = 7.2 Hz, 1H), 8.38 (t, J = 5.6 
Hz, 1H), 8.25 (d, J = 8.4 Hz, 2H), 8.16 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 2.4 Hz, 1H), 6.81 (dd, 
J = 7.2, 2.4 Hz, 1H), 4.35 (t, J = 6.0 Hz, 2H), 4.05 (t, J = 7.6 Hz, 2H), 3.92 (s, 3H), 3.47 (q, J 
= 6.4 Hz, 2H), 2.19–2.13 (m, 2H), 1.73 (sextet, J = 7.6 Hz, 2H), 1.00 (t, J = 7.6 Hz, 3H). 13C 
NMR (600 MHz, DMSO-d6, 348K) δ 164.0, 160.9, 153.4, 150.6, 150.5, 149.1, 141.3, 133.3 
(d, J = 96 Hz), 128.5, 127.9, 127.3, 107.0, 99.8, 95.4, 55.7, 41.5, 40.6, 36.8, 27.1, 20.5, 10.6. 
MS: [ESI+H]+: 518.1. HRMS-ESI+: [M + H] + calcd: 518.1510 found: 518.1540, 
C23H25O6N5FS. HPLC: 8.27 min. 
4-((4-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-
yl)butyl)carbamoyl)benzenesulfonyl fluoride (17c) The acid 9a (0.11 g, 0.53 mmol, 1.5 
equiv) was dissolved in an excess of thionyl chloride (20 mL) at 75 °C under nitrogen for 3 h. 
After removal of solvent and other volatiles in vacuum, 10a was obtained as colorless oil. 
Subsequently the amine 16c (0.12 g, 0.35 mmol, 1.0 equiv), K2CO3 (0.073 g, 0.53 mmol, 1.5 
equiv)) and dry DMF were added and the reaction as stirred at 40 °C overnight. After 
completion of the reaction, 1M HCl (200 mL) was added and extracted with CH2Cl2 (150 mL). 







was dried, filtered and concentrated in vacuo. The residue was purified by column 
chromatography using CH2Cl2 with 1% methanol as eluent to give 17c as white solid (5.0 mg, 
0.0094 mmol, 4%). 1H NMR (400 MHz, CDCl3): δ 8.87 (d, J = 7.6 Hz, 1H), 8.17 (d, J = 8.4 
Hz, 2H), 8.09 (d, J = 8.4 Hz, 2H), 7.54 (brs, 1H), 6.85 (s, 1H), 6.80 (dd, J = 7.2, 2.4 Hz, 1H), 
4.29 (t, J = 7.6 Hz, 2H), 4.06 (t, J = 7.6 Hz, 2H), 3.92 (s, 3H), 3.68 (q, J = 6.0 Hz, 2H), 2.01 
(pent, J = 6.8 Hz, 2H), 1.84-1.70 (m, 4H), 1.02 (t, J = 7.6 Hz, 3H). MS: [ESI+H]+: 532.3 . 
HPLC: 8.28 min.  
3-((2-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-
yl)ethyl)carbamoyl)benzenesulfonyl fluoride (18a) EDC (0.12 g, 0.60 mmol, 1.2 equiv) 
was dissolved in CHCl3 (4 mL). To this stirring solution was added the acid 9b (0.11 g, 0.55 
mmol, 1.1 equiv). The amine 16a (0.16 g, 0.50 mmol, 1.0 equiv) was suspended in CHCl3 (6 
mL), then was added dropwise via an automatic syringe at a rate of 0.2 mL/min. The reaction 
was stirred for 3 h at room temperature and monitored by TLC (CH2Cl2: Acetone = 3:2). 
After completion, the solvent was removed in vacuo and the residue was resolubilized in 
CHCl3 (40 mL). The organic layer was washed with 1 M HCl (40 mL), twice with H2O (2 × 
40 mL), dried over MgSO4 and concentrated in vacuo to give 18a as white solid (0.17g, 0.35 
mmol, 70%). 1H NMR (400 MHz, CDCl3): δ 8.81 (d, J = 7.6 Hz, 1H), 8.37 (s, 1H), 8.29 (d, J 
= 8.0 Hz, 1H), 8.11 (d, J = 7.6 Hz, 1H), 8.04 (br s, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.02 (d, J = 
2.4 Hz, 1H), 6.77 (dd, J = 7.6, 2.4 Hz, 1H), 4.61 – 4.54 (m, 2H), 4.03 (t, J = 7.6 Hz, 2H), 3.96 
(s, 3H), 3.94 – 3.89 (m, 2H), 1.76 – 1.63 (m, 2H), 0.97 (t, J = 7.6 Hz, 3H). MS: [ESI+H]+: 
504.1. HPLC: 7.67 min.  
3-((3-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-
yl)propyl)carbamoyl) benzenesulfonyl fluoride (18b) The acid 9b (0.42 g, 2.0 mmol, 3.0 
equiv) was dissolved in thionylchloride (20 mL) and stirred for 3 h at 75 °C. The 
thionylchloride was evaporated and the residue was co-evapped twice with toluene. Then the 
amine 14b (0.23 mg, 0.7 mmol, 1.00 equiv), K2CO3 (0.073 g, 0.53 mmol, 1.5 equiv) and dry 
DMF were added and the reaction as stirred at 40 °C overnight. 1M HCl (200 mL) was added 
and extracted with CH2Cl2 (150 mL). The organic layer was washed with water (100 mL) and 
brine (100 mL). The organic layer was dried, filtered and concentrated in vacuo. The residue 
was purified by column chromatography using CH2Cl2 with 1% methanol as eluent to give 
18b as white solid (0.0050g, 0.01 mmol, 2.7%). 1H NMR (400MHz, CDCl3) δ: 8.88 (d, J = 
7.2 Hz, 1H), 8.68 (s, 1H), 8.55-8.50 (m, 2H), 8.20 (d, J = 8.0 Hz, 1H),  7.82 (t, J = 8 Hz, 2H), 
7.00 (d, J = 2.4 Hz, 1H), 6.80 (dd, J = 7.2, 2.4 Hz, 1H), 4.33 (t, J = 6.0 Hz, 2H), 4.05 (t, J = 
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7.6 Hz, 2H), 3.94 (s, 3H), 3.47 (q, J = 6.0 Hz, 2H), 2.17-2.12 (m, 2H), 1.74 (sextet, J = 7.6 Hz, 
2H), 1.00 (t, J = 7.6 Hz, 3H). MS: ESI [M+H]+: 518.1 HPLC: 8.28 min.  
3-((4-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-
yl)butyl)carbamoyl)benzenesulfonyl fluoride (18c) EDC (0.13 g, 0.69 mmol, 1.2 equiv) 
was dissolved in CH2Cl2 (3 mL). The acid 9b (0.13 g, 0.63 mmol, 1.1 equiv) was added to 
this solution and the mixture was stirred. The amine 16c (0.20 g, 0.57 mmol, 1 equiv) was 
dissolved in CHCl3 (8 mL) and added dropwise via an automatic syringe  at a rate of 0.2 
mL/min to the stirring solution. After 3 h at room temperature the reaction was completed and 
the mixture was concentrated in vacuo. The residue was dissolved in CH2Cl2 (40 mL) and 
washed with 1 M HCl (40 mL) and twice with H2O (2 × 40 mL). The organic layer was dried 
over MgSO4 and concentrated in vacuo. Purification by column chromatography (CH2Cl2: 
acetone = 3:2) gave the 18c as a white solid(0.14 g, 0.26 mmol, 47%). 1H NMR (400 MHz, 
CDCl3): δ 8.84 (d, J = 7.2 Hz, 1H), 8.54 (s, 1H), 8.36 (d, J = 7.6 Hz, 1H), 8.12 (d, J = 7.6 Hz, 
1H), 7.72 (t, J = 7.6 Hz, 1H), 7.62 (br s, 1H), 6.84 (s, 1H), 6.80 – 6.70 (m, 1H), 4.27 (t, J = 
7.2 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 3.89 (s, 3H), 3.74 – 3.60 (m, 2H), 2.07 – 1.92 (m, 2H), 
1.85 – 1.64 (m, 4H), 0.98 (t, J = 7.2 Hz, 3H). MS: [ESI+H] +: 532.3. HPLC: 8.21 min.  
N-(3-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-yl)propyl)-4-
(methylsulfonyl)benzamide (19).To a solution of EDC (0.061 g, 0.32 mmol, 1.2 equiv) in 
CHCl3 (5 mL) was added 4-(methylsulfonyl)benzoic acid (0.060 g, 0.30 mmol, 1.1 equiv). 
The amine 16b (0.090 g, 0.27 mmol, 1 equiv) was taken up in CHCl3 (5 mL) and was 
subsequently added dropwise via an automatic syringe at a rate of 0.15 mL/min. The reaction 
was stirred at room temperature and monitored by TLC (4% MeOH in CH2Cl2). After 3 h the 
reaction was completed and CHCl3 (50 mL) was added. The organic layer was washed with 1 
M HCl (60 mL), H2O (60 mL), brine (60 mL), dried over MgSO4 and concentrated under 
vacuum. The product was purified by column chromatography using 2% MeOH in CH2Cl2 to 
afford the title compound (0.075 g, 0.14 mmol, 54%). 1H NMR (400 MHz, CDCl3): δ 8.86 (d, 
J = 7.2 Hz, 1H), 8.36 (t, J = 5.6 Hz, 1H), 8.19 (d, J = 8.4 Hz, 2H), 8.09 (d, J = 8.4 Hz, 2H), 
6.90 – 6.71 (m, 2H), 4.45 – 4.28 (m, 2H), 4.13 – 3.99 (m, 2H), 3.91 (s, 3H), 3.55 – 3.41 (m, 
2H), 3.11 (s, 3H), 2.27 – 2.09 (m, 2H), 1.83 – 1.61 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C 
NMR (600 MHz, DMSO-d6, 318K): δ 164.7, 161.1, 153.5, 150.7, 150.6, 149.3, 142.8, 138.9, 
127.9, 127.5, 126.7, 107.4, 99.9, 95.4, 56.0, 43.2, 41.6, 40.8, 36.8, 27.4, 20.7, 10.9. MS: 
[ESI+H]+: 514.2. HRMS-ESI+: [M + H]+ calcd: 518.1760 found: 518.1791, C24H28O6N5S. 







4.2. Computational studies  
All calculations were performed using the Schrodinger Suite [31].Since compound 17b shares 
a high similarity with the ligands on which we previously published [7],  the same homology 
model based on the high resolution antagonist-bound crystal structure of the adenosine A2A 
receptor (PDB: 4EIY [27]) was used for the docking studies performed here. Based on those 
proposed docking poses, we used induced fit docking [32] with core constraints on the 
pyridopurinedione to dock the different ligands.  
4.3. Biology  
[3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one 
([3H]PSB-11, specific activity 56 Ciꞏmmol−1) was a gift from Prof. C.E. Müller (University of 
Bonn, Germany). Unlabeled PSB-11, 1-deoxy-1-[6-[((3- and 2-chloro-N6-(3-iodobenzyl)-
adenosine-5′-N-methyluronamide (2-Cl-IB-MECA) were purchased from Tocris Ltd. 
(Abingdon, UK). 5′-N-ethylcarboxamidoadenosine (NECA) was purchased from Sigma-
Aldrich (Steinheim, Germany). Adenosine deaminase (ADA) was purchased from Boehringer 
Mannheim (Mannheim, Germany). Bicinchoninic acid (BCA) and BCA protein assay 
reagents were purchased from Pierce Chemical Company (Rockford, IL, USA). Chinese 
hamster ovary (CHO) cells stably expressing the human A3 adenosine receptor (CHOhA3) 
were a gift from Dr. K-N Klotz (University of Würzburg, Germany). All other chemicals were 
obtained from standard commercial sources and were of analytical grade. 
Cell Culture and Membrane Preparation. Chinese Hamster Ovary (CHO) cells, stably 
expressing the human A3 adenosine receptor (CHOhA3), were cultured and membranes were 
prepared and stored as previously reported [7, 33].  Protein determination was performed 
based on the bicinchoninic acid (BCA) method [34].  
Y265F7.36 Site-Directed Mutagenesis. The single tyrosine mutation introduced in TM7 of the 
hA3AR was performed with the QuickChange II Site Directed Mutagenesis system 
(Stratagene, Huizen, The Netherlands). The wild type pcDNA3.1(+)-A3AR plasmid DNA 
with N-terminal 3 x HA-tag was used as a template for polymerase chain reaction (PCR) 
mutagenesis. Mutant primers for directional PCR product cloning were designed using the 
online Quickchange primer design program (Agilent Technologies, Santa Clara, CA), and 
obtained from Eurogentec (Maastricht, The Netherlands). Forward primer used for this 
procedure was 5'-cacagcttgtgctgttcatgggcatcctgct-3' and the reverse primer was 5'-
agcaggatgcccatgaacagcacaagctgtg-3'. All DNA sequences were verified by Sanger sequencing 
at LGTC (Leiden, The Netherlands). 
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Transient Expression of Wild Type (WT) and Mutant Receptors in CHO-K1 Cells. CHO-K1
cells were seeded into 150-mm culture dishes to achieve 60% confluence in the presence of 
20 ml culture medium consisting of DMEM/F12 (1:1) supplemented with 10% (v/v) newborn 
calf serum, streptomycin (50 µg/mL) and penicillin (50 IU/mL). Cells were transfected 
approximately 24 h later with plasmid DNA (20 μg of DNA/dish) by the PEI method [35] 
(PEI:DNA = 3:1) and left for 24 h. Subsequently medium was removed and fresh medium 
containing 5 mM sodium butyrate was added (to enhance the receptor expression level [36]), 
and cells were grown for an additional 24 h at 37 °C and 5% CO2. Membrane preparation 
followed the procedure described above for the CHO cell membranes stably expressing 
hA3AR. [7, 33] 
Radioligand Displacement Assay. Radioligand displacement experiments were performed as 
in previously published methods [7]. Membrane aliquots containing 15 μg of protein were 
incubated in a total volume of 100 µL assay buffer (50 mM Tris-HCl, 5 mM MgCl2, 
supplemented with 0.01% CHAPS and 1 mM EDTA, pH 7.4) at 25 °C for 120 min. 
Displacement experiments were performed using six concentrations of competing antagonist 
in the presence of ∼10 nM [3H]PSB-11. Nonspecific binding (NSB) was determined in the 
presence of 100 μM NECA and represented less than 10% of total binding. Incubation was 
terminated by rapid filtration performed on 96-well GF/B filter plates (Perkin Elmer, 
Groningen, the Netherlands) in a PerkinElmer Filtermate-harvester (Perkin Elmer, Groningen, 
the Netherlands). After the filter plate was dried at 55 °C for 30 min, the filter-bound 
radioactivity was determined by scintillation spectrometry using a 2450 MicroBeta2 Plate 
Counter (Perkin Elmer, Boston, MA). 
Radioligand Competition Association Assay. The competition association assay was 
performed by incubation of ~10 nM [3H]PSB-11 in the absence or presence of competing 
hA3AR antagonist at its IC50 concentration with membrane aliquots. The amount of receptor-
bound radioligand was determined at different time points up to 240 min. Incubations were 
terminated and samples were obtained as described under Radioligand Displacement Assay.  
[35S] GTPγS Binding Assay. The assays were started by adding 15 μg of homogenized 
CHOhA3 membranes in an ice-cold assay buffer to a total volume of 80 µL containing 50 
mM Tris-HCl buffer, 5 mM MgCl2, 1 mM EDTA, 0.05% BSA and 1 mM DTT, 100 mM 
NaCl, pH 7.4, supplemented with 1 µM GDP and 5 µg saponin. The assays were performed in 







of 100 µL using an HP D300 Digital Dispenser (Tecan, Männedorf, Switserland). The final 
concentration of DMSO per assay point was ≤0.1%. The basal level of [35S] GTPγS binding 
was determined in the absence of ligand, whereas the maximal level of [35S] GTPγS binding 
was determined in the presence of 10 μM 2-Cl-IBMECA. For the insurmountability 
experiments, membrane preparations were pre-incubated with or without antagonists (1-, 3-, 
10-fold Ki values) for 60 min at 25 °C, prior to the addition of 2-Cl-IBMECA (10 µM to 0.1 
nM) and 20 µl [35S] GTPγS (final concentration ~0.3 nM), after which incubation continued 
for another 30 min at 25 °C. For the surmountability (control) experiments, antagonists (1-, 3-, 
10-fold Ki values) and 2-Cl-IBMECA (10 µM to 0.1 nM) were co-incubated with [35S] 
GTPγS for 30 min at 25 °C. For all experiments, incubations were terminated and samples 
were obtained as described under Radioligand Displacement Assay, by using GF/B filters 
(Whatman International, Maidstone, UK). 
Data Analysis. All experimental data were analyzed using the nonlinear regression curve 
fitting program GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA). Data from 
the radioligand displacement assays were fit into one-site binding mode, and the obtained IC50 
values were converted into Ki values using the Cheng-Prusoff equation to determine the 
affinity of the ligands [37]. The observed association rate constants (kobs) derived from both 
assays were obtained by fitting association data using one phase exponential association. The 
dissociation rate constants were obtained by fitting dissociation data to a one phase 
exponential decay model. The kobs values were converted into association rate constants (kon) 
using the equation kon = (kobs – koff)/[L], where [L] is the amount of radioligand used for the 
association experiments. Association and dissociation rate constants for unlabeled compounds 
were calculated by fitting the data into the competition association model using “kinetics of 














































































Where X is the time (min), Y is the specific [3H]PSB-11 binding (DPM), k1 and k2 are the kon 
(nM-1min-1) and koff (min-1) of [3H]PSB-11, Bmax is the total binding (DPM), L is the 
radioligand concentration (nM), I is the concentration of the unlabeled competitor (nM). 
Association and dissociation rate constants for [3H]PSB-11 (k1 = 0.281 ± 0.04 ×108 M-1ꞏmin-1 
and k2 = 0.3992 ± 0.02 min-1) were obtained from Xia et al [7]. With that the k3, k4 and Bmax 
were calculated, where k3 represents the kon (nM-1min-1) of the unlabeled ligand, k4 stands for 
the koff (min-1) of the unlabeled ligand and Bmax equals the total binding (DPM). All 
competition association data were globally fitted. The residence time (RT, in min) was 
calculated using the equation RT = 1/ koff, as koff values are expressed in min-1. [35S] GTPγS 
binding curves were analyzed by nonlinear regression using “log (agonist) vs response-
variable slope” to obtain potency, inhibitory potency or efficacy values of agonists and 
antagonists (EC50 and Emax, respectively). In the (in)surmountability assays, Schild EC50 shift 
equations were used to obtain Schild-slopes and pA2 values. All experimental values obtained 




Figure S1. Overlay of a view from crystal structure of compound 2 (mustard carbon sticks) bound to 
human adenosine A1 receptor (mustard; PDB: 5UEN)[11] and the hA3AR (violet) homology model 
docking with 17b (violet carbon sticks). Atoms color code: red = oxygen, blue = nitrogen, white = 
hydrogen, yellow = sulfur, cyan = fluorine. Hydrogen bonds between ligands and relevant amino acid 
residues are indicated by dashed lines.  
Abbreviations used 
ADA, adenosine deaminase. BCA, bicinchoninic acid. CHAPS, 3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate. CHO, Chinese hamster ovary. CHO-K1, a subclone 
from the parental CHO cell line. 2-Cl-IB-MECA, 1-[2-chloro-6-[[(3-iodophenyl) methyl] 
amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide. DBU, 1,8-diazabicyclo 
[5.4.0] undec-7-ene. EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. Emax, maximum 







membranes of CHO cells stably expressing the A3 adenosine receptor. EtOAc, ethylacetate. 
FBS, fetal bovine serum. G418, geneticin. GTPγS, guanosine 5’-O-[γ-thio] triphosphate. 
hA1AR, human A1 Adenosine Receptor. hA3AR, human A3 Adenosine Receptor. MeCN, 
acetonitrile. NECA, 5’-(N-ethylcarboxamide) adenosine . PSB-11, 8-Ethyl-4-methyl-2-
phenyl-(8R)-4,5,7,8-tetrahydro-1H- imidazo[2,1-i]-purin-5-one. PET, petroleum ether 
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Abstract 
Partial agonists for G protein-coupled receptors (GPCRs) provide opportunities for novel 
pharmacotherapies with enhanced on-target safety compared to full agonists. For the human 
adenosine A1 receptor (hA1AR) this has led to the discovery of capadenoson, which has been 
in phase IIa clinical trials for heart failure. Accordingly, the design and profiling of novel 
hA1AR partial agonists has become an important research focus. In this study, we report on 
LUF7746, a capadenoson derivative bearing an electrophilic fluorosulfonyl moiety, as an 
irreversibly binding hA1AR modulator. Meanwhile, a nonreactive ligand bearing a 
methylsulfonyl moiety, LUF7747, was designed as a control probe in our study.     
In a radioligand binding assay LUF7746’s apparent affinity increased to nanomolar range 
with longer pre-incubation time, suggesting an increasing level of covalent binding over time. 
Moreover, compared to the reference full agonist CPA, LUF7746 was a partial agonist in a 
hA1AR-mediated G protein activation assay, and resistant to blockade with an 
antagonist/inverse agonist. An in silico structure-based docking study combined with site-
directed mutagenesis of the hA1AR demonstrated that amino acid Y2717.36 was the primary 
anchor point for the covalent interaction. Additionally, a label-free whole-cell assay was set 
up to identify LUF7746’s irreversible activation of an A1 receptor-mediated cell 
morphological response. 
These results led us to conclude that LUF7746 is a novel covalent hA1AR partial agonist and 
a valuable chemical probe for further mapping the receptor activation process. It may also 
serve as a prototype for a therapeutic approach in which a covalent partial agonist may cause 
less on-target side effects, conferring enhanced safety compared to a full agonist.   
Keywords 
G protein-coupled receptors, adenosine A1 receptor, covalent ligand, partial agonist, 






G protein-coupled receptors (GPCRs) are one of the largest families of drug targets [1]. Being 
transmembrane proteins they, however, pose problems in studying their structure and 
function, due to their low expression and profound instability. To solve these problems, 
covalent ligands have been shown to be useful tools for the structure elucidation of 
active/inactive receptor structures and mapping of the ligand-binding domains [2]. Beyond 
that, covalent ligands are beginning to be applied in GPCR chemical biology and proteomics 
applications [3]. 
Historically, the few covalent agonists for the human adenosine A1 receptor (hA1AR) 
available have all been derivatives of the endogenous ligand adenosine, containing an intact 
ribose moiety. Chemical modification of the adenosine structure at the N6 position has yielded 
several selective chemo-reactive agonists [4, 5]. One such example is N6-[4- [[[4-[[[[2-[[[(m-
isothiocyanatophenyl)amino]- thiocarbonyl]amino]ethyl]amino] carbonyl]methyl]aniline]-
carbonyl] methyl]phenyl]adenosine  (m-DITC-ADAC), an adenosine analogue incorporating 
a chemoreactive isothiocyanate group to form a covalent bond with the receptor [5]. These 
covalent agonists were validated as full agonists for adenosine A1 receptor [5, 6]. However, 
full activation of the hA1AR influences a broad physiologic spectrum of cardiac functions 
associated with unwanted effects, such as atrioventricular block [7]. Thus, partial agonists, 
triggering submaximal effects compared to a full agonist, have emerged as a new therapeutic 
option in treating cardiovascular indications [8]. Research from Bayer and our group has 
unveiled the existence of 2-aminopyridine-3,5-dicarbonitrile derivatives such as capadenoson 
and LUF5853 as non-ribose agonists for the hA1AR [9-11]. Here, we used the 2-
aminopyridine-3,5-dicarbonitrile scaffold as a starting point in our design and synthesis 
efforts towards a covalent partial agonist probe for the hA1AR, the fluorosulfonyl-equipped 
derivative LUF7746. Meanwhile, a chemically similar, but non-reactive methylsulfonyl-
equipped ligand, LUF7747, was designed to be used as a reversible control ligand. We then 
validated LUF7746 to bind covalently and partially activate the receptor in a series of in vitro 
experiments. We finally provided evidence for its point of attachment to the receptor. The 
results presented here constitute the initial report and pharmacological profiling of a novel, 
non-ribose covalent partial agonist and also shed light on the rational design of partial 
agonists as therapeutics. Furthermore, this reported covalent ligand could serve as a valuable 
pharmacological tool to investigate the contribution of partial activation of hA1AR 
physiological functions.   
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2. Materials and Methods
2.1. Chemistry
All solvents and reagents were purchased from commercial sources and were of analytical 
grade. Demineralised water is referred to as H2O, as was used in all cases unless stated 
otherwise (i.e., brine). All reactions were routinely monitored with thin layer chromatography 
(TLC), using aluminium silica gel coated 60 F254 plates from Merck. Purification by column 
chromatography was carried out with the use of VWR silica gel irregular ZEOprep particles 
(60-200 m). Solutions were concentrated using a Heidolph Hei-VAP Value rotary 
evaporator. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AV-400 
liquid spectrometer (1H NMR, 400 MHz) at ambient temperature and subsequently analysed 
with MestReNova v.12 software. Chemical shifts are reported in parts per million (ppm), 
designated by δ and corrected to the internal standard tetramethylsilane (δ = 0). Coupling 
constants are reported in Hz and are designated as J. Mass analyses were performed with 
liquid chromatography mass spectrometry (LC-MS) using an LCQ™ Advantage MAX system 
from Thermo Finnigan together with a Phenomenex Gemini C18 110Å column (50 mm × 
4.6 mm × 3 μm). Samples were eluted using an isocratic system of H2O/CH3CN/1% TFA in 
H2O, through decreasing the polarity of the solvent mixture from 80:10:10 to 0:90:10 in an 
elution time of 15 minutes. Analytical purity of the obtained final compounds was determined 
with high performance liquid chromatography (HPLC) using a Shimadzu HPLC system with 
a Phenomenex Gemini C18 110Å column (50 mm × 4.6 mm × 3 μm) coupled to a 254 nm 
UV detector. Samples were eluted using the same method as mentioned for LC-MS. For both 
LC-MS and HPLC, 0.3-0.8 mg of compound was dissolved in 1 mL of a 1:1:1 mixture of 
CH3CN/H2O/tBuOH as sample preparation. All reactions were performed under nitrogen 
atmosphere unless stated otherwise. Ligands were synthesized in two step protocol from 
compound 1 (Fig.1) as described below. 
4-((3-((6-amino-4-(benzo[d][1,3]dioxol-5-yl)-3,5 -dicyanopyridin-2-yl) 
thio)propyl)carbamoyl)benzenesulfonylfluoride (4, LUF7746).  
A mixture of 4-(fluorosulfonyl)benzoic acid (1.5 mmol, 0.30 g, 1.0 equiv), 3-
bromopropylamine hydrobromide (1.9 mmol, 0.42 g, 1.3 equiv) and EDCꞏHCl (1.8 mmol, 
0.33 g, 1.2 equiv) in anhydrous DMF was cooled down to 0 °C. Subsequently, DIPEA (3.0 
mmol, 0.52 mL, 2.0 equiv) was added dropwise and the solution was stirred for 4 h at 0 C, 
followed by overnight stirring at room temperature. After completion was observed on TLC,  , 





extracted three times with ethyl acetate. The combined organic layers were washed three 
times with 1M HCl three times, dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography (PE: EtOAc = 2:1) to give the N-(3-
bromopropyl)-4-(fluorosulfonyl)benzamide (2) as a white solid (1.1 mmol, 0.35 g, 74%). 
Compound 2 was used without further purification. 2-amino-4-(benzo[d][1,3]dioxol-5-yl)-6-
mercaptopyridine-3,5-dicarbonitrile 1 (0.48 mmol, 0.14 g, 1.0 equiv) was dissolved in 
anhydrous DMF in the presence of 2 (0.48 mmol, 0.15 g, 1.0 equiv) and NaHCO3 (0.73 mmol, 
0.061 g, 1.5 equiv) and stirred at room temperature until completion of the reaction. Water 
was added to the mixture which was extracted with EtOAc four times. Subsequently, the 
combined organic layers were washed with brine 4 times, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified via column chromatography 
(EtOAc:PE = 1:1) to yield the desired compound as white solid (0.039 mmol, 0.021 g, 8%). 
1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 8.4 Hz, 2H), 8.02 (d, J = 8.3 Hz, 2H), 7.00 (dd, J = 
8.0, 1.6 Hz, 1H), 6.97-6.92 (m, 2H), 6.55 (t, J = 5.6 Hz, 1H), 6.07 (s, 2H), 5.92 (br s, 2H), 
3.65 (q, J = 6.7 Hz, 2H), 3.27 (t, J = 7.1 Hz, 2H), 2.16 (quin, J = 7.1 Hz, 2H) ppm. MS: 
[ESI+H]+: 540.0. HPLC tR = 8.36 min, purity 97%. 
N-(3-((6-amino-4-(benzo[d][1,3]dioxol-5-yl)-3,5-dicyanopyridin-2-yl)thio)propyl)-4-
(methylsulfonyl)benzamide (5, LUF7747). A mixture of (4-methyl sulfonyl)-benzoic acid 
(0.82 mmol, 0.16 g, 1.0 equiv), 3-bromopropylamine hydrobromide (1.1 mmol, 0.23 g, 1.3 
equiv) and EDCꞏHCl (0.98 mmol, 0.19 g, 1.2 equiv) in anhydrous DMF was stirred for 1 h at 
rt. Subsequently, DIPEA (1.7 mmol, 0.29 mL, 2.0 equiv) was added dropwise to the 
suspension and the reaction was stirred overnight at room temperature. After completion was 
observed on TLC, the mixture was concentrated in vacuo. Water was added to the residue and 
the mixture was extracted three times with ethyl acetate. The combined organic layers were 
washed three times with 1M HCl, dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography (EtOAc : PE = 2:1) to give N-(3-
bromopropyl)-4-(methylsulfonyl)benzamide (3) as a white solid (0.21 mmol, 0.068 g, 26%). 
Compound 3 was used without further purification.  2-amino-4-(benzo[d][1,3]dioxol-5-yl)-6-
mercaptopyridine-3,5-dicarbonitrile 1 (0.21 mmol, 0.062 g, 1.0 equiv) was dissolved in 
anhydrous DMF in the presence of 3 (0.21 mmol,  0.067 g, 1.0 equiv) and NaHCO3 (0.31 
mmol, 0.026 g, 1.5 equiv) and stirred at room temperature until completion of the reaction. 
Water was added to the mixture which was extracted with EtOAc four times. Subsequently, 
the combined organic layers were washed with brine 4 times, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified via column chromatography 
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(EtOAc:PE = 2:1)  to yield the desired compound as off-white solid (0.093 mmol, 0.050 g, 
45%). 1H NMR (400 MHz, DMSO-d6) δ 8.80 (t, J = 5.6 Hz, 1H), 8.07 (d, J = 8.4 Hz, 2H), 
8.02 (d, J = 8.4 Hz, 2H) 7.15 (d, J = 1.8 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 7.02 (dd, J = 8.1, 
1.8 Hz, 1H), 6.15 (s, 2H), 3.43 (q, J = 6.6 Hz, 2H), 3.31-3.24 (m, 5H), 1.96 (quin, J = 7.0 Hz, 
2H) ppm. MS: [ESI+H]+: 535.9 HPLC tR = 7.41 min, purity 99%. 
2.2. Biology 
Both radioligands 1,3-[3H]-dipropyl-8-cyclopentylxanthine ([3H]DPCPX, specific activity of 
120 Ci × mmol-1) and  [2-3H]-4-(2-[7-amino-2-(2-furyl)-[1,2,4]-triazolo-[2,3-a]-[1,3,5]-
triazin-5-yl amino]ethyl ([3H] ZM241385, specific activity of 50 Ci × mmol-1) were purchased 
from ARC Inc. (St.Louis, MO). [3H]PSB603 ([3H]8-(4-(4-(4-Chlorophenyl)piperazide-1-
sulfonyl)phenyl)-1-propylxanthine, specific activity 79 Ci × mmol-1) and [3H]8-Ethyl-4-
methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([3H]PSB-11, 
specific activity 56 Ci × mmol−1) were obtained with kind help of Prof. C.E. Müller 
(University of Bonn, Germany). [35S]-Guanosine 5’-(γ-thio)triphosphate ([35S]GTPγS, 
specific activity 1250 Ci × mmol-1) was purchased from PerkinElmer, Inc. (Waltham, MA, 
USA). 5’-N-ethylcarboxamidoadenosine (NECA) was purchased from Sigma-Aldrich 
(Steinheim, Germany). N6-cyclopentyladenosine (CPA) was purchased from Abcam 
(Cambridge, UK). Unlabeled ZM241385 was a gift from Dr. S.M.Poucher (Astra Zeneca, 
Macclesfield, UK). Adenosine deaminase (ADA) was purchased from Boehringer Mannheim 
(Mannheim, Germany). Bicinchoninic acid (BCA) and BCA protein assay reagent were 
obtained from Pierce Chemical Company (Rockford, IL, USA). Chinese hamster ovary cells 
stably expressing the hA1AR (CHOhA1AR) were provided by Prof. S. J. Hill (University of 
Nottingham, UK). Chinese hamster ovary cells stably expressing low levels of hA1AR (CHO-
hA1AR-low) were obtained from Prof. Andrea Townsend (University College London, UK). 
HEK293 cells stably expressing the hA2A adenosine receptor (HEK293 hA2AAR) were kindly 
provided by Dr J Wang (Biogen/IDEC, Cambridge, MA, USA). Chinese hamster ovary cells 
stably expressing the human adenosine A2B (CHOhA2BAR) and A3 receptor (CHOhA3AR) 
were obtained from Dr. S. Rees (AstraZeneca, Macclesfield, UK) and Dr. K-N. Klotz 
(University of Würzburg, Germany), respectively. All other chemicals were of analytical 
grade and obtained from standard commercial sources. 
Site-directed mutagenesis 
Site-directed mutant hA1AR-Y2717.36F was constructed by polymerase chain reaction 
mutagenesis using pcDNA3.1(+)-hA1AR with N-terminal HA and C-terminal His tag as the 





were designed using the online QuikChange® Primer Design Program (Agilent Technologies, 
Santa Clara, CA, USA) and obtained from Eurogentec Nederland b.v. (Maastricht, The 
Netherlands). All DNA sequences were verified by Sanger sequencing at the Leiden Genome 
Technology Center (Leiden, The Netherlands). 
Cell culture, transfection and membrane preparation 
Cell culture and membranes preparation were performed as previously described [12, 13].   
Transient expression of wild type (WT) and mutant receptors in CHO cells. 
CHO cells were seeded into 150-mm culture dishes to achieve 50-60 % confluence containing 
20 ml of medium consisting of DMEM/F12 (1:1) supplemented with 10% (v/v) newborn calf 
serum, streptomycin (50 µg/mL), and penicillin (50 IU/mL). Cells were transfected 
approximately 24 h later with plasmid DNA (20 μg of DNA/dish) by the PEI method 
(PEI:DNA = 3:1) and left for 48 h [14]. Subsequently, medium was removed and fresh 
medium was added, and cells were grown for an additional 24 h at 37 °C and 5% CO2. 
Membranes were prepared in the same way as previously described [12] and stored in 250 μL 
aliquots at -80 °C until further use.  
Radioligand displacement assays 
hA1AR [15]. Membrane aliquots containing 5 µg were incubated in a total volume of 100 µL 
assay buffer (50 mM Tris HCl, pH 7.4) at 25 °C for 60 min. Displacement experiments were 
performed using six concentrations of competing antagonist in the presence of ∼1.6 nM 
[3H]DPCPX. Nonspecific binding was determined in the presence of 100 µM CPA and 
represented less than 10% of total binding. Incubation was terminated by rapid filtration 
performed on 96-well GF/B filter plates (Perkin Elmer, Groningen, the Netherlands) in a 
PerkinElmer Filtermate-harvester (Perkin Elmer, Groningen, the Netherlands) and washed 
with buffer (50 mM Tris, pH 7.4) After the filter plate was dried at 55 oC for 30 min, the 
filter-bound radioactivity was determined by scintillation spectrometry using a 2450 
MicroBeta2 Plate Counter (Perkin Elmer, Boston, MA). 
 Adenosine A2A Receptor [13]. Membrane aliquots containing 20 µg of protein were incubated 
in a total volume of 100 µL of assay buffer (50 mM Tris-HCl, pH 7.4) at 25 °C for 120 min. 
Displacement experiments were performed using 1 µM of competing compound in the 
presence of ∼2.5 nM [3H]ZM241385. Nonspecific binding was determined in the presence of 
100 µM NECA. Incubations were terminated, washed and samples were obtained and 
analysed as described under hA1AR.  
 Adenosine A2B Receptor [16]. Membrane aliquots containing 25 µg of protein were incubated 
in a total volume of 100 µL of assay buffer (50 mM Tris-HCl, pH 7.4, supplemented with 
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0.1% (w/v) CHAPS) at 25 °C for 120 min. Displacement experiments were performed using 1 
µM of competing compound in the presence of ∼1.5 nM [3H]PSB603. Nonspecific binding 
was determined in the presence of 10 µM ZM241385. Incubations were terminated, filters 
were washed with buffer (50 mM Tris-HCl, pH 7.4, supplemented with 0.1% BSA and 0.1% 
(w/v) CHAPS) and samples were obtained and analyzed as described under hA1AR.  
Adenosine A3 Receptor [17]. Membrane aliquots containing 15 µg of protein were incubated 
in a total volume of 100 µL of assay buffer (50mM Tris, 10mM MgCl2, 1mM EDTA, 0.01% 
CHAPS, pH 8.0) at 25 °C for 120 min. Displacement experiments were performed using 1 
µM of competing compound in the presence of ∼10 nM [3H]PSB11. Nonspecific binding was 
determined in the presence of 100 µM NECA. Incubations were terminated, washed with 
buffer (50mM Tris, 10mM MgCl2, 1mM EDTA, pH 8.0) and samples were obtained and 
analyzed as described under hA1AR. 
Competition association assays 
The binding kinetics of unlabeled ligands were assessed as described previously [15]. Briefly, 
the association of the radioligand was followed over time in the absence or presence of a 
concentration corresponding to 10 × Ki value of unlabeled LUF7746 and LUF7747. In 
practice, to the mixture of equal volumes of 2.5 nM [3H]DPCPX, unlabeled compound and 
assay buffer (50 mM Tris-HCl supplemented with 5 mM MgCl2 and 0.1% CHAPS)  was 
added a 25 µL membrane aliquot containing 5 µg of protein at each time point from 0.5 min 
to 240 min at 25oC. Incubation was terminated as described above (radioligand displacement 
assay).  
Wash-out assay on both wild type hA1AR and hA1AR-Y7.36F cell membranes 
100 μL of assay buffer containing either 1% DMSO (blank control) or 1 μM of ligands 
(LUF7746 or LUF7747 ) and 200 μL additional assay buffer were added to a 2 mL Eppendorf 
tube containing 100 μL cell membrane suspension (20 µg and 40 µg of protein for  and 
Y7.36F, respectively, to obtain an assay window of 3000 dpm in both cases) to achieve a total 
volume of 400 μL. The tubes were incubated for 2 h in an Eppendorf® Thermomixer® at 900 
rpm and 25 °C. After incubation the tubes were centrifuged for 5 min at 16 000 × g and 4 °C 
and subsequently the buffer containing unbound ligands was removed. The membrane pellet 
was resuspended in 1 mL of assay buffer, incubated for 10 min at 25 °C and 900 rpm after 
which the tubes were centrifuged for 5 min at 16 000 × g and 4 °C and the cycle was repeated 
three more times. After the final washing step, the membrane pellet was resuspended in 300 
μL assay buffer to determine the radioligand binding activity. All samples were transferred to 





incubation was terminated by vacuum filtration through a GF/B filter using a Brandel M24 
Scintillation Harvester to separate bound and free radioligand. The filters were washed three 
times with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4). After drying the filters, 3.5 mL of 
scintillation liquid was added and the filter-bound radioactivity was determined in a Tri-Carb 
2900TR Liquid Scintillation Analyzer (PerkinElmer, Inc., Waltham, MA, USA). Results are 
expressed as percentage normalized to the maximum specific binding in the control group 
(100%).  
Computational modelling 
All calculations were performed using the Schrödinger Suite [18]. The X-ray structure of the 
hA1AR was extracted from the PDB (PDB: 5UEN) [19, 20]. The co-crystalized ligand DU172 
was removed and protein chain A was prepared for docking with the Protein Preparation tool. 
Additionally, missing side chains were added using Prime [21].  
Functional [35S]GTPγS binding assay 
Binding of [35S]GTPγS to membranes was adapted from a previously reported method [16]. 
The assays were performed in a 96-well plate format, where stock solutions of the compounds 
were added using an HP D300 Digital Dispenser (Tecan, Männedorf, Switserland). The final 
concentration of DMSO per assay point was ≤0.1%. For concentration-response assays 
transiently transfected membranes (hA1AR-WT, 5 μg and hA1AR-Y2717.36F, 20 µg to obtain 
an assay window of 3000 dpm in both cases) in 80 μL total volume of assay buffer containing 
50 mM Tris-HCl buffer, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 0.05% BSA and 1 mM 
DTT pH 7.4 supplemented with 3 μM GDP and saponin  (hA1AR-WT, 5 μg and hA1AR-
Y2717.36F, 20 µg) were added to a range of concentrations of ligand (10-10 to 10-5) for 30 min 
at 25 oC. After this, 20 μL of [35S]GTPγS (final concentration of 0.3 nM) was added and 
incubation continued for another 90 min at 25 oC. The basal level of [35S] GTPγS binding was 
determined in the absence of ligand, whereas the maximal level of [35S]GTPγS binding was 
determined in the presence of 1 µM CPA. For receptor activation/inhibition studies, hA1AR-
WT or hA1AR-Y2717.36F cell membranes were pre-incubated with LUF7746 or LUF7747 
(EC80 concentration) for 60 min. After this, [35S]GTPγS (final concentration of 0.3 nM) was 
added in the absence or presence of DPCPX (1 µM) for another 90 min. For all experiments, 
incubations were terminated by rapid vacuum filtration to separate the bound and free 
radioligand through Whatman™ UniFilter™ 96-well GF/B microplates using a PerkinElmer's 
FilterMate™ Universal Harvester (PerkinElmer, Groningen, Netherlands). Filters were 
subsequently washed three times with 2 mL of ice-cold buffer (50 mM Tris-HCl, pH 7.4 
supplemented with 5 mM MgCl2). The filter-bound radioactivity was determined by 
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scintillation spectrometry using a PerkinElmer MicroBeta2 2450 Microplate Counter 
(PerkinElmer, Groningen, Netherlands).      
Label-free whole-cell assays 
Label-free whole-cell assays were adapted from a previously reported method [22, 23] using 
the real-time cell analyser (RTCA) xCELLigence SP system (ACEA Biosciences, San Diego, 
CA, USA) [24]. The system measures electrical impedance generated by adherence of cells to 
gold-coated electrodes at the bottom of 96 wells PET E-plates (obtained from Bioké, Leiden, 
the Netherlands). Changes in impedance (Z) were measured continuously and are displayed as 
Cell Index (CI), which is defined as (Zi – Z0) Ω / 15Ω. Zi is the impedance at a given time and 
Z0 is the baseline impedance measured at the start of the experiment in the absence of cells. 
CHO cells stably expressing a relatively low level hA1AR (CHO-hA1AR-low) were cultured 
in medium of DMEM/F12 (1:1) supplemented with 10% (v/v) newborn calf serum, 
streptomycin (50 µg/mL), penicillin (50 IU/mL), and G418 (0.2 mg/mL) at 37 °C in 5% CO2 
as a monolayer on 10-cm ø culture plates to 70-80% confluency and subsequently harvested 
and centrifuged twice at 200×g for 5 min [25]. Initially, 60 µL of culture medium was added 
to wells in E-plates 96 to obtain background readings (Z0) followed by the addition of 40 µL 
of cell suspension containing 40,000 cells per well. After resting at room temperature for 30 
min, the plate was mounted in the RTCA recording station within a humidified 37°C, 5% CO2 
incubator. Impedance was measured every 15 min overnight. For agonist assays, after 17 
hours, medium was replaced with 95 µL serum free medium plus 1.2 IU ADA and kept in the 
37°C, 5% CO2 incubator for 3 h of starvation. After that, cells were stimulated with increasing 
concentrations of agonists or vehicle (final concentration of 0.25 % DMSO) in a final well 
volume of 100 µL. For the inverse agonist reversal assay, cells were placed in 90 µL serum 
free medium containing 1.2 IU/ml ADA for 3 h starvation. Then cells were stimulated with 5 
µL indicated compound (final concentration 1 µM) for 30 min, followed by the addition of 
100 nM DPCPX in a final well volume of 100 µL. For both assays, to record the signal 
changes, CI was recorded for at least 30 min with a recording schedule of 15 s intervals for 20 
min, followed by intervals of 1 min, 5 min and finally 15 min. For data analysis, the 
individual CI traces were normalized, by subtracting the baseline (vehicle control), to correct 
for any agonist-independent signals.  
Data analysis 
All the experimental data were analyzed with GraphPad Prism 7.0 software (GraphPad 
Software Inc., San Diego, CA). pIC50 values in radioligand displacement assays were 





using the equation: Y=Bottom + (Top-Bottom)/(1+10^(X-LogIC50)). pKi values were 
obtained from pIC50 values using the Cheng-Prusoff equation [26]. Association data for the 
radioligand were fitted using one-phase exponential association. Values for kon were obtained 
by converting kobs values using the following equation: kon = (kobs− koff)/[radioligand], where 
koff values (0.21 ± 0.01 min-1) were cited from Guo et al [15]. Association and dissociation 
rates for unlabeled ligands were calculated by fitting the data in the competition association 









































































Where X is the time (min), Y is the specific [3H]DPCPX binding (dpm), k1 and k2 are the kon 
and koff  of [3H]DPCPX and were obtained from Guo et al. [15], L is the concentration of 
[3H]DPCPX used (nM), Bmax the total binding (dpm) and I the concentration of unlabeled 
ligand (nM). Fixing these parameters allows the following parameters to be calculated: k3, 
which is the kon value (M-1min-1) of the unlabeled ligand and k4, which is the koff value (min-1) 
of the unlabeled ligand. The residence time (RT) was calculated using RT = 1/koff. pEC50 and 
EC80 values in the [35S]GTPγS binding assays were determined using non-linear regression 
curve fitting into a sigmoidal dose-response curve with variable slope. For the label-free 
whole-cell assays, ligand responses were normalized to obtain normalized cell index (NCI) 
and then subtracted baseline (vehicle control), which correct for ligand-independent effects. 
Area-under-curve (AUC) values from the NCI were determined for a 100 min period after 
compound addition, which were used for concentration-response curves. pEC50 values from 
the label-free whole-cell assays were determined using the same non-linear regression as for 
the [35S]GTPγS binding assays. Data shown represent the mean ± SEM of three individual 
experiments each performed in duplicate or a representative graph is shown. Statistical 
analysis was performed as indicated. If p-values were below 0.05, observed differences were 
considered statistically significant.  




3.1. Design and synthesis of LUF7746 and LUF7747 
Over the years our research group has explored a series of hA1AR agonists based on the 6-
amino-4-aryl-3,5-dicyano-2-thiopyridine template, to investigate their structure-activity and 
structure-kinetics relationships (SAR and SKR) [9, 28]. We learned that the benzo[1,3]dioxol-
5-yl moiety generally provided selective and potent agonists for hA1AR. Based on that 
finding, we used 2-amino-4-(benzo[d][1,3]dioxol-5-yl)-6-mercaptopyridine-3,5-dicarbonitrile 
as a scaffold (Fig.1), and developed a potentially covalent ligand by incorporating the 
fluorosulfonyl moiety as a warhead through an amide linker at the position of the sulfur atom. 
Hence, LUF7746, 4-((3-((6-amino-4-(benzo[d][1,3]dioxol-5-yl)-3,5 -dicyanopyridin-2-
yl)thio)propyl)carbamoyl)benzenesulfonylfluoride (Fig.1), was synthesized in one step by 
alkylating the template with the corresponding alkyl bromide. Additionally, to remove the 
reactivity of the warhead a methylsulfonyl substitution was used to replace the fluorosulfonyl 
moiety, which yielded a nonreactive control compound, N-(3-((6-amino-4-
(benzo[d][1,3]dioxol-5-yl)-3,5-dicyanopyridin-2-yl)thio)propyl)-4-
(methylsulfonyl)benzamide (LUF7747, Fig.1). The reaction conditions and other reagents 
used in the synthesis of both compounds are described in Materials and Methods. 
 
Fig. 1 Chemical structures of the hA1AR agonists examined in this study. 
3.2. Affinity characterization at different incubation times for LUF7746 and 
LUF7747 
To determine the affinity of the synthesized ligands we tested both ligands in a [3H]DPCPX 
displacement assay at 25 oC. After 0.5 h co-incubation time, both compounds were able to 
concentration-dependently inhibit specific [3H]DPCPX binding to the hA1AR (Fig.2). As 
presented in Table 1, both compounds showed similar binding affinities in the submicromolar 
range (pKi = 7.7 ± 0.2 and 7.3 ± 0.04 for LUF7746 and LUF7747, respectively). We then 
tested the time dependency of the affinity for both compounds. In detail, the CHO cell 






Fig.2 Time-dependent affinity assessment of LUF7746 and LUF7747. Displacement of specific 
[3H]DPCPX binding from the adenosine CHOhA1AR receptor at 25°C by LUF7746 (a), and LUF7747 
(b) with or without a pre-incubation of 4h. Data are normalized to 100% of the total binding and 
represent the mean ± SEM of three individual experiments performed in duplicate. 
followed by a 0.5 h co-incubation with the radioligand [3H]DPCPX. LUF7746 showed a 
significantly increased affinity with 4 h preincubation time (pKi = 8.4 ± 0.1; Table 1), while 
LUF7747’s affinity did not change (pKi  = 7.3 ± 0.02; Table 1). Representative graphs for this 
effect are shown in Fig.2, in which the curve representing a concentration-dependent 
inhibition of specific [3H]DPCPX binding was shifted to the left with 4 h pre-incubation of 
LUF7746 (Fig.2a), with no difference for LUF7747 (Fig.2b). It is worth to mention that for a 
covalent ligand no dynamic equilibrium can be reached. We thus expressed LUF7746’s 
affinity for hA1AR as “apparent Ki”. Compared to the reversible ligand LUF7747 covalent 
LUF7746 showed an increase in apparent pKi with 0.7 log unit. The increased receptor 
affinity by LUF7746 with prolonged incubation time, indicated an increased level of covalent, 
non-displaceable binding over time.  
Additionally, we tested these compounds in a single-point radioligand binding assay for other 
adenosine receptor subtypes (Table 1). Both compounds displaced less than 50% of the total 
radioligand binding at 1 μM for other subtypes of human adenosine receptors (i.e. yielding 
estimated IC50 values higher than 1 μM), even when the incubation time was doubled. Thus, 
both ligands are selective towards the hA1AR.  
3.3. Kinetic characterization of LUF7746 and LUF7747 in a competition 
association binding assay 
The apparent affinity shift of LUF7746 inspired us to examine the kinetic characteristics of 
the ligand-receptor interaction and to investigate the ligand’s dissociation rate. In our previous 
research, the kinetic binding parameters kon (k1 = 1.2 ± 0.1 × 108 M-1ꞏmin-1 ) and koff  (k2 = 
0.23 ± 0.01 min-1 ) of [3H]DPCPX at 25 °C had been determined in traditional association and  
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Displacement at 1 μM (%) pIC50 
cpd hA1AR hA2AARc hA2BARd hA3ARe 
hA1AR-
Y2717.36Ff 







7.2 ± 0.05 







7.0 ± 0.06 
Values represent pKi ± SEM (n=3) or mean percentage displacement at 1 μM (n=2) of separate 
experiments each performed in duplicate. **P < 0.01 compared with the pKi values in displacement 
experiments without pre-incubation; Student’s t-test.  
aAffinity determined from displacement of specific [3H]DPCPX binding on CHO cell membranes 
stably expressing hA1AR at 25 oC after 0.5 h co-incubation;  
bAffinity determined from displacement of specific [3H]DPCPX binding on CHO cell membranes 
stably expressing hA1AR at 25 oC with compounds pre-incubated for 4 h, followed up by a 0.5 h co-
incubation with [3H]DPCPX ;  
c% displacement at 1 μM concentration of specific [3H]ZM241385 binding on HEK293 cell 
membranes stably expressing human adenosine A2A receptors at 25 oC after 2 h co-incubation; 
d% displacement at 1 μM concentration of specific [3H]PSB-603 binding on CHO cell membranes 
stably expressing human adenosine A2B receptors at 25 oC after 2 h co-incubation; 
e% displacement at 1 μM concentration of specific [3H]PSB11 binding on CHO cell membranes stably 
expressing human adenosine A3 receptors at 25 oC after 2 h co-incubation; 
fAffinity determined from displacement of specific [3H]DPCPX binding on CHO cell membranes 
transiently expressing hA1AR-Y271F7.36 at 25 oC after 2 h co-incubation ;  
gFor LUF7746, affinity values can only be apparent, as true equilibrium cannot be reached. 
dissociation assays [15, 27, 29]. In this study we derived the kinetic binding parameters for 
the two unlabeled ligands by performing a competition association assay at a concentration of 
IC50 value. The association in the presence of LUF7747 (Fig.3) reached a plateau within 30 
mins, indicating a dynamic equilibrium was reached between [3H]DPCPX, ligand and 
hA1AR. Interestingly, LUF7746’s behavior caused an initial ‘overshoot’ of [3H]DPCPX 
binding in the competition association curve which decreased over time (Fig.3). Analysing 
these curves with the (equilibrium) Motulsky and Mahan model [27] led to the summarized 
data in Table 2. Reversible ligand LUF7747 showed an association rate constant of 6.3 ± 0.9 
× 106 M-1min-1, and a fast dissociation rate constant (0.42 ± 0.03 M-1min-1) which equalled to 
a receptor residence time (RT) of 2.3 ± 0.2 min. For LUF7746, this competition association 
assay generated a negligible dissociation rate constant (koff = 0.0046 ± 0.0020 min-1) and thus 
an infinite RT for LUF7746 (>1000 min, Table 2). These data provided further evidence for a 






Fig.3 Characterization of target binding kinetics of LUF7746 and LUF7747. Competition 
association radioligand binding assay with [3H]DPCPX in the absence or presence of indicated 
compounds (at 10 x Ki value) at 25oC. Data were fitted to the equations described in the methods to 
calculate the kon (k3) and koff (k4) values of unlabeled ligands by using the k1 and k2 values of 
[3H]DPCPX. Representative graphs from one experiment performed in duplicate. Parameters obtained 
from these graphs are listed in Table 2. 







LUF7746b ((4.1±0.9) x105) (0.0046±0.0020) (1118±963) 
LUF7747 (6.3±0.9) x106 0.42±0.03 2.3±0.2 
aAssociation (kon) and dissociation (koff) rate constants were determined by competition association 
assay at 25 °C; all values were determined using the mathematical model described by Motulsky and 
Mahan [27] 
bNo equilibrium between receptors and ligand was reached for LUF7746; the values obtained are 
therefore shown in parentheses and are considered to provide qualitative insight only. 
3.4. Washout assay between LUF7746 and hA1AR 
We then performed a “washout” experiment to investigate the irreversibility of the ligand-
receptor interaction. We first exposed hA1AR cell membranes to LUF7746 or LUF7747 at 1 
µM concentration with [3H]DPCPX for 2 h, without any washing step, to assess the binding 
capacity of the receptor (“Unwashed” group; Fig.4a). Both ligands achieved a high receptor 
occupancy, resulting in a lower radioligand-occupied receptor population of 23 ± 2% for 
LUF7746 and 38 ± 4% for LUF7747, respectively. For the “washed” groups, the pre-
incubated hA1AR membranes were washed four times to remove the non-covalently bound 
ligands (“washed” group; Fig.4a), after which they were exposed to [3H]DPCPX. Membranes 
pretreated with LUF7746 showed no increase in specific [3H]DPCPX binding with only 9 ± 
4% recovery despite the intensive washing treatment. In contrast, membranes pretreated with 
LUF7747 showed a full recovery of radioligand binding (104 ± 6%), ensuring the efficiency 
of the washing procedure to remove the reversible ligand.  
Covalent Partial Agonist for the Human A1R 
129
Fig.4 Involvement of Y2717.35 in the covalent binding of LUF7746. CHOhA1AR wild-type cell 
membranes (a) or mutant hA1AR-Y271F7.36 cell membranes (b) were pre-treated with 1 μM LUF7746, 
LUF7747 or buffer (vehicle) followed by no washing (filled column) or four washing cycles (hatched 
column). The membranes were then subjected to a standard [3H]DPCPX radioligand binding assay. 
Data are expressed as the percentage of vehicle group (100%) and represent mean ± SEM of three 
individual experiments performed in triplicate. Statistical analyses were performed using unpaired 
Student’s t-test between groups. ns: no significant difference; Significant difference: (*) p < 0.05; (**) 
p<0.01.   
3.5. Functional characterization of LUF7746 and LUF7747 in a [35S]GTPγS 
assay 
To extend the functional profiling of what emerged from the data presented above from the 
radioligand binding assays, we evaluated the compounds’ functional activities in a GTPγS-
binding assay on CHO cell membranes transiently transfected with wild type hA1AR 
(hA1AR-WT). This assay reflects the functional response of ligands at the level of GDP/GTP 
exchange by the ternary G protein complex, or G protein activation [30].  
The results showed that LUF7746 is a partial agonist (Emax = 56 ± 5%) in comparison to CPA, 
a reference full agonist with a pEC50 value of 8.1 ± 0.1 (Emax set to 100%, at a concentration 
of 1μM). The potency of LUF7746 (pEC50 = 7.3 ± 0.1; Fig.5a, Table 3) was comparable to its 
affinity (pKi = 7.7 ± 0.2; Fig.2a, Table 1). In addition, LUF7747 was also identified as a 
partial hA1AR receptor agonist (Emax = 53 ± 2 %) with a potency (pEC50 = 7.2 ± 0.02; Fig.5a, 






Fig.5 Functional profile of LUF7746 and LUF7747 in [35S]GTPγS binding assays on both 
hA1AR-WT and hA1AR-Y2717.36F (a) Functional ([35S]GTPγS binding) concentration-effect curves 
for CPA, LUF7746 and LUF7747 on transiently transfected hA1AR-WT cell membranes. Data are 
expressed as the percentage of maximal response induced by 10µM CPA (100% ) and represent the 
mean ± SEM of three individual experiments performed in duplicate. (b) Functional ([35S]GTPγS 
binding) concentration-effect curves for CPA, LUF7746 and LUF7747 on transiently transfected 
hA1AR-Y2717.36F cell membranes. Data are expressed as the percentage of maximal response induce 
by 1 µM CPA (100%) and represent the mean ± SEM of three individual experiments performed in 
duplicate. Parameters obtained from these graphs are described in Table 3. (c) hA1AR-WT or hA1AR-
Y2717.36F cell membranes were pre-incubated with LUF7746 or LUF7747 (EC80, obtained from figure 
6a or 6b) for 1 h, followed by incubation with [35S] GTPγS in the absence (filled columns) or presence 
(hatched columns) of DPCPX (1 µM) to determine residual [35S]GTPγS binding. Data are expressed as 
the percentage of response induced by LUF7746 at EC80 (100%) and represent the mean ± SEM of 
three individual experiments performed in duplicate. Statistical analyses were performed using 
unpaired Student’s t-test between groups. ns: no significant difference; Significant difference: (*) p < 
0.05; (***) p<0.005;  (****) p<0.001. 
To investigate the irreversible agonistic effect of LUF7746, we added an inverse agonist, 
DPCPX to hA1AR-WT pre-incubated with the designed agonist at EC80 concentration In the 
absence of agonist pre-incubation, DPCPX showed a (small, but significant) reduction in the 
basal level of G protein activity (-4 ± 1%; Fig.5c), consistent with an inverse agonistic 
behavior. Moreover, the G protein activation induced by LUF7746 and LUF7747 at EC80 
concentration was inhibited by subsequent addition of DPCPX to varying degrees. 
Specifically, LUF7747 stimulation of G protein activity was completely reversed (-4 ± 2%; 
Fig.5c), to an extent that was also obtained by treatment with DPCPX alone (-4 ± 1%; Fig.5c). 
[35S]GTPγS binding upon LUF7746 stimulation was only slightly reversed by DPCPX (83 ± 
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2%; Fig.5c), possibly due to the fact that not all receptors are irreversibly labeled by LUF7746 
at an EC80 concentration. 




pEC50 Emax (%)a pEC50 Emax (%)b 
CPA 8.1 ± 0.1 100 ± 13 8.4 ± 0.03 100 ± 4 
LUF7746 7.3 ± 0.1 56 ± 5* 6.8 ± 0.1 66 ± 1*** 
LUF7747 7.2 ± 0.02 53 ± 2* 7.1 ± 0.1 66 ± 4*** 
Values represent the mean ± SEM of three individual experiments performed in duplicate. 
aExpressed as percentage of [35S]GTPγS binding induced by 10 µM CPA (set at 100%). 
*P < 0.05, compared to CPA efficacy (Emax) using one way ANOVA with Dunnett’s post-test.
bExpressed as percentage of [35S]GTPγS binding induced by 1 µM CPA (set at 100%).
***P < 0.001, compared to CPA efficacy (Emax) using one way ANOVA with Dunnett’s post-test.
3.6. Binding mode of LUF7746 in the hA1AR binding pocket 
The characterization of the irreversible binding nature between LUF7746 and hA1AR 
prompted us to further investigate the target residue of the reactive warhead. Thus, we first 
retrieved the receptor atomic coordinates from a reported hA1AR X-ray crystal structure 
(PDB: 5UEN) [19] and constructed a receptor model in which hA1AR and LUF7746 interact. 
The binding pose of LUF7746 (Fig.6), is comparable to that of DU172, the ligand present in 
the crystal structure. Specifically, one cyano group at the C5 position participated in H-bond 
formation with Nδ2 of N2546.55. The dioxomethylene substituent functioned as H-bond 
acceptor with T913.36, while carbonyl-oxygen in the amide position of the linker hydrogen-
bonded with N702.65. Of note, the flexibility of the three-carbon linker allowed the warhead, 
the fluorosulfophenyl group of LUF7746, to form a covalent sulfonyl amide bond with the 
phenolic hydroxyl group of Y2717.36.  
3.7. Tyrosine Y2717.36 residue is the possible anchor point for covalent bond 
formation 
To verify this structural feature of the ligand-receptor interaction, we mutated the potential 
target tyrosine to phenylalanine (hA1AR-Y2717.36 F) and determined the affinities of both 
ligands for the mutant construct. As presented in Table 1, both compounds showed similar 
binding affinities in the submicromolar range (pIC50 = 7.2 ± 0.05 and 7.0 ± 0.06 for LUF7746 
and LUF7747, respectively; Table 1). Then we repeated the “washout” assay. As shown in 
Fig.4b, LUF7746 caused a significant recovery (53 ± 10 % remaining) compared to the 





assay on hA1AR-WT, which showed no recovery at all (Fig.4a). As a control, LUF7747 was 
rapidly washed off the membranes overexpressing hA1AR-Y2717.36F, as a full recovery of 
radioligand binding was observed (95 ± 11 %). 
 
Fig.6 Binding model of LUF7746 in the hA1AR-binding pocket. The ligand binding pocket present 
in the hA1AR crystal structure (PDB: 5UEN) was used for the modeling of LUF7746 into it. Receptor 
helices are in green with some amino acids marked.  LUF7746 is represented by light brown carbon 
sticks, together with oxygen, nitrogen, sulfur and hydrogen atoms (colored red, blue, yellow and 
white, respectively). The hydrogen bonds between ligand and receptor are indicated by yellow dashed 
lines. The ligand’s fluorosulfonyl group and Y2717.36 are in close proximity to facilitate covalent bond 
formation.    
In addition to the radioligand binding assay, potency and efficacy of both ligands were also 
evaluated in a GTPγS-binding assay on cell membranes transiently transfected with hA1AR-
Y2717.36 F. Both LUF7746 and LUF7747 showed a comparable Emax value (66 ± 1% and 66 ± 
4%; Fig.5b; Table 3) compared to reference full agonist CPA that had a pEC50 value of 8.4 ± 
0.03 (maximum response Emax set to 100%, at a concentration of 1 μM). This indicates that 
the two compounds are still partial agonists on mutant hA1AR-Y2717.36 F receptors. The 
potency of LUF7746 was slightly decreased on hA1AR-Y2717.36 F (pEC50 = 6.8 ± 0.1; Fig.5b, 
Table 3) compared to hA1AR-WT (pEC50 = 7.3 ± 0.1; Fig.5a, Table 3), while the potency 
value of LUF7747 was identical between hA1AR-Y2717.36 F (pEC50 = 7.1 ± 0.1; Fig.5b, Table 
3) and hA1AR-WT (pEC50 = 7.2 ± 0.02; Fig.5a, Table 3). Then on hA1AR-Y2717.36 F, we 
repeated the DPCPX inhibition experiments on cell membranes pretreated with both 
LUF7746 and LUF7747 at EC80 concentration. As shown in Fig.5c, DPCPX caused a more 
pronounced effect to reverse the stimulation of [35S]GTPγS binding induced by LUF7746 (29 
± 6%) on the mutant membranes, compared to the inhibition on hA1AR-WT (83 ± 2 %). As a 
control, LUF7747’s stimulation on hA1AR-Y2717.36 F was completely reversed (-5 ± 4%), 
comparable to the group only treated with DPCPX (-11 ± 2%). 
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3.8. Characterization of the covalent interaction in a label-free whole cell assay 
To further evaluate receptor activation by these ligands, we used a label-free, impedance-
based technology (xCELLigance) capable of real-time monitoring of hA1AR-mediated cell  
Table 4. Pharmacological characterization of LUF7746 and LUF7747 in a label-free whole-cell assay 
Compound 
CHO-hA1AR-low cells 
pEC50 Emax (%)a 
CPA 8.9 ± 0.06 100 ± 6 
LUF7746 7.7 ± 0.1 61 ± 1** 
LUF7747 7.6 ± 0.03 69 ± 4** 
Values represent the mean ± SEM of three individual experiments performed in duplicate. 
aData were normalized to the CPA response at 1 µM (100%). **P  < 0.01, compared to CPA efficacy 
(Emax) response using one way ANOVA with Dunnett’s post-test. 
Fig. 7 Functional characterization of CPA, LUF7746 and LUF7747 in a label-free whole 
cell assay. CHO-hA1AR-low cells were seeded into E-plate 96 wells (40,000 cells/well) for 
17 h, followed by 3 h serum free medium plus ADA (1.2 IU/ml) starvation, prior to the 
indicated agonist effects. (a) Representative example of a baseline-corrected CPA response [1 
μM–10 pM]. (b) Concentration-response curves of the three agonists, derived from similar 
curves as in (a). Data are expressed as the percentage of maximal response induced by 1 µM 
CPA (analysis of area-under-curve (AUC) at 100 min, 100%) and represent mean ± SEM of 
three individual experiments performed in duplicate. 
morphological changes over time [24]. Typically, CHO cells stably expressing a relative low 
level of hA1AR (CHO-hA1AR-low) were plated on an E-plate 17 h before the experiment 
[31]. Upon agonist addition to these cells, the impedance (shown as cell index, CI) was dose-
dependently increased, followed by a gradual decrease until reaching a plateau in most cases 
after 100 min. A representative experiment of CPA-induced impedance changes is shown in 
Fig.7a. Dose-response curves for CPA and the two LUF compounds were derived from the 





Specifically, compared to CPA, LUF7746 and LUF7747 again behaved as partial agonists 
with similar Emax values and potencies (see Fig.7b and Table 4).  
To probe the putative irreversibility of the designed agonist, we used this label-free assay to 
determine whether the activation of the receptor is reversed by subsequent addition of the 
A1AR antagonist/inverse agonist DPCPX (i.e. similar to the GTPgS experiments of 
membranes). After the CHO-hA1AR-low cells were incubated with compounds for 30 min  
 
Fig. 8 Characterization of the irreversible receptor activation induced by LUF7746 in a label-
free whole assay. CHO-hA1AR-low cells were pre-incubated with 1 µM LUF7746 (a) or LUF7747 
(b) for 30 min, followed by the addition of vehicle (0.25% DMSO) or 100 nM DPCPX (in 0.25% 
DMSO) to track the cell index changes for another 60 min. Representative graphs from one 
experiment performed in duplicate. 
DPCPX (100 nM) or 0.25% DMSO (vehicle) was added and the impedance change was 
measured until 100 min. As shown in Fig.8a, cells exposed to LUF7746 showed a slight drop 
of CI values with a recovery trend back to control (0.25% DMSO). A more outspoken 
decrease of CI was detected upon antagonist exposure of cells pretreated with LUF7747 
(Fig.8b). This behavior showed that LUF7746-pretreated cells were quite resistant to DPCPX 
compared to LUF7747, consistent with an irreversible mode of receptor activation. 
4. Discussion 
Covalent ligands have been invaluable in the study of ligand-receptor interactions and in 
GPCR structural biology. Recently, several GPCR structures, such as cannabinoid receptor 
CB1 [32] and adenosine A1 receptor [19], have been determined in the presence of chemo-
reactive ligands contributing to the formation of stable and functional ligand-receptor 
complexes. More generally, the use of covalent affinity probes for the exploration of the 
ligand binding pocket is widespread in GPCR research [2].  
The non-ribose agonists’ design dates back to the discovery of a former drug candidate, 
capadenoson, withdrawn from phase IIa clinical studies when it failed to show heart rate 
reduction for patients with atrial fibrillation [10, 11]. The structure modifications in 
capadenoson derivatives revealed that the dicyanopyridine scaffold with a benzo[1,3]dioxol-
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5-yl moiety at the C4 position showed good selectivity and efficacy at the hA1AR [9, 28].
Building on that, we introduced a reactive warhead (i.e. sulfonyl fluoride), connected to the
scaffold’s sulfur atom with an amide bond linked spacer, yielding the covalent
dicyanopyridine ligand LUF7746. Meanwhile, a nonreactive methylsulfonyl derivative
LUF7747, was designed and synthesized as a reversible control compound.
The first hint of covalent interaction of LUF7746 was found in time-dependent radioligand 
displacement assays, while the control ligand LUF7747 reached equilibrium independent of 
pre-incubation time. Similar experiments were performed on other subtypes of GPCRs, such 
as the M4 muscarinic receptor and cannabinoid CB1 receptor. All of the functionalized 
covalent ligands generated a time-dependent affinity increase [33, 34]. Subsequently, a 
continuing decrease of specific radioligand binding was observed for LUF7746 when the 
kinetic experiments were performed over a 4 h incubation at 25oC (Fig.3). The inadequacy of 
the Motulsky-Mahan model to fit this data is further evidence for the non-equilibrium features 
of the binding of LUF7746 to the receptor. In addition, extensive washing failed to restore 
[3H]DPCPX binding (Fig.4a) to membranes pretreated with LUF7746, validating the 
irreversible nature of LUF7746 to hA1AR. Likewise, on other GPCR subtypes, there are 
reported cases showing a covalent interaction was wash-resistant [13, 35, 36]. Furthermore, 
receptor activation induced by LUF7746 was not or hardly inhibited by the inverse agonist 
DPCPX (Fig.5c). This confirmed the covalent nature of LUF7746 binding to the receptor 
from a functional perspective, similar to other subtypes of GPCRs, where an excess of inverse 
agonist was unable to reverse covalent ligand-induced G protein activation [37]. Taking all 
data together we concluded LUF7746 showed a covalent interaction with hA1AR under many 
different experimental conditions.  
The next step was to identify the anchor point of the covalent probe. The reported active 
structure of the hA1AR is in the presence of the ribose-based full agonist adenosine, which is 
structurally and functionally distinct from our non-ribose partial agonist LUF7746 [38]. In 
addition, our previous study on the dicyanopyridine scaffold showed that upon the addition of 
GTP this compound class only caused a minor shift to a lower affinity on hA1AR [39]. It is 
thus possible that this non-ribose partial agonist-bound receptor adopts a conformation 
distinct from the fully active state. Therefore, we adopted the inactive state of the hA1AR 
receptor (PDB:5UEN) for our docking studies [19]. Based on the LUF7746 binding pose in 
our model of the hA1AR, we hypothesized that LUF7746 covalently interacts with a tyrosine 





To investigate our hypothesis, this tyrosine was mutated to phenylalanine (hA1AR-Y2717.36F) 
to remove the nucleophilic reactivity of the phenolic hydroxyl group and potentially prevent 
the covalent bond from being formed. Since control compound LUF7747 showed a similar 
affinity for both the Y2717.36F (pIC50 = 7.0 ± 0.06) and WT receptors (pIC50 = 7.0 ± 0.02), we 
assumed that the difference in radioligand binding recovery was not due to a point mutation 
within the receptor binding site, which has the potential to affect ligand binding properties. 
Moreover, there were no marked affinity differences on hA1AR-Y2717.36F between LUF7746 
(pIC50 = 7.2 ± 0.05) and LUF7747 (pIC50 = 7.0 ± 0.06). This suggests that the chemically 
dissimilar ligands LUF7746 (reactive) and LUF7747 (nonreactive) exhibit a similar binding 
interaction with hA1AR-Y2717.36F. Lastly, the extensive washing treatment caused a four-fold 
increase of [3H]DPCPX  binding recovery on hA1AR-Y2717.36F pre-incubated with LUF7746 
(Fig. 4b), which is in sharp contrast to the findings in the wild type washout assay. Hence, we 
concluded Y2717.36 is involved in the covalent attachment of LUF7746’s fluorosulfonyl group 
within the hA1AR binding pocket.  
A similar result was observed in the functional [35S]GTPγS assay. Since LUF7747 showed a 
comparable potency for hA1AR-Y2717.36F  and  hA1AR-WT,  the receptor functionality was 
not altered by the point mutation. Furthermore, receptor stimulation by LUF7746 was largely 
reversed by DPCPX due to the amino acid Y2717.36 mutation, unlike in the WT receptor (Fig. 
5c). This marked contrast confirms the hypothesized covalent interaction between ligand and 
receptor and validates the primary role of the tyrosine residue in the formation of the covalent 
activation. It may be though that a second site of covalent interaction exists, as the reversal of 
the functional effect was not complete under the experimental conditions examined. Similar 
results from functionalized covalent probes were also obtained on other GPCR subtypes. On 
M1 and M2 muscarinic receptors, nitrogen mustard analogs alkylate more than one residue 
besides a well-known reactive center Asp3.32 [40]. Likewise, on the human cannabinoid 2 
receptor, two possible cysteines were validated to mediate the covalent binding of affinity 
probe AM1336 [41]. Mutagenesis of nucleophilic residues near the orthosteric binding pocket 
is useful to study the mode and site of interaction, but may also drive the covalent ligand to 
react with secondary nucleophilic amino acid residues. 
Building on our understanding of the chemical properties of LUF7746, we further performed 
an in vitro A1 receptor-mediated whole-cell assay. To reveal the partial agonistic behavior, the 
cell line used for this label-free assay has a relatively low hA1AR expression level (Bmax = 
0.968 ± 0.014 pmol/mg protein for [3H] DPCPX derived from saturation experiments) [25]. In 
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particular, the inhibition of reversible activation (LUF7747, Fig.8b) demonstrated a continued 
decrease in cell impedance, whereas covalent activation by LUF7746 (Fig.8a) was first 
inhibited by DPCPX, although less than for LUF7747, and appeared to return towards the 
activation state. Hence, we substantiated that the intrinsic cellular effect induced by LUF7746 
is vastly different from cellular responses generated by LUF7747. This phenomenon was 
found in other studies as well. For instance, in the case of the cannabinoid CB1 receptor, 
covalent agonist AM841 generates an inhibition on synaptic transmission, which cannot be 
reversed by antagonist [42]. In another study, Jorg et al found that hA1AR modulation by 
covalent agonists appeared to be insensitive to post-reversal by antagonist [4].  
In conclusion, we report the rational design of non-ribose hA1AR ligand LUF7746, with a 
chemically reactive electrophilic (SO2F) warhead at a judiciously selected position. A series 
of assays, comprising time-dependent affinity determination, kinetic assay, washout 
experiments and [35S]GTPγS binding assays, then validated LUF7746 as the first covalent 
partial agonist for the hA1AR. A combined in silico hA1AR-structure based docking and site-
directed mutagenesis-study was performed to demonstrate amino acid residue Y2717.36 was 
responsible for the covalent interaction. Furthermore, we demonstrated that LUF7746 
behaved as covalent partial agonist under near-physiological conditions at the cellular level. 
Thus, our covalent ligand LUF7746 behaves as a covalent partial agonist on membranes and 
intact cells and may serve as a tool compound for further studies on receptor desensitization 
or internalization and target validation in in vivo studies. This useful approach for 
investigating ligand-receptor interactions can be enhanced through the design of other higher 
affinity electrophiles, and it can be applied to study molecular mechanisms involved in partial 
agonism. Future work in this regard could involve proteomics studies with LUF7746 e.g., 
peptide-level LC/MS/MS, to experimentally identify other potential amino acid residues 
critical to hA1AR orthosteric ligand binding and function and would serve to map structural 
features and the topology of the hA1AR non-ribose partial agonist binding pocket.  
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Using activity-based protein profiling (ABPP) functional proteins can be interrogated in their 
native environment. Despite their pharmaceutical relevance G protein-coupled receptors 
(GPCRs), have been difficult to address through ABPP. In the current study we took the 
prototypical human adenosine A2A receptor (hA2AR) as the starting point for the construction 
of a chemical toolbox allowing two-step affinity-based labeling of GPCRs.  
Firstly, we equipped an irreversibly binding hA2AR ligand with a terminal alkyne to serve as 
probe. We showed that our probe irreversibly and concentration-dependently labeled purified 
hA2AR. Click-ligation with a sulfonated cyanine-3 fluorophore allowed us to visualize the 
receptor on SDS-PAGE. We further demonstrated that labeling of the purified hA2AR by our 
probe could be inhibited by selective antagonists. Lastly, we showed successful labeling of 
the receptor in cell membranes overexpressing hA2AR making our probe a promising affinity-









The adenosine receptors, belonging to the family of G protein-coupled receptors (GPCRs), 
have been coined adenosine A1, A2A, A2B, and A3. These receptors are widely distributed 
through the human body and are considered promising targets for a wide range of diseases [1]. 
Regadenoson, a selective human adenosine A2A receptor (hA2AR) agonist used to increase 
vasodilation during cardiac imaging, has been approved by the FDA, exemplifying the 
potential therapeutic applications for the hA2AR. Likewise, hA2AR antagonists are currently 
being pursued as potential treatment of Parkinson’s disease and as adjuvants in cancer 
immunotherapy [2, 3].  
The hA2AR was one of the first GPCRs for which a crystal structure was elucidated [4]. 
However, the challenges in structural biology of GPCRs, including the low expression level in 
native tissue and inherent poor protein stability, still exist [5]. To overcome these obstacles, 
covalent probes have been developed as useful pharmacological tools. Such probes, also 
named affinity labels, represent compounds that feature a reactive cross-linking moiety, which 
can irreversibly and specifically bind to a receptor. For example, an irreversible antagonist 
was used to stabilize the adenosine A1 receptor for co-crystallization, resulting in the 
visualization of key amino acids important for ligand-receptor binding [6].  
The design of covalent probes for GPCRs generally follows a similar strategy, which is to 
incorporate a warhead in a high-affinity, reversibly binding ligand. Based on the type of 
warhead used, two categories of irreversible ligands can be discerned: photoaffinity- and 
chemoreactive ligands [7, 8]. Whereas in the former type a photoreactive warhead is 
employed, the latter is equipped with an electrophilic chemical moiety capable of binding 
nucleophilic residues in the target protein. A commonly used warhead is aryl sulfonyl fluoride, 
which is capable of covalently binding to many nucleophilic amino acid residues, such as 
serine, threonine, lysine, and cysteine [9]. This warhead has been incorporated in several 
reported covalent ligands for the adenosine receptors, including FSCPX [10], FSPTP [11], 
fluorosulfonyl functionalized pyrimidine derivatives [12] and LUF7445 [13]. Likewise, 
fluorescent tags have been incorporated into adenosine receptor ligands to visualize the 
receptor, which yielded e.g., FITC-ADAC [14], MRS5422 [15] and NBD-NECA [16]. 
However, fluorescent moieties are of significant size and a priori derivatization of a ligand 
with such a group may negatively affect receptor affinity. Here, two-step affinity-based 
probes (AfBPs) might be a better alternative, as a reporter tag is added after the reactive 
ligand has bound its target [17].  
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Interestingly, from the field of activity-based protein profiling (ABPP), combined with click 
chemistry, many techniques have emerged that could potentially be applied to GPCRs using 
our covalent ligand. Normally in ABPP, an irreversible ligand is equipped with a ligation 
handle and after binding to the protein of interest is paired with a clickable fluorophore. In 
this way, via a Huisgen 1,3-dipolar cycloaddition, a stable triazole-linked product is formed, 
effectively attaching a fluorescent label to the protein [18-20]. Currently, this technique serves 
as a tool to profile the activities of drug targets (currently mainly enzymes) in native 
biological systems. One-step labeling, where the reporter group is pre-attached to the probe, 
has been applied on GPCRs before [21-23]. Moreover, similar two-step labeling strategies 
have been applied for other targets[24, 25]. However, due to their low abundance GPCRs are 
difficult to address with this otherwise promising technique. Within the entire GPCR family 
with over 800 members, until recently, only the mGlu5 receptor had been the subject of this 
approach, albeit with limited success [26]. Very recently, the type 2 cannabinoid receptor 
(CB2R) has been probed with a two-step photoaffinity probe, leading to great insights into 
receptor localization and target engagement [27]. 
Figure 1. Chemical structures of the hA2AR antagonists examined in this study. The lead compound 
ZM241385, a selective hA2AR antagonist, inspired the design of covalent antagonist 1.13 In the current 
study the effect of the linker length between scaffold and warhead on affinity was further examined, 
yielding compound 2 and, preferably, compound 3. The affinity-based probe 4 was then synthesized 
from compound 3, bearing an alkyne ligation-handle and a fluorosulfonyl electrophilic warhead. The 
electrophilic warhead is in red and the click-ligation handle is in blue. 
In this study, we describe our efforts to obtain a clickable affinity-based probe, with an 
electrophilic warhead, as a logical extension of our previous research on the successful design 
of a covalent antagonist of hA2AR, compound 1 (LUF7445) [13]. We used the antagonist 
ZM241385 as the starting point in our design efforts, and synthesized a series of 







potent ligand, with low nanomolar affinity, was retained for further structural modification 
and was equipped with an alkyne-click handle, resulting in probe 4, as shown in Figure 1. We 
then validated that the ligand’s binding to the receptor was wash-resistant. Additionally, we 
demonstrated the ligand’s covalent labeling capacity of purified receptors via a bioorthogonal 
copper catalyzed azide-alkyne ligation reaction with a fluorescent moiety, sulfonated cyanine 
3 ((E)-2-((E)-3-(1-(6-((3-azidopropyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfo-3H-indol-1-
ium-2-yl)allylidene)-3,3-dimethyl-1-(3-sulfopropyl)indoline-5-sulfonate). Finally, this probe 
was able to profile the presence of hA2AR in a relatively complex biological sample. Hence, 
this is one of the first AfBPs for a GPCR, and may set the stage for similar probes to facilitate 
target discovery and bioanalysis of GPCRs associated with human disease.  
2. Results and discussions 
2.1. Chemistry.  
In the past, our research group has been evaluating structural modifications of triazolotriazine 
derivatives based on the selective adenosine A2A antagonist 4-(2-(7-amino-2-(furan-2-yl)-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol (ZM241385), to obtain a covalent 
ligand for the hA2AR. The rational design of this covalent ligand originated from a reported 
hA2AR crystal structure (PDB: 4EIY) in complex with ZM241385 [4]. In it, the ligand binding 
pocket demonstrated a deep, planar and narrow cavity embracing the aromatic core and furan 
ring of ZM241385. Therefore, an extension of the hydroxyphenethylamine moiety into the 
extracellular domain of the receptor offered us the playground for integration of the 
electrophilic reactive groups. Our earlier covalent antagonist, compound 1 (Figure 1), in 
which the 4-hydroxyphenylethylamine-side chain in ZM241385 was replaced with a similar 
side chain harboring an electrophilic fluorosulfonyl moiety, was recognized by hA2AR with an 
apparent pKi of 8.99 [13]. In order to optimize the irreversible binding potential of our 
compound, with our current aim of developing an AfBP in mind, an exploration of linker 
length was performed, varying the linker between the fluorosulfonyl warhead moiety and the 
aromatic recognition element from three to five carbon atoms. To this end, compounds 2 and 
3 were synthesized as detailed in Scheme 1. The synthesis starts from 2-(furan-2-yl)-5-
(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 5, synthesized as previously 
reported [13],  and involves a linear sequence comprising aromatic substitution with either 
commercially available mono-Boc-protected butyldiamine or pentyldiamine and subsequent 
Boc-deprotection towards intermediates 8 and 9. Introduction of the fluorosulfonylbenzoyl 
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warhead proceeded with low yields due to difficult purification, providing ligands 2 and 3 in 4% 
and 2% yield respectively.  
The synthetic route towards probe 4 (LUF7487, Figure 1) is depicted in Scheme 1. First, the 
amino group of 5-aminopentanol was protected with a Boc group and the hydroxyl was 
converted to a bromide using an Appel reaction, providing intermediate 12. Nucleophilic 
substitution of the bromide with propargylamine afforded amine 13, which was acylated with 
4-fluorosulfonylbenzoylchloride to give Boc-protected bi-functional spacer 14 uneventfully.
Finally, in a two-step process, the spacer was deprotected and coupled to scaffold 5, to
provide probe 4 in 45% yield.
Scheme 1. Synthesis of compounds 2, 3 and 4.
 
Reagents and conditions: a) tert-butyl (4-aminobutyl)carbamate or tert-butyl (5-
aminopentyl)carbamate, DiPEA, MeCN, 70-85˚C, 46-74%; b) TFA, quant; c) 4-
fluorosulfonylbenzoylchloride, DiPEA, MeCN, 70˚C, 2-4%; d) Boc2O, DCM, quant; e) PPh3, CBr4, 
90%; f) propargylamine, DiPEA, 46%; g) 4-fluorosulfonylbenzoylchloride, DiPEA, MeCN, quant; h) 
i. 5, TFA, DCM, ii. DiPEA, MeCN, 70˚C, 45%
2.2. Biology
To assess the affinity for the hA2AR, compounds 2 and 3 were tested in [3H]ZM241385 
displacement experiments (n = 3), which demonstrated a concentration-dependent inhibition 
of radioligand binding to hA2AR overexpressed in HEK293 cells. To better understand the 
time-dependent binding characteristics of these compounds, we then carried out displacement 








Figure 2. Displacement of specific [3H]ZM241385 binding from HEK293 cell membranes stably 
expressing the hA2AR receptor at 25°C by compound 2 (a), 3 (b) and 4 (c) with an incubation time of 
0.5h (blue curve) and 3h (red curve), respectively. Representative graphs are from one experiment 
performed in duplicate. ndependent experiments performed in duplicate with error bars representing 
SEM values 
experiments are given in Figure 2a and 2b, in which the concentration-dependent inhibition of 
specific [3H]ZM241385 binding shifted to the left with an incubation time extension from 0.5 
h (standard) to 3 h. As detailed in Table 1, the affinities of both compound 2 and 3 
significantly increased by approximately 5-fold to sub-nanomolar values with longer 
incubation times. In other words, both designed covalent ligands became more potent in 
displacing the radioligand [3H]ZM241385 from the receptor over time. Similarly, to 1 [13], 
this pronounced affinity increase may be attributed to an irreversible binding nature of the 
compounds, leading to a higher receptor occupancy with a longer incubation time. It should 
be kept in mind that due to the covalent nature of the interaction; affinity values can only be 
apparent as no dynamic equilibrium can be reached. Compound 3 inhibited the specific 
[3H]ZM241385 binding to the hA2AR with a pKi of 9.21, compared to the affinity of 
compound 2 (pKi = 9.05 ± 0.07) and 1 (pKi = 8.99 ± 0.01). Thus, the extension of the linker to 
five carbon atoms slightly increased the apparent affinity. This could be caused by more steric 
freedom allowing the fluorosulfonyl group to orient towards the adjacent nucleophilic residue 
in the receptor binding site compared to ligands with a shorter linker. A similar example is an 
electrophilic probe for the cannabinoid CB1 receptor, 7’-NCS-1’,1’-DMH-Δ8-THC, in which 
lengthening the C-3 alkyl side chain to seven carbons, resulted in a significantly improved 
affinity [28]. Above all, high affinity is a key requirement for the development of irreversible 
ligands, as it increases the presence of the chemoreactive moiety in proximity to a 
nucleophilic residue in the binding site, thereby improving receptor occupancy and causing a  
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1f 8.27 ± 0.04 8.99 ± 0.01*** 0.72 
2 8.20 ± 0.13 9.05 ± 0.07*** 0.85 
3 8.56 ± 0.03 9.21 ± 0.01*** 0.65 
4 8.41 ± 0.02 8.82 ± 0.02*** 0.41 
a Data are expressed as means ± SEM of three separate experiments each performed in duplicate. ***P 
< 0.001 compared with the pKi values in displacement experiments with a 0.5h incubation time; 
Student’s t-test.
b For all the designed covalent antagonists, pKi values can only be apparent, as true equilibrium cannot 
be reached; 
c Affinity, expressed as pKi value, determined from displacement of specific [3H]ZM241385 binding 
from the hA2AR at 25oC during a 0.5h incubation; 
d Affinity, expressed as pKi value, determined from displacement of specific [3H]ZM241385 binding 
from the hA2AR at 25oC during a 3h incubation; 
e Affinity shift was calculated as [pKi (3h)-pKi (0.5h)]; 
f Data previously reported provided for comparison [13]. 
decrease in non-specific binding to other unrelated targets. As we anticipated a greater 
demand for steric freedom for the incorporation of the alkyne group and the subsequent 
ligation between the alkyne moiety and a bulky fluorescent dye, we retained the preferable 
five carbon atom linker length for the design of our probe.  
Inspired by the most promising compound 3, we incorporated the alkyne click-handle to 
afford a novel covalent probe, compound 4 (LUF7487, Figure 1). As detailed in Table 1, 
affinity-based probe 4 demonstrated a high affinity, displacing [3H]ZM241385 with an 
apparent pKi value of 8.82. Under these conditions 4 was at least 10-fold selective over human 
A1 and A3 receptors (SI Table S1). In a time-dependent study, probe 4 generated a significant 
increase in specific [3H]ZM241385 displacement over time (Table 1). In analogy to the 
covalent ligand 3, the designed probe was markedly influenced by prolonged incubation times 
(Figure 2c), suggesting an increasing level of covalent binding over time. However, compared 
to 3, the slight decrease in affinity may be attributed to the incorporation of the click handle, 
possibly leading to a steric hindrance in the ligand-receptor complex, and/or the formation of 
a covalent bond between the warhead and other nucleophilic residues.  
To better understand the receptor-ligand binding nature, the novel affinity-based probe was 
then evaluated for its covalent nature by determining its capacity to irreversibly block 
[3H]ZM241385 to hA2AR binding sites. Membranes overexpressing hA2AR were pretreated 








Figure 3. Probe 4 irreversibly binds to hA2AR HEK293 cell membranes stably expressing hA2AR were 
pre-incubated with probe 4 (a) or ZM241385 (b) at the indicated comparable concentrations. 
Pretreated membranes were washed three times extensively before further displacement studies of 
specific [3H]ZM241385 binding from the hA2AR at 25°C by non-labelled ZM241385 were performed. 
Representative graphs are from three independent experiments performed in duplicate with error bars 
representing SEM values 
followed by a three-cycle washing step to remove the non-covalently bound material. The 
membranes pretreated with probe 4 (Figure 3a) at increasing concentrations revealed a 
concomitant decline in specific [3H]ZM241385 binding, which was reduced from 65 ± 2% to 
43 ± 2%. However, membranes pretreated with the reversible antagonist ZM241385 (Figure 
3b) at increasing concentrations showed no decrease in specific [3H]ZM241385 binding, 
proving that the washing procedure was extensive enough to remove all non-covalently 
binding compound. Meanwhile, the affinity of unlabeled ZM241385 was not influenced 
significantly by the preincubation and washing procedure, indicating that the extensive 
washing did not damage the membrane integrity or alter the membrane binding sites (SI Table 
S2). Therefore, it could be concluded that the concentration-dependent decrease in specific 
[3H]ZM241385 binding observed with probe 4 resulted from an irreversible occupancy of the 
hA2A receptor binding pocket. Similar results have been obtained on other GPCRs, e.g., for 
the adenosine A1 receptor irreversible antagonist FSCPX [29, 30] and the covalent histamine 
H4 receptor partial agonist VUF14480 [31], although these compounds lack the alkyne moiety 
to perform a click chemistry approach.  
2.3. Fluorescent labeling of the hA2AR.  
Having shown that the designed probe 4 meets the requirement of covalent binding, we then 
set out to evaluate its ability to function as an affinity-based probe. Purified hA2AR was first 
incubated with the alkyne-containing probe 4 to ensure formation of a covalent probe-hA2AR 
adduct. Then all samples were subjected to a copper (I)-catalyzed sulfonated cyanine 3-azide  
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Figure 4. Concentration-dependent affinity labeling of purified, His-tagged hA2AR by probe 4. (a) 
Purified hA2AR material was incubated with the indicated concentrations of probe 4 or vehicle (1% 
DMSO), and subjected to click chemistry ligation with Cy3-azide, followed by SDS-PAGE separation 
and in-gel fluorescence scanning (left). The blotted membranes were probed with anti-histidine 
antibody, wherein bands corresponding to purified hA2AR molecular weight (∼47 kDa) were evident 
in all samples (right). (b) Quantification of fluorescence intensity from purified hA2AR labeled by 
probe 4 clicked to Cy3-azide. Representative graphs are from three independent experiments, with 
errors bars representing SEM values. In-gel fluorescence of the hA2AR band at ~47 kDa was 
normalized to the corresponding hA2AR immunoreactivity in each sample.         
(Cy3-azide) attachment to the terminal alkyne [32, 33]. The subsequent fluorescence scanning 
of a SDS-PAGE showed that in the presence of fluorescent dye Cy3-azide (Figure 4a), probe 
4 was concentration-dependently incorporated into a fixed amount of purified hA2AR, while in 
the absence of probe, little fluorescence intensity was detected. Importantly, western blot 
analysis using the purified hA2AR receptor and specific anti-histidine antibodies 
unambiguously validated the labeling band was hA2AR (Figure 4a). Interestingly, a second 
band was observed in both affinity labeling results and western blots, most likely resulting 
from posttranslationally modified receptors,34 as has been shown before on CB2R [27]. 
Quantification of the fluorescence intensity of the main labeling bands in the hA2AR is 
reflected in the concentration-effect curve in Figure 4b. This revealed that clickable probe 4 
labeled hA2AR with a pEC50 value of 6.10 ± 0.04, resulting in a maximal labeling achieved 
with 10 µM probe 4 when incubated with 0.1 mg mL–1 of purified hA2AR. Collectively, these 
data demonstrate that probe 4 can be used as an affinity-based probe for purified hA2AR.  
To further characterize our affinity-based probe, we then investigated whether competitive 








Figure 5. Competitive affinity labeling of the purified hA2AR by probe 4 (a) Affinity labeling of 
purified hA2AR by probe 4 (1 µM) is inhibited by preincubation with either compound 1 (10 µM) or 
ZM241385 (10 µM) (left). The blotted membranes were probed with anti-histidine antibody, wherein 
bands corresponding to purified hA2AR molecular weight (∼47 kDa) were evident in all samples 
(right). (b) Quantification of fluorescence intensity from pretreated purified hA2AR labeled by probe 4 
clicked to Cy3-azide. Representative graphs are from three independent experiments, with errors bars 
representing SEM values. ***P < 0.001 compared with the fluorescent intensity of purified hA2AR 
labeled by probe 4 (1 µM); Student’s t-test.  In-gel fluorescence of the hA2AR band at ~47 kDa was 
normalized to the corresponding hA2AR immunoreactivity in each sample 
reversible antagonist ZM241385 and irreversible compound 1, at saturating concentrations 
(10 µM, i.e. 10 times higher than the concentration of the clickable probe 4). Purified hA2AR, 
preincubated with the competitors and subsequently treated as mentioned before to 
incorporate the sulfonated cyanine 3 fluorophore, showed little if any fluorescence intensity of 
labelling bands under these conditions. This revealed that both a reversible and an irreversible 
antagonist competed with probe 4 (Figure 5a, left panel) for the same binding site at the 
hA2AR, which was available at identical amounts in all conditions (as evidenced by His-
tagging: Figure 5a, right panel). Theoretically, both reversible and irreversible ligands inhibit 
affinity labelling, provided that they target the same receptor binding site and are present in a 
sufficient concentration. Of note, in practice, this is not always easily observed, as in the 
competition between reversible ligand and covalently binding probe there is an inherent bias 
towards the irreversible pathway, hindering the interaction between the receptor and a 
reversible ligand. For instance, in the few other studies where an AfBP has been used on 
GPCRs it was found that a reversible mGlu5 negative allosteric modulator, MPEP, could not 
inhibit the tandem photoaffinity labeling of purified mGlu5, whereas on CB2R, inhibition of 
labeling by various competitors was observed [26, 27]. Apparently, this was less of a problem 
on the hA2AR. Our results demonstrate that the developed AfBP system can serve as an 
effective chemical tool for profiling the purified hA2AR in vitro, prompting us to further  
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evaluate the potency and selectivity of probe 4 in profiling the activity of the adenosine A2A 
receptor in more complex biological samples.
We further explored the ability of probe 4 to label 
hA2AR in cell membranes prepared from HEK293 
cells, which were transiently transfected with N-
terminally FLAG-tagged and C-terminally His-
tagged human adenosine A2A receptors (FLAG-
hA2AR-His). Therefore, FLAG-hA2AR-His cell 
membranes were incubated with probe 4 at room 
temperature for 1 h, followed by click ligation to 
Cy3-azide treatment. As detailed in Figure 6, a band 
corresponding to the molecular weight of the FLAG-
hA2AR-His was observed on fluorescent SDS-PAGE 
scanning, which was then validated by Western blot 
using specific anti-FLAG antibodies. In these initial 
proof-of-concept experiments we highlighted the 
versatility of probe 4, which can be efficiently used 
to label the adenosine A2A receptor in cell membrane 
samples. Background signals caused by nonspecific 
labeling of abundant proteins in complex proteomes 
may sometimes confound the analysis of on-target 
labeling of low expression proteins such as GPCRs. 
Figure 6. Affinity labeling of hA2AR in 
HEK293 cell membranes transiently 
expressing FLAG-tagged hA2AR using 
probe 4. (a) cell membranes 
overexpressing FLAG-tagged hA2AR 
were incubated with either 1 µM probe 4 
or vehicle (1% DMSO), then subjected to 
click chemistry ligation with Cy3-azide, 
followed by SDS-PAGE separation and 
in-gel fluorescence scanning (left). The 
blotted membranes were probed with 
anti-FLAG antibody, wherein bands 
corresponding to the hA2AR molecular 
weight (∼50 kDa) are evident in all 
samples.
Thus, we utilized cell membranes transiently transfected with FLAG-hA2AR-His, which have 
a relatively high level of receptor expression. Additionally, instead of premixing the copper 
sulfate and sodium ascorbate reagents, we slightly altered the click procedure by adding the 
copper sulfate last to achieve efficient and selective labeling of the A2A receptors [35, 36]. 
Although we were able to decrease the strong background signals, a significant non-specific
fluorescent dyes and labeled receptors, non-specific protein binding of the probe due to the 
inherently reactive warhead and the sensitivity of the used detection method. Hence, further 
technological refinement should help us in achieving better labeling of endogenously 
expressed GPCRs, e.g. in human tissues as has been shown recently on CB2R [27]. The 
monitoring of endogenous GPCR expression and target engagement in human cells holds 








Starting from a selective antagonist, ZM241385, we designed and synthesized a series of 
covalent ligands using the electrophilic nature of sulfonyl fluorides, eventually yielding probe 
4, the first affinity-based probe for the hA2AR. We successfully demonstrated a concentration-
dependent labelling of purified receptor by probe 4 via an experimental two-step labeling 
strategy, which could be inhibited by both reversible and irreversible competing ligands. 
Additionally, probe 4 displayed target selectivity in cell membranes overexpressing the 
hA2AR, indicating that it may become a useful pharmacological tool to identify the hA2AR in 
living organisms for target validation or to assess receptor subtype distribution. In this 
strategy a probe depicts the native binding with less perturbation, which bridges the chemical 
biology study with molecular pharmacology to better investigate receptor-ligand interactions.  
In future research, different tags may be introduced; for instance, a biotin-tag would allow for 
streptavidin-mediated receptor enrichment followed by LC/MS analysis. Similarly, the 
approach developed in this study may be applied to other GPCRs, such as the other adenosine 
receptor subtypes. 
4. Experimental sections 
4.1. Chemistry  
All solvents and reagents were purchased from commercial sources and were of analytical 
grade. 1H NMR spectra were recorded on a Bruker AV 400 liquid spectrometer (1H NMR, 
400 MHz) at ambient temperature. Chemical shifts are reported in parts per million (ppm) and 
are designated by δ. Coupling-constants are reported in Hz and are designated as J. Analytical 
purity of the final compounds was determined by high pressure liquid chromatography 
(HPLC) with a Phenomenex Gemini 3μ C18 110A column (50 × 4.6 mm, 3 μm), measuring 
UV absorbance at 254 nm. Sample preparation and HPLC method was as follows: 0.5 mg of 
compound was dissolved in 1 mL of a 1:1:1 mixture of CH3CN/H2O/tBuOH and eluted from 
the column within 15 min, with a three component system of H2O/CH3CN/1% TFA in H2O, 
decreasing polarity of the solvent mixture in time from 80/10/10 to 0/90/10. All compounds 
showed a single peak at the designated retention time and are at least 95% pure. Liquid 
chromatography–mass spectrometry (LC–MS) analyses were performed using Thermo 
Finnigan Surveyor – LCQ Advantage Max LC-MS system and a Gemini C18 Phenomenex 
column (50 × 4.6 mm, 3 μm). The sample preparation was the same as for HPLC analysis. 
The elution method was set up as follows: 1–4 min isocratic system of H2O/CH3CN/1% TFA 
in H2O, 80:10:10; from the 4th min, a gradient was applied from 80:10:10 to 0:90:10 within 9 
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min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer 
chromatography (TLC) was routinely performed to monitor the progress of reactions, using 
aluminum coated Merck silica gel F254 plates. Purification by column chromatography was 
achieved by use of Grace Davison Davisil silica column material (LC60A 30–200 micron). 
Solutions were concentrated using a Heidolph laborota W8 2000 efficient rotary evaporation 
apparatus and by a high vacuum on a Binder APT line Vacuum Drying Oven. 
4-((4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)butyl)carbamoyl)benzene sulfonyl fluoride (2) Previously synthesized N5-(4-
aminobutyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 8 (TFA salt, 250 
mg, 0.40 mmol, 1.0 eq) was suspended in acetonitrile (10 mL) and purged with N2. Then 
DiPEA (0.42 ml, 2.4 mmol, 6.0 eq) was added after which 4-fluorosulfonylbenzoylchloride 
(134 mg, 0.60 mmol, 1.5 eq) was added last and the mixture was heated to 70 oC for 7 h, and 
then stirred at room temperature for another 17 h. A flash column (MTBE + 1% AcOH → 90% 
MTBE + 10% EtOAc + 1% AcOH), a subsequent preparative TLC (1:1 MTBE:EtOAc + 1% 
MeOH) and an extraction using acetonitrile (10 mL) and petroleum ether (4 x 10 mL) 
afforded the product as a white solid (8 mg, 0.017 mmol, 4% yield). 1H NMR (DMSO-d6, 400 
MHz) : δ  8.29–8.18 (m, 5H), 7.75 (s, 1H), 7.40 (br s, 2H), 7.05 (d, J = 3.2 Hz, 1H), 6.73 (m, 
1H), 6.62 (s, 1H), 3.55–3.46 (m, 4H), 1.75–1.74 (m, 4H). HPLC: 96.5 %, RT 7.478 min. LC-
MS: [ESI+H]+: 475.20 
4-((5-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)pentyl)carbamoyl) benzenesulfonylfluoride (3) N5-(5-aminopentyl)-2-(furan-2-
yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 9 (TFA salt, 674 mg, 0.85 mmol, 1 eq) 
was suspended in acetonitrile (5 mL) . 4-Fluorosulfonylbenozylchloride (208 mg, 0.94 mmol, 
1.1 eq) was added, along with DiPEA (0.8 mL, 5 mmol, 5.8 eq). The mixture was heated at 
70 °C under N2 atmosphere for 2.5 h. A flash column (DCM → 60% DCM, 40% EtOAc) with 
subsequent preparative TLC (100% EtOAc) was used to obtain the title compound as a 
colorless solid (9 mg, 0.018 mmol, 2% yield). 1H NMR (C3D6O, 400 MHz): δ 8.27–8.16 (m, 
4H), 7.73 (dd, J = 1.7, 0.8 Hz, 1H), 7.39 (s, 2H), 7.05 (d, J = 3.2 Hz, 1H), 6.80–6.63 (m, 1H), 
6.62 (dd, J = 3.4, 1.8 Hz, 1H), 3.52–3.38 (m, 4H), 1.78–1.62 (m, 4H), 1.56–1.44 (m, 2H). 
HPLC: 100%, RT 7.637 min, LC-MS:[ESI+H]+: 489.00 
4-((5-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)pentyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl fluoride (4) tert-butyl (5-(4-
(fluorosulfonyl)-N-(prop-2-yn-1-yl)benzamido)pentyl)carbamate 14 (586 mg, 1.38 mmol, 1 







solvents were removed in vacuo. This crude intermediate was suspended in acetonitrile (10 
mL), 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 5 (386 mg, 
1.38 mmol, 1 eq) was added, along with DiPEA (2 mL, 11.0 mmol, 8 eq). The reaction 
mixture was heated at 70 °C for 2 h. Then the reaction mixture was concentrated and purified 
by a flash column (EtOAc) to yield a yellow solid (330 mg, 0.62 mmol, 45%). 1H NMR 
(DMSO-d6, 353K, 400 MHz,) δ 8.17 (d, J = 8.3 Hz, 2H), 7.93–7.73 (m, 5H), 7.12 (t, J = 5.3 
Hz, 1H), 7.03 (d, J = 3.3 Hz, 1H), 6.64 (dd, J = 3.0, 1.5 Hz, 1H), 4.17 (s, 2H), 3.41 (s, 2H), 
3.29 (d, J = 6.2 Hz, 2H), 3.14 (s, 1H), 1.73–1.61 (m, 2H), 1.61–1.44 (m, 2H), 1.40–1.23 (m, 
2H) ppm. HPLC: 95.772%, RT: 8.117 min, MS: [ESI+H] +: 527.20 
tert-butyl(4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)butyl)carbamate (6) 2-(Furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-amine 5 (435 mg, 1.55 mmol, 1.0 eq), synthesized as previously reported,13 
was suspended in acetonitrile to yield a 0.1 M solution. tert-butyl (4-aminopropyl) carbamate 
(0.33 mL, 1.71 mmol, 1.1 eq) was added, followed by the addition of N,N-
diisopropylethylamine (1.08 mL, 6.21 mmol, 4 eq). The mixture was heated at 85 °C for 29 
hours and stirred at r.t. for another 18 hours. A flash column (DCM:EtOAc, 0% → 90% 
EtOAc) was used to purify the crude mixture. This gave a yellowish solid (444 mg, 1.14 
mmol, 74% yield). 1H NMR (DMSO-d6, 400 MHz): δ 8.49–7.92 (m, 2H), 7.86 (s, 1H), 7.51 (t, 
J = 5.9 Hz, rotamer 1, 0.3H), 7.44 (t, J = 5.7 Hz, rotamer 2, 0.7H), 7.07–7.00 (m, 1H), 6.87–
6.76 (m, 1H), 6.67 (dd, J = 3.2, 1.7 Hz, 1H), 3.29–3.19 (m, 2H), 2.92 (d, J = 6.5 Hz, 2H), 1.48 
(d, J = 7.2 Hz, 2H), 1.44–1.29 (m, 11H). 
tert-butyl (5-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl)amino)pentyl)carbamate (7) 2-(Furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-amine 5 (280 mg, 1.0 mmol, 1.0 eq) and commercially available tert-butyl 
(5-aminopentyl)carbamate (0.2 mL, 1.0 mmol, 1.1 eq) were put in a microwave tube and 
dissolved in acetonitrile (1.5 mL). DIPEA (0.3 mL, 1.7 mmol) was added, the tube was 
charged with a stirring bar, sealed and heated at 70 °C for 1.5 h. After 1.5 h HPLC analysis 
indicated full conversion. The mixture was concentrated, EtOAc (50 mL) and HCl (1M in 
H2O, 50 mL) were added for extraction. The organic layer was washed with H2O (50 mL) and 
brine (50 mL). After drying over MgSO4 the solvent was removed in vacuo to give the title 
compound as a yellow foam (186 mg, 0.46 mmol, 46% yield). 1H NMR (DMSO-d6, 400 MHz,) 
δ 8.48–7.96 (m, 2H), 7.86 (s, 1H), 7.48 (t, J = 5.1 Hz, rotamer, 0.38H), 7.41 (t, J = 5.7 Hz, 
rotamer, 0.62H), 7.10–7.01 (m, 1H), 6.77 (t, J = 5.0 Hz, 1H), 6.67 (dd, J = 3.0, 1.7 Hz, 1H), 
3.28–3.17 (m, 2H), 2.90 (d, J = 6.6 Hz, 2H), 1.57–1.44 (m, 2H), 1.44–1.21 (m, 13H). 
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N5-(4-aminobutyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (8) 
TFA (4.3 mL, 57 mmol, 50 eq) was added to the suspension of Boc-protected amine 6 (444 
mg, 1.14 mmol, 1 eq) in DCM (equal volume as TFA). solvents were removed under reduced 
pressure after completion of the reaction (5 min). This gave the product as brown oil (899 mg, 
1.13 mmol, quantitative yield). Products were confirmed by 1H NMR first and then stored 
under N2 until used. 1H NMR (DMSO-d6, 400 MHz): δ 8.49–8.05 (m, 3H (R-NH3+), 7.88 (dd, 
J = 1.7, 0.7 Hz, 1H), 7.62 (br s, 3H (R-NH3+)), 7.52 (t, J = 6.0 Hz, 1H), 7.09–7.02 (m, 1H), 
6.68 (dd, J = 3.4, 1.7 Hz, 1H), 3.35–3.23 (m, 2H), 2.87–2.76 (m, 2H), 1.63–1.50 (m, 4H). 
N5-(5-aminopentyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (9) 
TFA (3 mL, 40 mmol, 50 eq) was added to the suspension of Boc protected amine 7 (324 mg, 
0.8 mmol, 1 eq) in DCM. Once the reaction was completed, the solvent was removed and the 
mixture was co-evaporated twice with water and dried using high vacuum. This gave a brown 
oil (556 mg, 0.8 mmol, quantitative yield) as a TFA salt. The crude product was used without 
further purification. 
tert-butyl (5-hydroxypentyl) carbamate (11) 5-amino-1-pentanol 10 (4.2 mL, 38.8 mmol) 
was dissolved in DCM (20 mL). Di-tert-butyl dicarbonate (8.4 g, 38.8 mmol) was slowly 
added as a solid. The reaction was left stirring at r.t. for 18 h, then the solvent was removed to 
give a yellow oil (8.83 g, quantitative yield, some t-BuOH left). 1H NMR (CDCl3, 400 MHz) 
δ 4.57 (s, 1H), 3.65 (t, J = 6.5 Hz, 2H), 3.13 (t, J = 6.5 Hz, 2H), 1.67 – 1.35 (m, 15H (under 
water peak)).  
tert-butyl (5-bromopentyl) carbamate (12) tert-butyl (5-hydroxypentyl) carbamate 11 (8.83 
g, 38.8 mmol, 1eq) and PPh3 (15.3 g, 58.2 mmol, 1.5 eq) were dissolved in THF (120 mL). A 
solution of CBr4 (19.3 g, 58.2 mmol, 1.5 eq) in THF (40 mL), was added over 2 h using a 
syringe pump. After 3 h at room temperature the reaction mixture was filtered and the filtrate 
was concentrated. This crude product was dissolved in DCM (~5 mL) and purified by flash 
column chromatography (100% PE → 90% PE + 10% EtOAc). This gave the product as a 
colorless oil (9.31 g, 35.0 mmol, 90% yield). 1H NMR (400 MHz, CDCl3) δ 4.54 (s, 1H), 3.41 
(t, J = 6.7 Hz, 2H), 3.13 (m, 2H), 1.97–1.80 (m, 2H), 1.58–1.36 (m, 13H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 40.5, 33.8, 32.5, 29.4, 28.6, 25.5. 
tert-butyl (5-(prop-2-yn-1-ylamino) pentyl) carbamate (13) Propargylamine (1 mL, 15 
mmol, 3 eq) was dissolved in acetonitrile (10 mL). To this stirred solution a solution of tert-
butyl (5-bromopentyl) carbamate 12 (798 mg, 3 mmol, 1 eq) and DiPEA (1 mL, 6 mmol, 2 eq) 
in acetonitrile (18 mL) was added using a syringe pump. Afterwards the solvent was removed 







(331 mg, 1.38 mmol, 46% yield) with EtOAc as an impurity. 1H NMR (CDCl3, 400 MHz) δ 
4.54 (s, 1H), 3.44 (d, J = 2.0 Hz, 2H), 3.12 (q, J = 6.4 Hz, 2H), 2.70 (t, J = 7.1 Hz, 2H), 2.22 
(t, J = 2.2 Hz, 1H), 1.55–1.34 (m, 15H) ppm. 
tert-butyl (5-(4-(fluorosulfonyl)-N-(prop-2-yn-1-yl)benzamido)pentyl)carbamate (14) 
tert-butyl (5-(prop-2-yn-1-ylamino)pentyl)carbamate 13 (664 mg, 1.38 mmol, 1 eq) was 
dissolved in acetonitrile (10 mL), 4-fluorosulfonyl benzoylchloride (338 mg, 1.52 mmol, 1.1 
eq) was added and followed by the addition of  DiPEA (0.75 mL, 4.14 mmol, 3 eq). Once the 
reaction was completed, the solvent was removed and the crude mixture purified by flash 
column chromatography (DCM + 5% MTBE → DCM + 7.5% MTBE). This yielded a yellow 
oil (586 mg, 1.52 mmol, quantitative yield). 1H NMR (DMSO-d6, 332K, 400 MHz) δ 8.19 (d, 
J = 8.0 Hz, 2H), 7.77 (d, J = 7.9 Hz, 2H), 6.37 (brs, 1H), 4.16 (brs, 2H), 3.37 (brs, 2H), 2.90 
(m, 2H), 1.61 (m, 2H), 1.44–1.29 (m, 9H), 1.29–1.14 (m, 4H). 
4.2. Biology  
The radioligand [3H]ZM241385 with a specific activity of 50 Ci × mmol-1 was purchased 
from ARC Inc. (St. Louis, MO). Unlabeled ZM241385 was a kind gift from Dr. S.M. Poucher 
(Astra Zeneca, Macclesfield, UK). 5’-N-ethylcarboxamidoadenosine (NECA) was purchased 
from Sigma-Aldrich (Steinheim, Germany). Adenosine deaminase (ADA) was purchased 
from Sigma-Aldrich Chemie N.V. Bicinchoninic acid (BCA) and BCA protein assay reagent 
were obtained from Pierce Chemical Company (Rockford, IL, USA). Human embryonic 
kidney (HEK) 293 cells stably expressing the hA2A receptor (hA2AR-WT) were kindly 
provided by Dr J Wang (Biogen/IDEC, Cambridge, MA, USA). The purified hA2A receptor 
material was kindly provided by Dr. Niek Dekker and Dr. Euan Gordon (AstraZeneca).  All 
other chemicals were of analytical grade and obtained from standard commercial sources.  
Cell culture, transfection and membrane preparation.  We followed the procedures reported 
previously.13, 37 Briefly, HEK293 cells were grown as monolayers in Dulbecco’s modified 
Eagle’s medium supplemented with 2 mM glutamine, 10% newborn calf serum, 50 µg mL–1 
streptomycin, and 50 IU mL–1 penicillin at 37°C and 7% CO2 atmosphere. Cells were 
subcultured twice a week at a ratio of 1:20 on 10 cm ø culture plates. The cells were 
transfected with pcDNA3.1(-) plasmid containing the hA2AR with N terminal FLAG and C-
terminal His tags (FLAG-hA2AR-His4) using the calcium phosphate precipitation method (1 
µg plasmid DNA), followed by a 48-hour incubation, as previously described.38 Stably 
transfected hA2AR-WT cells were grown in the same medium but with the addition of G-418 
(500 mg ml–1). For both transiently transfected cells and stably hA2AR-WT cells were 
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detached from the plates by scraping them into PBS and centrifuged to remove PBS buffer. 
The pellets were resuspended in ice-cold Tris-HCl buffer (50 mM, pH 7.4) and then 
homogenized. The cell membrane suspensions were centrifuged at 100,000 × g at 4°C for 20 
minutes, after which the procedure was repeated one more time. After this, the same Tris-HCl 
buffer was used to resuspend the pellet, and adenosine deaminase was added to break down 
endogenous adenosine. HEK293 cells stably expressing hA2AR were grown as monolayers in 
same culture medium and detached from plates by same treatment for membrane preparation. 
For both membranes were stored in 250 μL aliquots at -80°C until further use. Membrane 
protein concentrations were measured using the BCA method.39  
[3H]ZM241383 radioligand displacement assay. Radioligand displacement experiments were 
performed as previously described.13 hA2AR-WT cell membrane aliquots stably expressing 
hA2AR containing 10 µg of protein were incubated in a total volume of 100 µL of assay buffer 
to obtain an assay window of approximately 3000 DPM of receptor-specific radioligand 
binding. Nonspecific binding was determined in the presence of 100 µM NECA and 
represented less than 10% of the total binding. Briefly, to each tube were added 25 µL cell 
membranes (10 µg of protein), 25 µL of radioligand [3H]ZM241383, 25 µL of assay buffer 
[25 mM Tris-HCl, pH 7.4 at 25°C, supplemented with 5 mM MgCl2 and 0.1% (w/v) CHAPS 
and 25 µL of the indicated compounds in increasing concentrations in the same assay buffer. 
The mixture was incubated at 25oC for 60 min to reach equilibrium. Incubations were 
terminated by rapid vacuum filtration to separate the bound and free radioligand through 96-
well GF/B filter plates using a Perkin Elmer Filtermate-harvester (PerkinElmer, Groningen, 
Netherlands). Filters were subsequently washed three times with 2 mL of ice-cold buffer (25 
mM Tris-HCl, pH 7.4, supplemented with 5 mM MgCl2). The filter-bound radioactivity was 
determined by scintillation spectrometry using a P-E 1450 Microbeta Wallac Trilux 
scintillation counter (PerkinElmer). 
Heterologous displacement binding of probe 4 and ZM241385 to hA2AR-WT cell membranes. 
To assess the irreversible binding level, cell membranes stably expressing hA2AR were 
incubated with either 50 mM Tris-HCl (pH = 7.4) or two concentrations (0.3 IC50 and IC50) of 
probe 4 or ZM241385 for 3h at 25oC on a Eppendorf Thermomixer. Subsequently, the 
mixture was centrifuged at 16,100 × g at 4oC for 5 minutes and the supernatant was removed, 
followed by a resuspension of the pellet in 1 mL assay buffer and spun again for 5 min at 
16,100 × g at 4oC. This washing procedure was repeated three times. 50 µL aliquots of these 







a concentration range (100 pM-1 µM) of unlabeled ZM241385 for 1h at 25 oC. Incubation 
was terminated as described under [3H]ZM241385 radioligand displacement assay. 
Expression and purification of wild type hA2AR. The gene coding for hA2AR (residues 1-316) 
was synthesised by Genscript and cloned into pPICZb with an N-terminal α-factor signal 
sequence from Saccharomyces cerevisiae 
(MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNS
TNNGLLFINTTIASIAAKEEGVSLEKRLVPRGS), followed by hA2AR and a C-terminus 
biotinylation domain from Propionibacterium shermanii (TSEFENLYFQGQFGGGTGG 
APAPAAGGAGAGKAGEGEIPAPLAGTVSKILVKEGDTVKAGQTVLVLEAMKMETEI
NA PTDGKVEKVLVKERDAVQGGQGLIKI) for enhanced expression40 and a decaHis tag 
(GHHHHHHHHHHGS).  
The receptor was expressed in Pichia pastoris SMD1168 at 3 L scale in a fermentor 
essentially as described,41 except that dissolved oxygen was maintained at 25%, and 2.5% 
DMSO and 10 mM theophylline were included in the fermentation media. Approximately 200 
grams of wet cells were harvested per litter. 200 g cells were resuspended using a Turax in 
600 mL ice-cold lysis buffer (50 mM HEPES pH 7.4, 200 mM NaCl, Complete EDTA free 
protease inhibitor tablets (Roche) at 1/50 mL). Cells were lyed by a single passage through a 
Constant Cell system at 30 kpsi with extensive cooling. Cell debris was removed by 
centrifugation at 1000 × g for 10 min at 4°C. Membranes were collected by 
ultracentrifugation at 100,000 × g for 45 minutes at 4°C. Membrane pellet was resuspended in 
buffer to a total protein concentration of 20 mg mL–1 (final volume of 180 mL) and stored at -
80°C. 
Membranes (20 mL) were resuspended in 200 mL solubilization buffer (25 mM HEPES, 
pH7.4, 300 mM NaCl, 20% glycerol, 1% DDM/0.1% CHS, Complete tablets (1/50 mL), 200 
µM theophylline). The suspension was incubated for 2 hours at 4˚C on a rolling table, prior to 
centrifugation for 30 min at 100,000 × g to remove unsolubilized material. Imidazole was 
added to a final concentration of 15 mM and the clarified solution was  loaded on a 5 mL 
HisTrap crude column at 2.5 mL min–1. The column was washed with 100 mL buffer A (25 
mM HEPES, 25 mM imidazole pH 7.4, 300 mM NaCl, 10% glycerol, 0.05% DDM/0.0005% 
CHS, 100 µM theophylline) to which imidazole was added to final concentration of 25 mM to 
reduce nonspecific binding, followed by step wise washes with increasing concentrations of 
imidazole in this buffer (50 mM and 75 mM) and hA2AR was eluted in 25 mM HEPES  pH 
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7.4, 300 mM NaCl, 10% glycerol, 0.05% DDM/0.0005%CHS, 300 mM imidazole, 100 µM 
theophylline. Fractions were analyzed on SDS-PAGE and those containing hA2AR were 
pooled and concentrated to 2.5 mL using a 50 kDa filter. High imidazol is harmful to hA2AR 
and the buffer was changed to buffer A on a PD10 G25 column. Eluted fraction was further 
concentrated to 0.5 mL and loaded on a Superdex-200 10/30 column running in in 25mM 
NaPi pH7.2, 100 mM NaCl, 10 µM LMNG, 500 µM Caffeine. Fractions were analyzed on 
SDS-PAGE. hA2AR eluted as single peak at expected position for the detergent-protein 
complex (around 80kDa). Fractions were pooled and concentrated on a 50 kDa filter to final 
volume of 0.4 mL and stored at -80°C. Protein concentration was determined using 
absorbance measurement against buffer A (Abs280(0.1%) =1.05). Final concentration was 7 
mg mL–1 with a total of ~2mg hA2AR. 
Affinity-based protein labeling assay on purified hA2AR with probe 4. For purified hA2AR, 
both affinity labeling and click reactions were performed on ice, unless indicated otherwise. 
Purified hA2AR was diluted to a concentration of 0.1 mg mL–1 in assay buffer (25 mM HEPES 
pH 7.5, 100 mM NaCl and 10 µM LMNG). 38 µL samples were incubated with 2 µL probe 4 
at indicated concentrations or vehicle control (1% DMSO) for 1 h. To initiate the click 
reaction, 5.6 mM CuSO4 (2.5 µL / reaction, from a 100 mM stock solution in water) was 
mixed vigorously with 33 mM sodium ascorbate (1.5 µL / reaction, freshly made as a 1 M 
stock solution in water) to obtain a yellow mixture, followed by the immediate addition of 1.1 
mM THPTA (0.5 µL / reaction, from a 100 mM stock solution in water) and 4.4 µM 
fluorescent tag Cy3-azide (0.5 µL / reaction, from a 400 µM stock solution in DMSO).  The 
reaction mixtures were incubated for 1h and quenched with 15 µL 4xSDS loading buffer. 
Proteins in the mixture were separated by SDS-PAGE on 10% polyacrylamide gels. In-gel 
fluorescence was detected with a ChemiDoc MP system (605/50 filter). Proteins were 
transferred from gel to a PVDF membrane by Trans-Blot®Turbo (BioRad). Then the 
membrane was washed in 20 mL TBS for 10 min on a roller bench, followed by a three times 
wash with TBST (PBS with 0.1% Tween-20). Afterwards, the membrane was blocked in 5% 
(w/v) non-fat milk for 1h at room temperature and probed with rabbit-anti-His antibody 
(Rockland)(1:1000 [v/v] dilution in blocking buffer) overnight at 4 oC, washed three times 
again with TBST and incubated with goat-anti-rabbit IgG-HRP (1:5000 in 5% milk in TBST; 
Santa Cruz) for 1 h at room temperature. After two wash cycles in TBST and one in TBS, the 
blot was developed in the dark using a 10 mL luminal solution, with 100 μL ECL enhancer 







Competitive labeling assays in purified hA2A AR by probe 4. Prior to the two-step labeling 
experiment purified hA2AR was diluted to a concentration of 0.1 mg mL–1 in assay buffer and 
incubated with 10 µM compound 1, ZM241385 or vehicle control (1% DMSO) for 1h on ice, 
followed by labeling with 1 µM probe 4 for 0.5 h on ice. Samples were then subjected to the 
click chemistry procedure using the protocol described above. 
Affinity-based protein labeling of membranes transiently overexpressing FLAG-HA-hA2AR-
His. hA2AR -FLAG-His membranes were diluted to a concentration of 1 mg mL–1 in 50 mM 
Tris-HCl (pH = 7.4 at 25 oC). Either 2 µL probe 4 at indicated concentrations (0.1 µM, 0.3 
µM, 1 µM and 3 µM) or vehicle control (1% DMSO) was added to 38 µL samples for 1 h 
incubation at room temperature. Then all samples were subjected to the click chemistry 
conjugation reaction. The click reagents were added in the following sequence: 4.4 µM 
fluorescent Cy3-azide (0.5 µL / reaction, 400 µM stock in DMSO) was added to the mixture 
followed by 33 mM sodium ascorbate (1.5 µL / reaction, freshly made in 1M stock in water) 
and 1.1 mM THPTA (0.5 µL / reaction, 100 mM stock in water). Finally, 5.6 mM CuSO4 (2.5 
µL / reaction, 100 mM stock in water) was added to start and run the cycloaddition reaction 
for 1 h at room temperature. Then, the reaction was quenched with 15 µL 4xSDS loading 
buffer and protein material denatured for 30 min at 37 oC. Proteins (60 µL sample) were 
separated by SDS-PAGE on 10% polyacrylamide gels. In-gel fluorescence was detected with 
the ChemiDoc MP system (605/50 filter). Proteins were transferred from gel to a PVDF 
membrane by Trans-Blot®Turbo (BioRad). Then the membrane was washed in 20 mL TBS 
for 10 min on a roller bench, followed by a three times wash with TBST (PBS with 0.1% 
Tween-20). Then the membrane was blocked in 5% (w/v) non-fat milk and incubated with 
mouse-anti-FLAG (Sigma) (1:5000 [v/v] dilution in blocking buffer) as primary antibody. 
Thereafter, the membrane was washed in TBST three times and incubated with goat-anti-
mouse HRP (Sigma) (1:5000 [v/v] dilution in blocking buffer) as secondary antibody. After 
two wash cycles in TBST and one in TBS, the blot was developed in the dark using a 10 mL 
luminal solution, with 100 μL ECL enhancer and 3 μL H2O2. Chemiluminescence was imaged 
using a ChemiDoc XRS (BioRad). 
Abbreviations used  
ADA, Adenosine deaminase; BCA, Bicinchoninic acid; CHAPS,3-[(3-cholamidopropyl) 
dimethylammonio]-1-propane sulfonate; Cy3-azide, sulfonated Cyanine 3 dye azide; DiPEA, 
Di-isopropylethylamine; ECL, enhanced chemiluminescence; HEPES, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; LMNG, Lauryl Maltose Neopentyl Glycol; MTBE, Methyl 





tert-butyl ether; NaPi, Sodium Phosphate Buffer; NECA, 5’-N-ethylcarboxamidoadenosine; 
TBS, Tris-buffered saline; TBST, Tris Buffered Saline with 0.05% Tween; THPTA, Tris(3-




Table S1. Apparent affinities of 4 at the human A1 and A3 adenosine receptor subtypes. Data are 
expressed as pKi values (means ± SEM) of three separate experiments each performed in duplicate.  
Compound 
pKi 
hA1a     hA2Ab hA3c 
4 7.72 ± 0.05 8.82 ± 0.02 7.22 ± 0.01 
aAffinity determined from displacement of specific [3H]DPCPX binding on CHO cell membranes 
stably expressing human adenosine A1 receptors at 25oC during 3h incubation; b Affinity determined 
from displacement of specific [3H]ZM241385 binding from the hA2AR at 25oC during 3h incubation; 
cAffinity determined from displacement of specific [3H]PSB-11 binding on CHO cell membranes 
stably expressing human adenosine A3 receptors at 25oC during 3h incubation. 










4b 9.01 ± 0.05ns 8.84 ± 0.04ns 9.03 ± 0.10 
ZM241385c 8.94 ± 0.07ns 8.84 ± 0.03ns 8.77 ± 0.04 
a Data are expressed as means ± SEM of three separate experiments each performed in duplicate. ns 
indicates a non-significant difference with p>0.05 when compared with the pKi values in control 
groups; One-way ANOVA test. b Affinity of ZM241385, expressed as pKi value, determined from 
displacement of specific [3H]ZM241385 binding from the hA2AR cell membranes preincubated with 
compound 4 at indicated concentrations for 3h at 25oC and then treated with a three-cycle washing 
step.c Affinity of ZM241385, expressed as pKi value, determined from displacement of specific 
[3H]ZM241385 binding from the hA2AR cell membranes preincubated with ZM241385 at indicated 
concentrations for 3h at 25oC and then treated with a three-cycle washing step. 
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This thesis delves into the design and pharmacological profiling of covalent ligands for 
adenosine receptors (ARs). In this chapter, insights gained from case studies at three 
adenosine receptor subtypes are elaborated on, and remarks for further research on covalent 
probes for GPCRs are presented. 
1. Conclusions
1.1. Guidelines for the design of covalent probes targeting ARs
Covalent probes, or affinity labels, are pharmacological tools that can be used to study the 
structural and functional properties of GPCRs [1]. As illustrated in Chapter 2, these ligands 
comprise three elements: a pharmacophore, a linker and a reactive group. The pharmacophore 
generates affinity and selectivity towards a specific adenosine receptor subtype, whereas a 
linker moiety connects the pharmacophore to the reactive moiety that forms a covalent bond 
with an amino acid residue near the binding pocket. An ideal reactive moiety, also referred to 
as warhead, shows a low nonspecific reactivity in solution or outside the binding pocket. 
Once accommodated in the binding pocket, it has the capacity to react with a neighboring 
nucleophilic amino acid residue to form a covalent interaction. In this regard, sulfonyl 
fluorides were chosen as warhead for all the covalent ligand design in this thesis (Chapters 3-
6). This privileged functionality holds a good combination of physiochemical properties (i.e., 
aqueous or thermodynamic stability) and electrophilic reactivity [2]. The targeted nucleophilic 
amino acid residues include serine, threonine, tyrosine, lysine, cysteine and histidine. 
Building on that, throughout this thesis I present examples that demonstrate the rational ligand 
design based on a well-defined structure-activity relationship (SAR) profile of the 
pharmacophore and extensive structural information of the binding site of the adenosine 
receptor.  
First, a high-affinity pharmacophore is deemed to be an important starting point towards a 
successful design, as it increases the ligand concentration in the binding site, eventually 
triggering covalent interaction. Logically, it is essential that the introduction of a warhead to 
the original pharmacophore should not jeopardize the key properties of the ligand such as 
affinity and selectivity. As shown in Figure 1, the design of the covalent antagonist LUF7445 
(Chapter 3) was based on a high-affinity non-xanthine antagonist, ZM241385, a molecular 
template co-crystalized with hA2AR (PDB: 4EIY) [3]. Analysis of the binding site in the 
crystal structure shows that the phenylethylamine chain in ZM241385 is directed toward the 
more solvent exposed extracellular region (EL2 and EL3), where this 







extensive SAR studies performed by our group [4, 5], we introduced the electrophilic 
fluorosulfonyl group at the phenylethylamine side chain to achieve a covalent interaction with 
amino acid K153ECL2.  
 
Figure 1. Chemical structures of covalent ligands for hA2AR examined in Chapters 3 and 6. Here, 
the effect of the linker length between scaffold and warhead on affinity was further examined, yielding 
compound LUF7461 and, preferably, compound LUF7519 with an improved affinity.  
A case based on an agonist scaffold is described in Chapter 5. The non-ribose agonists’ 
scaffold was inspired by a former drug candidate, capadenoson [6, 7]. This dicyanopyridine 
scaffold with a benzo[1,3]dioxol-5-yl moiety at the C4 position (LUF7174, Figure 2) showed 
good selectivity and efficacy at the hA1R [8, 9]. This pharmacophore led to the discovery of a 
covalent partial agonist, LUF7746 (Figure 2), which maintained its high affinity and 
selectivity toward hA1R. 
 
Figure 2. Chemical structures of covalent partial agonists examined in Chapter 5. The lead 
compound, capadenoson, a selective hA1R partial agonist inspired the design of covalent partial 
agonist, LUF7746. 
Of note, in the case with limited structural insights of the receptor binding pocket, altering the 
linker length is not the only way in which key properties of ligands (affinities) can be 
affected. Chapter 4 presents the case of covalent antagonist design for the hA3R, in which 
both the linker type and orientation of the warhead appeared relevant. The position of the 
warhead and linker type and length were given equal weight to the design strategy. It was 
found that the 4-position of the sulfonyl fluoride on the warhead’s phenyl group was favored 
for high affinity.  More importantly, the replacement of the ester group with the more 
metabolically stable amide linker resulted in irreversible probes with a slightly increased 
affinity. This led to the discovery of LUF7602 (Figure 3) as a best-in-class ligand among the 
series. 
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Lastly, in some cases the incorporation of a linker unit can be likewise important to maintain 
the properties of the pharmacophore and orient the ligand into a suitable direction for covalent 
interaction. As illustrated in Chapter 6, an extension of linker length based on LUF7445 
(Figure 1) slightly increased the apparent affinity. This concurs with available literature 
reporting an electrophilic probe for the cannabinoid CB1 receptor, also demonstrating that a 
significantly improved affinity resulted from a longer linker [10]. This might be the result of 
more steric freedom allowing the warhead to reach the adjacent nucleophilic amino acid 
residue in the receptor binding site more efficiently.  
Figure 3. Chemical structures examined in Chapter 4. The antagonist scaffold, 1H,3H-pyrido[2,1-
f]purine-2,4-dione (blue color), was employed to study the effect of the linker length, type and position
of warheads on affinity. It led to the discovery of LUF7602 as a best-in-class covalent antagonist in
this study.
In summary, cases presented in this thesis provide insight and clues towards a universal 
strategy for the design of covalent ligands. The efficiency of the ligation reaction is ultimately 
dependent on an optimal combination of 1) the affinity of the pharmacophore for the target 
receptor, 2) the warhead’s proximity to an appropriate nucleophilic amino acid residue and 3) 
the warhead’s reactivity. 
1.2. Research workflow to characterize the covalent ligands  
The examples summarized in thesis (Chapter 3-6) demonstrate a research workflow (Figure 
4) to profile the pharmacological activities of the covalent ligand-receptor interaction. As
summarized in section 7.1.1, the design of covalent ligands needs to be balanced between
high-affinity pharmacophore, linker unit and reactive functionality. Moreover, a control
ligand is required to maintain a similar binding mode but in a nonreactive reversible manner,
where it is crucial to maintain a structural similarity with the corresponding covalent ligand.
In Chapter 3 for instance, both a long residence time compound LUF6632 and a short-
residence time prototypical ligand ZM241385 are employed as control ligands to perform the
pharmacological evaluations. Although, these control compounds were structurally very
similar to the covalent ligand, even closer analogues were possible. Hence, in the cases







were designed as control ligands, resulting in significant, if not the best possible, structural 
similarities with covalent ligand. Subsequently, both covalent ligand and control ligand are 
subjected to streamlined biological evaluation, including time-dependent affinity 
determination, binding kinetics investigation, wash-out assays, mutagenesis study and 
functional characterization (Figure 4).  
 
Figure 4. Research workflow to design, select and validate covalent ligands for GPCRs 
In detail, the first hint of a covalent interaction by the probe is represented by a leftward shift 
of the concentration-dependent radioligand displacement curve at different incubation times. 
A longer incubation time renders the covalent ligand to be more potent in displacing the 
radioligand from the receptor, resulting in an increased apparent affinity. However, it is far 
from conclusive to verify a covalent interaction from an affinity shift alone, as pseudo-
irreversible interactions can also occur caused by slow dissociation rates. This is actually 
shown in Chapter 3, where a long residence time compound, LUF6632, also achieves a better 
affinity with a longer incubation time. To this end, the binding kinetic profiles are explored as 
a second hint for covalence, with specific focus on a ligand’s dissociation rate constant (koff) 
and residence time (RT = 1/koff; Figure 4). The covalent ligands presented in Chapters 3-5 
cause an initial ‘overshoot’ of the competition association curve, followed by a linear decline 
over time indicating that no equilibrium was reached. The data analysis of these cases yield a 
negligible dissociation rate, and a concomitant, almost infinite residence time. In addition, the 
inadequacy of the Motulsky-Mahan equations to fit this data is further evidence for the non-
equilibrium features of the irreversible interaction with the receptor [11]. Thirdly, a 
“washout” experiment to ascertain the irreversible ligand-receptor interaction are often 
performed (Figure 4). Here, the washing treatment failed to regenerate the binding capacity of 
the radioligand used, which demonstrated wash-resistance of the covalent ligand at the 
receptor.  





A final (fourth) confirmation, is obtained by locating the target amino acid of the warhead 
responsible for the covalent interaction of the ligand in the receptor binding pocket (Figure 4). 
Structural knowledge of the receptor binding pocket greatly aids in docking the covalent 
compound, and thus pinpointing towards a potential anchor point. Finding the anchor point 
for covalent probes of GPCR families is always challenging. Mutagenesis of nucleophilic 
residues near the ligand’s binding pocket appears to be one of the most useful tools to identify 
where the ligands bind covalently. Under the circumstance that receptor mutation does not 
alter the receptor binding site and functionality, a regained recovery of radioligand binding 
capacity in “wash-out” assays demonstrates the involvement of covalent bonding with the 
selected amino acid residue. In the studies of LUF7445 (Chapter 3) and LUF7746 (Chapter 
5), the mutation led to the identification of the primary anchor point engaged in the covalent 
interaction. Still, this recovery failed to regenerate a 100% radioligand binding capacity, 
suggesting that other unidentified residues may play a similar role. In this context, an 
incomplete receptor activation recovery was observed in the functional [35S] GTPγS assay for 
covalent partial agonist (LFU7746, Chapter 5). Of note, site-directed mutagenesis studies for 
hA3R (Chapter 4) showed that removal of the nucleophilic group of the targeted amino acid 
residue resulted in the complete loss of covalent binding, validating that Y2657.36 is the only 
anchor point of reactive covalent ligand LUF7602. The results presented in this thesis 
therefore agree with previous investigations to some degree, i.e. a high-affinity 
pharmacophore is a crucial starting point for a successful design of covalent ligands. 
Nevertheless, in future research, more extensive knowledge of receptor structure may improve 
the feasibility to locate the covalent interaction anchoring point. Overall, mutagenesis of 
nucleophilic residues near the ligand binding pocket is useful to study the mode and site of 
interaction, but may also drive the covalent ligand to react with secondary nucleophilic amino 
acid residues. 
Although covalence can be confirmed by the experiments listed above, the irreversible 
activation/inhibition can be further evaluated on receptor function (Figure 4). For example, 
the covalent antagonistic nature of LUF7445 (Chapter 3) was confirmed in a cAMP 
functional assay, as it irreversibly blocked hA2AR-mediated cAMP accumulation by agonist 
NECA. For Gi-coupled receptors, a membrane functional assay using [35S]GTPγS was 
employed. An insurmountable antagonism caused by the covalent interaction was 
demonstrated for LUF7602 (Chapter 4), while a persistent activation by LUF7746 (Chapter 







interest in Chapter 5 were further evaluated for their covalent partial agonistic behavior in 
the label-free xCELLigence assay detecting changes in cell morphology. Compared to 
conventional in vitro functional assays, these assays provide new opportunities, as they 
determine integrated receptor-mediated responses under near-physiological conditions at the 
cellular level that are recorded in real time without the need for any labels. Consistent with an 
irreversible mode of receptor activation in a membrane-based [35S]GTPγS assay, the obtained 
results validated the irreversible activation induced by LUF7746, also by its resistance to 
inhibition by antagonist DPCPX. 
1.3. Applications of covalent ligands 
The application of covalent ligands summarized in this thesis mainly focuses on the 
investigation of the topography of the GPCR-ligand binding pockets, as well as on receptor-
signaling. However, in Chapter 6, we developed a covalent antagonist LUF7445 into an 
affinity-based probe LUF7487, which was used for two-step labeling of adenosine receptors. 
The previously synthesized covalently binding ligand LUF7445 (described in Chapter 3) was 
diversified to yield a few novel derivatives with different linker lengths. The most potent 
ligand was further equipped with a terminal alkyne allowing conjugation to azide-tailed 
fluorescent dyes, yielding probe LUF7487. Once bound, probe LUF7487 was concentration-
dependently reacted with a fluorescent Cy3 moiety onto purified hA2ARs via a bio-orthogonal 
copper catalyzed azide-alkyne click-ligation reaction. We further demonstrated that this 
affinity-based covalent labeling of the purified hA2AR by probe LUF7487 was inhibited by 
hA2AR selective antagonists. Lastly, we showed successful labeling of the receptor in cell 
membranes overexpressing hA2AR making probe LUF7487 a promising affinity-based probe 
(AfBP) that will be useful in identifying and profiling the presence of the hA2AR in complex 
biological samples. 
In summary, by applying this research workflow (Figure 4), including rational design of 
covalent ligands and non-reactive control compounds, covalent interaction characterization 
and anchoring position capture, we shed light on the molecular mechanism of covalent 
modulation of the adenosine receptors. The obtained insights are valuable for the design of 
covalent antagonists (Chapter 3 and 4) and agonists (Chapter 5) for the orthosteric ligand 
binding site, for which novel assays were set up to study receptor pharmacology (Chapters 3, 
4 and 5). The results obtained with novel tool compounds (Chapters 6) depict native receptor 
binding, and bridge the fields of chemical biology and molecular pharmacology to better 
investigate receptor-ligand interactions. Together, these insights are valuable in future 





discovery projects for drugs targeting the adenosine receptor, and this research methodology 
may serve as an example to study the structural details on ligand recognition for other GPCR 
subtypes.  
2. Future perspectives 
2.1. The “druggability” of adenosine receptors  
Adenosine receptors have been recognized as therapeutic targets for various diseases, such as 
cerebral and cardiac ischemic diseases [12], sleep disorders [12], immune and inflammatory 
disorders [13] and cancer [14]. Therefore, numerous attempts to develop potent and selective 
ligands have been made in recent decades [12, 15]. In the end, the first approved AR ligand is 
a selective A2AR agonist, regadenoson (Lexiscan®), for medical use related to myocardial 
perfusion imaging [16]. Another example is a xanthine-derived A2AR antagonist, 
istradefylline, (NOURIAST®), for the treatment of Parkinson’s disease in Japan [17]. Many 
other clinical trials targeting ARs are currently in progress with a focus on indications 
including Parkinson’s disease, chronic heart failure and inflammatory and autoimmune 
disorders [15, 18]. More recently, with the discovery of the adenosine-mediated 
immunosuppressive mechanism in cancer therapy [14], several A2A antagonists, initially 
developed for the CNS system, have entered clinical trials as immune-oncology agents alone 
and in combination with anti‑PD1 or anti‑PDL1 therapies [19]. Since oxygen deprivation in 
the tumor microenvironment causes an augmented extracellular adenosine level [14], it is 
essential that high-affinity adenosine antagonists are able to maintain their potencies in 
competition with the local adenosine levels, especially for small molecule antagonists with a 
fairly short in vivo half-life. In this regard, a covalently binding antagonist such as LUF7445 
(described in Chapter 3), potentially prolonging the duration of action, may be a better 
proposition under these conditions. Moreover, as discussed in Chapter 1, the complexity of 
adenosine-mediated signaling and potential side effects compromises the development of 
pharmacological agents for specific applications. In such cases, the current fundamental 
research efforts on receptor structure and function still provide novel insights to facilitate the 
development of clinical candidates for adenosine receptors. More importantly, novel covalent 
AR ligands, including those discussed in this thesis, should be developed to investigate the 
topography of the GPCR-ligand binding pocket, as well as receptor-signaling and further 
pharmacological research. It is anticipated that such future molecules will possess enhanced 







2.2. Covalent inhibitors for drug targets - what are the future opportunities? 
In this thesis I have presented a design strategy for covalent probes that entails the 
identification of a reversibly binding lead compound, which is further optimized and used 
as a scaffold to incorporate a warhead for the targeted receptor. Notwithstanding the 
successful cases studied in this thesis, there are concerns that the addition of warheads 
and/or linkers might alter the key properties of the synthesized ligands. Meanwhile, the full 
dependency on the topology information of the binding pocket sometimes limits the 
successful application of this strategy to new targets. As in the hA3R study in Chapter 4, 
one solution is to build a homology model based on other target, in this case hA2AR 
subtype, with similar binding pockets. Knowledge of targets with similar binding pockets 
and anchoring locations is a valuable resource for designing selective compounds, as 
overlaying structures can often highlight where modifications can be made to gain 
selectivity. Still, this strategy can only be applicable if a suitable reversible lead exists. 
Alternatively, covalent fragment screening appears to be a potential solution to cases where 
no available reversible ligands/inhibitors for the targets are known [20, 21]. It starts with a 
low molecular weight or drug-like fragment with an electrophilic reactive center, which is 
then developed into a fragment library. Specifically, when the electrophilic fragments bind 
proximal to the nucleophilic residue on the target protein, they will be covalently trapped on 
the target protein surface and detected using X-ray crystallography, mass spectrometry and 
digestion studies to identify the residue targeted [22]. The robust discovery of covalent 
ligands relies on the size of fragment libraries covering a broad range of reactivity. 
Nevertheless, potential issues that arise from this approach reveal that such simple hits will 
be dominated by strong reactivity of the fragments instead of specific recognition (as is the 
case for a pharmacophore), consequently increasing the risk of non-specific labeling, off-
target toxicity, and promiscuous activity [21].  
In addition, the availability of proper bioassays to measure covalent binding is essential. 
The examples illustrated in this thesis focus on the time-dependent radioligand binding 
assay and site-directed mutagenesis studies aided by computational docking studies. 
Another technique, mass spectrometry (MS)-based proteomics, emerged as a powerful 
structural biological tool to characterize protein confirmation providing further structural 
insight [23, 24]. Depending on the availability of high-resolution structures, MS-based 
structural strategies can provide valuable, previously inaccessible information on protein 
conformational changes and dynamics, protein flexibility, and ligand-protein binding [25, 26]. 
Conclusions and Future Perspective 
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The power of combining mass spectrometry-based proteomics and site-directed covalent 
labeling in the elucidation of GPCR ligand binding sites has shown great impact on the 
understanding of the structural features involved in ligand binding [27-29]. As summarized in 
Chapter 2, so far there is only one case that uses a photoaffinity probe to investigate the 
precise nucleophilic anchor point in the hA2AR binding pocket by mass spectrometry [30]. 
In this regard, the development of diverse experimental paradigms opens promising 
avenues for covalent ligands to obtain focused insights in structure-enabled GPCR ligand 
design. Ultimately, this may help in increasing the number and the quality of drug candidates 
targeting adenosine receptors as well as other GPCRs in the near future. 
2.3. Covalent probes for GPCRs - where should we go?  
Covalent ligands for GPCRs have shown to be valuable tool compounds to facilitate GPCR 
structure and function determination [31]. In the field of the adenosine A3 receptor, an 
experimental crystal or cryo-EM structure would be a valuable addition to the currently 
available structures in the adenosine receptor family. The covalent ligands described in 
Chapter 4 could be valuable tools for the elucidation of the inactive state of the human 
adenosine A3 receptor structure.  
The advent of covalent probes for chemical biology has been assisted by the development of 
click chemistry methods [32-34]. As demonstrated in Chapter 6, these covalent probes 
equipped with a ligation handle are paired with tags (e.g., biotin and/or a fluorophore) after 
they covalently bound to the receptors. This strategy underlays chemical biology or 
proteomics studies, to gain deeper insights into receptor localization and target engagement. 
The uncoupling of the ligand binding from the reporter tag labeling steps by click chemistry 
allows for tracking tissue and organ distribution of covalent probes in vivo [35]. In future 
research on adenosine receptors, different tags may be introduced; for instance, a biotin-tag 
would allow for streptavidin-mediated receptor enrichment for in‐depth profiling using the 
Multi‐dimensional Protein Identification Technology (MudPIT) analysis [36].  Similarly, 
the approach developed in this study may be applied to other GPCRs in similar 
physiological and pathological conditions. 
2.4. Covalent drugs for GPCRs - worth a try? 
In the history of drug discovery, covalent drugs have returned to the stage of the drug market 
in recent years, despite the past reluctance to pursue a covalent mechanism of interaction due 
to potential off-target toxicities. In approximately one-third of all enzyme targets for which 







The number of literature citations concerning covalent drugs appears to be rapidly increasing 
[37-41]. The continued and renewed interest in covalent drugs came from several recognized 
benefits, such as increased target potency, prolonged duration of action and the decreased 
therapy-induced drug resistance in clinical studies of cancer or infection. There is currently 
only one covalent drug targeting GPCR families, chopidogrel [42, 43]. It blocks the P2Y12 
receptor to inhibit platelet aggregation, occurring in e.g., thrombosis. However, clopidrogel 
can come with unwanted (on target) side-effects, such as extensive bleeding and 
thrombotic thrombocytopenic purpura.  
In general, the bar to introduce a covalent drug for GPCRs is higher than is the case for 
kinases, a target class which has so far been well recognized and represented by several 
recently approved covalent drugs (ibrutinib, afatinib, and osimertinib) [44, 45]. Part of the 
reason is owing to the absence of an active reaction center in receptors and thus in the 
deficiency of mechanism-based inhibitors. Several considerations for rational design 
summarized in the conclusion paragraph may increase the rate of success. In addition, 
designing a compound targeting a poorly conserved residue may improve the selectivity of 
a compound. For instance, cysteine residues are in low abundance in proteins and possess a 
high nucleophilicity, appealing to be targeted with a low-reactivity warhead, Michael 
acceptors being key examples [46, 47]. This warhead reactivity is certainly an important 
consideration, demonstrating a balance between target engagement and idiosyncratic 
adverse drug reactions. To this end, warheads with low reactivity are generally preferred as 
a “safer” choice for a future drug candidate. Overall, the successful development of covalent 
kinase inhibitors as safe and efficacious cancer therapies will support the efforts towards other 
targets, such as GPCRs. If the selectivity and thus the safety of covalent molecules can be 
guaranteed these molecules provide valuable opportunities for future drug therapy. 
Final notes 
This thesis is focused on rational design and pharmacological profiling paradigms of covalent 
probes for adenosine receptors. The results obtained in this thesis contribute to an improved 
understanding of the molecular aspects of receptor structure and function. We provide 
evidence that covalent modulation of GPCRs adds indispensable information on structural 
insights. Besides, we set up a work flow of in vitro pharmacological assays as a robust tool for 
measuring and quantifying covalent modulation. Finally, we developed affinity-based probes, 
which allow monitoring of GPCR expression in cell fragments. 





Hopefully, all findings from this thesis add to a further molecular understanding of covalent 
ligand-receptor interactions, and contribute to the design of better covalent ligands with an 
appropriate profile, multiple tool compounds for future target validation, and ultimately 
suitable evaluation schemes for a better translation towards effective and safe drugs.  
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Most of the small-molecular drugs are tailored to reversibly interact with their biological 
targets. There are concerns that the formation of a covalent bond with their target may yield 
off-target reactivity and this has led to these covalent drugs being disfavored as a drug class. 
Nevertheless, a common focus in modern drug discovery programs to maximize the strength 
of the desired drug-protein interactions has brought the concept of ‘covalent interactions’ 
back into the drug discovery track. These interactions may cause prolonged duration of action 
and improved potency and selectivity, providing advantages as both chemical probes and drug 
candidates. It has been recognized that the deficiencies of covalent modes of action may be 
tuned by designing compounds that carefully combine reactivity with specific 
complementarity to the target.  Hence, in this thesis a covalent strategy is applied and shown 
to be compatible with a target-directed, structure-guided discovery paradigm, with a focus on 
G protein-coupled receptors as drug targets.  
Chapter 1 covers the main concepts studied throughout the thesis. The chapter starts with an 
introduction to G protein-coupled receptors (GPCRs), with a focus on the adenosine 
receptors. Subsequently, the concepts of covalent ligands for GPCRs and current state-of-the-
art and challenges are described. Chapter 2 continues with discussing the emerging 
molecular probes to profile adenosine receptors’ biological effects and summarizes the 
utilization of the probes to characterize and interrogate adenosine receptor subtypes both in 
vitro and in vivo, and to study their behaviors in physiological and disease conditions. The 
following Chapters 3-6 demonstrate the design of covalently binding ligands targeting 
adenosine receptors and highlight their utility to profile pharmacological effects. 
In Chapter 3, LUF7445 was introduced and characterized extensively. This covalent 
antagonist was designed based on a high affinity non-xanthine antagonist, ZM241385. This 
ligand has been co-crystalized with hA2AR, providing a clear blueprint of ligand-binding 
interactions. Analysis of the shape of the binding site shows that the phenylethylamine chain 
in ZM241385 is directed toward the more solvent-exposed extracellular region (EL2 and 
EL3), such that the ligand-receptor interactions offer us tremendous substituent flexibility to 
introduce the electrophilic fluorosulfonyl group responsible for the covalent interaction. Using 
time-dependent affinity shift and kinetic competition association assays, LUF7445 was likely 






silico A2A-structure-based docking model combined with site-directed mutagenesis studies 
suggested the binding mode of LUF7445 with an anchor point at lysine amino acid K153ECL2. 
Meanwhile, a functional assay combined with wash-out experiments was set up to investigate 
the efficacy of covalent binding of LUF7445. These findings advance the studies of covalent 
ligands to serve as a prototype for a therapeutic approach in which a covalent antagonist may 
be needed to counteract prolonged and persistent presence of the endogenous ligand 
adenosine. 
Inspired by the successful design of LUF7445, Chapter 4 starts with a structure-based design 
of covalent antagonists for human adenosine A3 receptors, a case with few structural insights 
of the receptor binding pocket. Starting from the 1H,3H-pyrido[2,1-f]purine-2,4-dione 
antagonist scaffold, a series of ligands bearing a fluorosulfonyl warhead with a varying linker 
length was obtained. The follow-up streamlined workflow to characterize these ligands was 
adapted from Chapter 3, suggesting LUF7602 behaves as a covalent antagonist for the 
human adenosine A3 receptor. Of note, in this research, a non-reactive methylsulfonyl 
derivative LUF7714 was developed as a reversible control compound. When combined with 
in silico hA3R-homology modeling and site-directed mutagenesis, LUF7602 was used to 
characterize the spatial orientation and topography of the receptor ligand binding site, 
demonstrating that amino acid residue Y2657.36 was the unique anchor point of the covalent 
interaction. In the end, using this structured approach a well-defined covalent ligand was 
quickly obtained and profiled.  
Of note, this research workflow, including rational design of covalent ligands and non-
reactive sulfonyl-bearing control compound, covalent interaction identification combined with 
in silico modeling and site-directed mutagenesis, may serve as a streamline to study the 
structural details of ligand recognition for other GPCR subtypes.   
Subsequently, Chapter 5 reports on the design, synthesis and application of a Capadenoson-
based covalent partial agonist probe, LUF7746, bearing an electrophilic fluorosulfonyl 
moiety. Similarly, a nonreactive ligand bearing a methylsulfonyl moiety, LUF7747, was 
designed as a control ligand. In addition to the streamlined workflow to profile covalent 
ligands, a hA1R-mediated G protein activation assay was used to identify LUF7746 as a 
partial agonist and it is resistant to blockade with an antagonist/inverse agonist. An in-silico 
structure-based docking study combined with site-directed mutagenesis of the hA1R 
demonstrated that amino acid Y2717.36 was the primary anchor point for the covalent 
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interaction, as it was for the adenosine A3 receptor. In the end, a label-free whole-cell assay 
was set up to identify LUF7746’s irreversible activation of an A1 receptor-mediated cell 
morphological response. 
After these demonstrations of covalent ligands to investigate adenosine receptor’s 
pharmacological effects, Chapter 6 reports on the development of A2AR covalent ligands into 
an affinity-based probe. In detail, an irreversible ligand LUF7445 was equipped with a 
terminal alkyne to serve as an affinity-based probe, LUF7487. After binding to the purified 
hA2AR, this probe was paired with a clickable fluorophore Cy3-azide, and irreversibly and 
concentration-dependently labelled purified hA2AR, which was visualized by SDS-PAGE. 
This labelling of the purified hA2AR by LUF7487 could be inhibited by both reversible and 
irreversible antagonists, provided that they target the same receptor binding site. In the end, a 
successful labeling of the receptor in cell membranes overexpressing hA2AR was 
demonstrated, making LUF7487 a promising affinity-based probe that sets the stage for the 
further development of probes for GPCRs. 
In summary, the approach to design and pharmacologically profile covalent ligands for 
adenosine receptors has been explored and detailed throughout this thesis. A universal 
strategy of covalent ligands’ design has been investigated, and the findings highlight several 
elements that can profoundly influence the covalent ligand-receptor interaction. These factors 
manifest an optimal combination dependent on the affinity of the pharmacophore, the 
warhead’s proximity to an appropriate nucleophilic amino acid residue and the warhead’s 
reactivity. The overall conclusion from the results described in this thesis and emerging 
opportunities for drug discovery are discussed in detail in Chapter 7. In concert, the novel 
insights that have been obtained in this thesis may provide valuable information for drug 









De meeste geneesmiddelen zijn op maat gemaakt om een reversibele interactie aan te gaan 
met hun biologische aangrijpingspunten, genaamd target eiwitten. Het vormen van 
eecovalente en irreversibele binding met een target eiwit kan mogelijk leiden tot nadelige 
gevolgen wat tot bedenkingen heeft geleid om covalente geneesmiddelen als een 
medicijnklasse te zien. Echter, gezamenlijke inspanningen en successen in het veld van 
medicijnontwikkeling om de sterkte van geneesmiddel-eiwitinteracties te maximaliseren, 
hebben het concept van "covalente interacties" nieuw leven ingeblazen. Covalente interacties 
kunnen de werkingsduur verlengen en de activiteit en selectiviteit verbeteren, wat voordelen 
biedt voor zowel chemische probes als kandidaat-geneesmiddelen. Mogelijke tekortkomingen 
van covalente werkingsmechanismen kunnen worden aangepast door verbindingen te 
ontwerpen die gecontroleerde activiteit vertonen en die uit te rusten met selectiviteit voor het 
target eiwit. Daarom wordt in dit proefschrift een covalente strategie toegepast die compatibel 
is met een target-gerichte, structuur-gestuurde ontdekkingsparadigma, met een focus op G-
eiwit-gekoppelde receptoren (GPCR’s) als aangrijpingspunten voor geneesmiddelen. 
Hoofdstuk 1 behandelt de belangrijkste concepten die in het proefschrift zijn bestudeerd. Het 
hoofdstuk begint met een inleiding over GPCR's, waarbij de focus ligt op de adenosine 
receptoren. Vervolgens worden de concepten van covalente liganden voor GPCR's en de 
huidige situatie en uitdagingen beschreven. Hoofdstuk 2 gaat verder met het bespreken van 
de opkomst van moleculaire probes om de biologische effecten van adenosine receptoren in 
kaart te brengen en vat samen hoe probes worden gebruikt om adenosine receptorsubtypen 
zowel in vitro als in vivo te karakteriseren. Verder wordt de rol van deze receptoren in 
fysiologische en ziektecondities bestudeerd. De hoofdstukken 3-6 beschrijven het 
ontwerpproces van covalente liganden voor adenosine receptoren en demonstreren het 
gebruik van deze liganden om farmacologische effecten te bewerkstelligen. 
In hoofdstuk 3 wordt LUF7445 geïntroduceerd en uitgebreid gekarakteriseerd. Deze 
covalente antagonist is ontworpen op basis van een niet-xanthine antagonist met hoge 
affiniteit, ZM241385. Deze moleculaire “mal” werd gecokristalliseerd met hA2AR, wat een 
heldere blauwdruk van de ligand-binding interacties opleverde. Analyse van de vorm van de 
bindingsplaats toont aan dat de fenylethylamine-keten in ZM241385 is gericht op het meer 
aan oplosmiddel blootgestelde extracellulaire gebied (EL2 en EL3), waar ook veel ruimte is 






covalente interactie. Met behulp van tijdsafhankelijke affiniteitsverschuiving en kinetische 
competitie associatie experimenten, werd LUF7445 geïdentificeerd als een waarschijnlijk 
covalente antagonist, wat verder werd bevestigd met wash-out experimenten. Een docking 
model gebaseerd op de structuur van de adenosine A2A receptor gecombineerd met 
plaatsgerichte mutagenesestudies suggereert een bindingsmodus van LUF7445 met als 
ankerpunt lysine-aminozuur K153ECL2. Ondertussen werd een functioneel experiment, 
gecombineerd met wash-out experimenten, opgezet om de sterkte van de covalente binding 
van LUF7445 te onderzoeken. Deze bevindingen bevorderen studies van covalente liganden 
en dienen als een prototype voor een therapeutische benadering waarbij een covalente 
antagonist nodig kan zijn om langdurige en persistente aanwezigheid van het endogene ligand 
adenosine tegen te gaan. 
Geïnspireerd door het succesvolle ontwerp van LUF7445, begint hoofdstuk 4 met het op 
structuur gebaseerd ontwerpen van covalente antagonisten voor menselijke adenosine A3-
receptoren, waarvoor maar weinig structurele inzichten in de receptor-bindingsplaats zijn. 
Uitgaande van de 1H,3H-pyrido[2,1-f]purine-2,4-dion-antagonist basisstructuur werd een 
reeks liganden gesynthetiseerd die een fluorosulfonyl “warhead” met een variërende linker 
dragen. De gestroomlijnde follow-up workflow om deze liganden te karakteriseren werd 
overgenomen van hoofdstuk 3, en de bevindingen suggereren dat LUF7602 zich gedraagt als 
een covalente antagonist voor de menselijke adenosine A3-receptor. Daarnaast werd in dit 
onderzoek een niet-reactief methylsulfonyl-derivaat LUF7714 ontwikkeld als een reversibel 
bindende controleverbinding. In combinatie met in silico hA3R-homologiemodellering en 
plaatsgerichte mutagenese werd LUF7602 gebruikt om de ruimtelijke oriëntatie en topografie 
van de receptor-ligandbindingsplaats te karakteriseren, waarbij werd aangetoond dat 
aminozuurresidu Y2657.36 het unieke ankerpunt van de covalente interactie is. Uiteindelijk 
werd uit deze gestructureerde benadering snel een goed gedefinieerd covalent ligand 
verkregen en geprofileerd.  
Notabene, deze onderzoekswerkstroom, inclusief rationeel ontwerp van covalente liganden en 
een niet-reactieve sulfonyl-dragende controleverbinding, alsmede de identificatie van 
covalente interactie gecombineerd met in silico-modellering en plaatsgerichte mutagenese, 
kan dienen als een gestroomlijnde aanpak om de structurele details over ligandherkenning 
voor andere GPCR’s te bestuderen. 
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Vervolgens beschrijft hoofdstuk 5 het ontwerp, de synthese en de toepassing van een op 
capadenoson gebaseerde covalente partiële agonist voor de adenosine A1 receptor, LUF7746, 
die een elektrofiele fluorosulfonylgroep bevat. Tevens werd een niet-reactief ligand met een 
methylsulfonylgroep, LUF7747, ontworpen als controle ligand. Naast de eerder genoemde 
gestroomlijnde aanpak om covalente liganden te karakteriseren, werd een analyse van hA1R-
gemedieerde G-eiwit-activering gebruikt om LUF7746 als een partiële agonist te identificeren 
alsook de ongevoeligheid voor blokkering door een antagonist/inverse agonist. Een in silico 
structuur-gebaseerde docking-studie gecombineerd met plaatsgerichte mutagenese van de 
hA1R toonde aan dat ook hier aminozuur Y2717.36 het primaire aangrijpingspunt was voor de 
covalente interactie. Uiteindelijk werd een label-vrij intacte-cel experiment opgezet om de 
morfologische celrespons te identificeren als gevolg van de onomkeerbare LUF7746-
activering van de A1-receptor. 
Volgend op deze demonstraties van covalente liganden om de farmacologische effecten van 
adenosine receptoren te onderzoeken, beschrijft hoofdstuk 6 de ontwikkeling van A2AR 
covalente liganden tot een op affiniteit gebaseerde probe. Hier werd een covalent ligand, 
LUF7445, uitgerust met een terminale alkyngroep om te dienen als een op affiniteit 
gebaseerde probe, LUF7487. Na binding aan de gezuiverde hA2AR werd deze probe 
gekoppeld aan de klikbare fluorofoor Cy3-azide en werd onomkeerbare en concentratie-
afhankelijke labelling aan gezuiverd hA2AR gevisualiseerd met behulp van SDS-PAGE. Het 
labellen van het gezuiverde hA2AR door LUF7487 kon worden geremd door zowel reversibele 
als irreversibele antagonisten, op voorwaarde dat ze zich richten op dezelfde receptor-
bindingsplaats. Uiteindelijk werd een succesvolle labeling van de receptor in celmembranen 
die hA2AR tot overexpressie brachten aangetoond, wat LUF7487 tot een veelbelovende op 
affiniteit gebaseerde probe maakt die hopelijk de basis vormt voor de verdere ontwikkeling 
van probes voor GPCR's. 
Samenvattend is de benadering van ontwerp en farmacologisch karakteriseren van covalente 
liganden voor adenosine receptoren onderzocht en gedetailleerd in dit proefschrift. Een 
universele strategie voor het ontwerp van covalente liganden is onderzocht en de bevindingen 
benadrukken verschillende elementen die de covalente ligand-receptor interactie sterk kunnen 
beïnvloeden. Deze factoren vertonen een optimale combinatie afhankelijk van de affiniteit 
van de farmacofoor, de nabijheid van de chemisch reactieve groep (‘warhead’) tot een 
geschikt nucleofiel aminozuurresidu en de reactiviteit van de ‘warhead’. De algemene 






de ontdekking van geneesmiddelen worden in hoofdstuk 7 gedetailleerd besproken. Met 
andere woorden, de nieuwe inzichten, verkregen door dit proefschrift, geven mogelijk 
waardevolle informatie voor geneesmiddelonderzoek gericht op de adenosine receptoren 
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